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Introduction
 
This doctoral thesis describes cardiovascular and metabolic risk factors in children 
and young adults with a small size at birth, either due to preterm or SGA birth. For 
those born SGA with persistent short stature, the effects of GH treatment on these risk 
factors were studied. This first chapter describes definitions, prevalence and etiologies 
of SGA, and clinical and endocrinological aspects associated with SGA. Finally, the 
aims of the study and outline of this thesis are described. 
 
1. Small for gestational age (SGA)
1.1 Definitions of SGA
 
In the past years, several definitions have been used for SGA, ranging from a birth 
weight and/or length below the 10th to 3rd percentile or –2 SD for gestational age. In 
2001, the International SGA Advisory Board Panel reached consensus on the definition 
of SGA, by defining SGA as a birth weight and/or length below –2 standard deviations 
(SD) for gestational age (1). This was confirmed in the consensus statement of 2007 
(2). 
SGA refers to the size of the infant at birth, and not to intrauterine growth. The term 
intrauterine growth retardation (IUGR) is used to describe reduced growth velocity in 
the fetus. This can be observed as a deviation of the fetal growth chart, as documented by 
prenatal ultrasound biometry. Although SGA is often related to IUGR, not all SGA infants 
have suffered from IUGR and infants who are born after a short period of IUGR are not 
necessarily SGA. Figure 1 shows the fetal growth patterns of SGA and IUGR newborns. 
Because the prenatal growth pattern is often unknown, we prefer to use the term SGA. 
 
 
 
 
 
 
Figure 1. Fetal growth chart showing dif-
ference between SGA and IUGR newborns
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1.2 Prevalence and etiology of SGA
 
When SGA is defined as a birth weight and/or length below –2 SD for gestational age, 
2.3 % of all live-born infants are born SGA. In 2005, 187,910 infants were born in the 
Netherlands (Central Bureau of Statistics, Voorburg, the Netherlands). According to 
the definition, 4322 of them were born SGA.
SGA can be caused by several factors, including fetal, maternal, placental and de-
mographic factors (3-5). Identification of the cause of SGA is important, as underlying 
mechanisms may affect prognosis and treatment. However, the cause of impaired fetal 
growth remains unidentified in up to 40% of cases. Table 1 shows factors that are as-
sociated with SGA. 
Fetal factors include chromosomal abnormalities, genetic defects, metabolic prob-
lems and congenital anomalies.
Maternal factors can be divided into medical conditions and environmental factors. 
Medical conditions include: chronic vascular diseases (secondary to hypertension, dia-
betes mellitus, renal disease, collagen vascular disease), conditions associated with 
maternal hypoxemia, infections (particularly toxoplasmosis, rubella, cytomegalovirus 
and herpes virus) and malnutrition. Environmental factors include cigarette smoking, 
alcohol abuse, use of illicit drugs (heroin, cocaine) and therapeutic drugs (e.g., anti-
convulsants, anticoagulants). 
Placental factors are associated with problems in placental perfusion resulting in 
reduced fetal oxygenation. These include structural abnormalities of the placenta, ma-
ternal or fetal thrombophilia, infarctions and suboptimal implantation site. 
Demographic factors involve maternal age, parental race and height, obstetric his-
tory, and multiple gestation, particularly in case of shared fetal circulation.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Factors associated with increased incidence of infants who are born SGA. Adapted from Bern-
stein and Divon (3), Pollack and Divon (5), Wollmann (4), and Keller et al. (6).
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Fetal factors
Karyotypic abnormalities Trisomy 21 (Down syndrome)
Trisomy 18 (Edward syndrome)
Monosomy X (Turner syndrome)
Trisomy 13 (gonadal dysgenesis)
Other chromosomal abnormalities Autosomal deletions
Ring chromosomes
Genetic diseases Achondroplasia
Bloom syndrome
Congenital anomalies Potter syndrome
Cardiac abnormalities
Maternal factors
Medical conditions Hypertension
Renal disease
Diabetes mellitus (advanced stages)
Collagen vascular diseases (e.g. systemic lupus erythematosus)
Maternal hypoxemia (cyanotic heart disease, chronic anemia, chronic 
pulmonary disease)
Toxoplasmosis
Infection Rubella
Cytomegalovirus
Herpes virus
Malaria
Trypanosomiasis
Human immunodeficiency virus
Nutritional status Low pre-pregnancy weight
Low pregnancy weight with poor weight gain during pregnancy
Substance use/abuse Cigarette smoking
Alcohol
Illicit drugs
Therapeutic drugs (e.g., warfarin, anticonvulsants, antineoplastic 
agents, folic acid antagonists)
Uterine/placental factors
Gross structural placental factors Single umbilical artery
Velamentous umbilical cord insertion
Bilobate placenta
Placental hemangiomas
Infarcts, focal lesions
Maternal and/or fetal thrombophilia 
Insufficient uteroplacental perfusion Suboptimal implantation site
Placenta praevia
Low-lying placenta
Placental abruption
Demographic factors
Maternal age Very young age
Older age
Maternal height
Maternal weight
Maternal and paternal race
Parity Nulliparity
Grand multiparity
Maternal history Previous delivery of SGA infants
Multiple gestation Particularly severe in syndromes associated with shared fetal circulation
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2. Clinical and endocrinological aspects associated
    with SGA
2.1 Short stature 
SGA is a common cause of short stature in childhood and adulthood, accounting for 
20% of all cases (7). Most children born SGA show spontaneous catch-up growth to a 
normal height above –2 SDS. However, approximately 10% of them do not and remain 
short throughout life. In a Swedish cohort of 111 infants born SGA, defined as a birth 
length below – 2 SD, 13% still had a height below – 2 SDS at the age of 2 years (8). In 
another group of 724 infants born SGA, defined as a birth length below –1.88 SDS, 
Hokken-Koelega et al. found that 15% did not show catch-up growth to a normal height 
at the age of 2 years (9). Catch-up growth is most pronounced during the first 6 months 
and is usually completed in the first 2 years of life. However, in premature SGA infants, 
catch-up growth may take longer (9, 10). This is most probably because prematures 
differ from term children with regard to several parameters, such as distance between 
height SDS at 2 years of age (height SDS
2y
) and target height SDS, and difference be-
tween height SDS
2y
 and birth length SDS (9, 10). By the age of 8 years, 91% has reached 
a height > -2 SDS (10). 
Chaussain et al. reported that SGA children with a birth length < -2 SD who remained 
short during childhood reached a mean adult height of 161.9 (8.0) cm (~ -2.1 SDS) for 
boys and 147.6 (7.0) cm (~ -2.8 SDS) for girls (11, 12). These values were significantly 
lower than the target heights of these children (p<0.001) (11). If a normal height above 
– 2 SDS has not been achieved by 2 years of age, there is a 7-fold increased risk for short 
stature for those born with a low birth length and a 5-fold increased risk for those born 
with a low birth weight (7). Therefore, a child born SGA who is still short at 3 years of 
age, should be referred to a pediatrician with expertise in endocrinology (1).
2.2. Cardiovascular disease associated with SGA
2.2.1 Historical data and hypotheses
Based on epidemiological studies, an inverse relation has been reported between birth 
weight and the risk of hypertension, cardiovascular disease and diabetes mellitus type 
2 in adulthood (13-15). Insulin resistance plays an important role in the pathogenesis of 
these diseases (16, 17), however, the exact mechanisms underlying these associations 
are still unknown. Several hypotheses have been proposed. 
Fetal origins hypothesis: Based on a number of epidemiological observations linking 
reduced birth weight and adult diseases, such as hypertension, hyperlipidemia, dia-
betes mellitus type 2, coronary artery disease and metabolic syndrome, Barker et al. 
suggested that fetal malnutrition could result in permanent metabolic alterations and 
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changes in organ structures in the fetus (13, 14). This re-programming would be in 
favor of short-term survival, but deleterious on the long-term as it would result in dis-
eases in adulthood (Figure 2).
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undernutrition 
Fetal 
undernutrition 
Hypertension Type 2 diabetes Hyperlipidemia 
Metabolic 
syndrome 
Other organ 
malfunction, e.g. 
liver 
Decreased !-
cell mass 
Insulin 
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Abnormal  vascular 
development 
Obesity 
Age 
Other maternal or placental 
abnormalities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Representation of the fetal origins of the metabolic syndrome. 
Adapted from Barker et al. (14, 18).
Fetal insulin hypothesis: The fetal insulin hypothesis was formulated by Hattersley et 
al. It was postulated that the association between low birth weight and adult insulin 
resistance is principally genetically mediated (19). Genes involved in insulin resistance 
could result in low-insulin-mediated fetal growth in utero as well as insulin resistance 
in childhood and adulthood (Figure 3). 
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Figure 3. Simplified representation of fetal insulin hypothesis. Adapted from Hattersley et al. (19).
 
Growth acceleration hypothesis: Singhal and Lucas suggested that rapid postnatal growth 
rather than birth weight per se, could have adverse long-term effects and might result 
in adult diseases (Figure 4) (20).
 ! Rapid postnatal 
growth in weight 
Low birth weight Adult diseases 
Figure 4. Simplified representation of growth acceleration hypothesis. 
Adapted from Singhal and Lucas (20).
Fat accumulation hypothesis: Based on detailed measurement of body composition by 
dual energy x-ray absorptiometry (DXA), our research group took the growth accelera-
tion hypothesis by Singhal and Lucas a step further by specifying growth acceleration 
into fat accumulation (Figure 5) (21). According to this hypothesis, small size at birth 
followed by growth in height and weight as such is not a problem as long as a normal 
amount of fat is accumulated. 
! Increased accumulation of 
fat during childhood 
Birth Adult diseases 
 
Figure 5. Simplified representation of fat accumulation hypothesis. Adapted from Leunissen et al. (21).
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2.2.2 Assessment of cardiovascular risk
Novel cardiovascular risk markers
In the past, several new cardiovascular risk markers have been identified with addi-
tional predictive value with respect to the development of cardiovascular disease and 
diabetes mellitus type 2. A majority of these new markers are produced in adipose tis-
sue (Figure 6). Some of them will be described below and the limited number of studies 
in SGA subjects will be summarized. 
Figure 6. Adipose tissue produces several substances associated with the development of cardiovascu-
lar disease. Adapted from Fantuzzi et al. (22) 
Adiponectin
Adiponectin was first described in 1995 as a novel adipocytokine, synthesized exclu-
sively by adipocytes and secreted in relatively large amounts into plasma (23). Adi-
ponectin has been inversely associated with insulin resistance and obesity parameters 
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in both animal models and human studies (24-31). Adiponectin knock-out mice devel-
oped insulin resistance, when fed a high fat/high sucrose diet (30), whereas in obese 
children, weight loss resulted in an increase of serum adiponectin levels (24). Though 
its mechanism of action is largely unknown, longitudinal studies have shown that low 
adiponectin is a risk factor for developing diabetes mellitus type 2 (31).
Resistin
Resistin was initially identified as an adipocytokine in mice that was downregulat-
ed by thiazolidinediones (TZDs, a class of Peroxisome Proliferator Activated Recep-
tor gamma (PPARγ) agonists) (32). TZDs are used in the treatment of type 2 diabetes 
mellitus and are known to enhance insulin sensitivity in vivo. Increased resistin levels 
were found in genetically and diet-induced animal models of obesity (32). In animals, 
inverse associations were described between resistin levels and glucose tolerance and 
positive correlations with obesity (32). In humans, however, the associations with insu-
lin resistance and obesity were less clear and could often not be reproduced (29, 33-36). 
Therefore, the role of resistin as a marker for insulin resistance in humans has been 
questioned (35, 37). Recent reports suggest that, instead of being a marker for insulin 
resistance, resistin might have proinflammatory properties as it is a member of the 
cytokine family (38, 39). Jung et al. showed that resistin is secreted from macrophages 
in atheromas and may contribute to atherogenesis because of its effects on vascular 
endothelial cells and smooth muscle cells (40). So, resistin might rather be considered 
as a parameter for inflammation and atherosclerosis than for insulin resistance. Be-
cause important crosstalks have been described between metabolic and inflammatory 
pathways (41), resistin might still be a marker of interest. 
Interleukin-6 and C-reactive protein
There is increasing evidence that the innate immune system in combination with nutri-
tional factors is involved in the pathogenesis of DM2 (42). Growing evidence indicates 
that the GH-IGF-I system and the immune system are correlated and several bidirec-
tional interactions have been described (43). Besides, the receptors and signaling cas-
cades activated by GH and IL-6 appear to be very similar (44). Hypopituitary adults have 
higher CRP and IL-6 levels (45). Interleukin-6 (IL-6) is an inflammatory cytokine and 
a primary determinant of the production of C-reactive protein (CRP). Both increased 
CRP and IL-6 levels have been associated with increased incidence of cardiovascular 
disease, obesity and diabetes mellitus type 2 in adults (46-52). In children, CRP levels 
were positively associated with BMI, systolic blood pressure and triglycerides and in-
versely with HDL-C levels (53).
MMP-9
Matrix metalloproteinases (MMPs) are zinc-dependent endoproteinases, which par-
ticipate in remodelling the extracellular matrix (ECM) (54, 55). Since alterations in the 
elastic properties of the vasculature in atherosclerosis result from constant remodel-
ling of the arterial wall, MMPs are thought to play a role in the development of athero-
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sclerosis and cardiovascular disease (55, 56). One of the interesting MMPs with respect 
to atherosclerosis is MMP-9, which can degrade elastin. Elastin is the main elastic 
component of the arterial wall. In MMP-9 knock-out mice, MMP-9 deficiency resulted 
in less intima hyperplasia and less atherosclerosis (57). MMP-9 deficient smooth mus-
cle cells had decreased migratory activity as well as a decreased capacity to contract 
collagen (57). Increased MMP-9 levels were found in hypertensive subjects (58, 59) and 
high plasma MMP-9 levels predict cardiovascular mortality in patients with coronary 
artery disease (60).
Novel cardiovascular risk factors in SGA
Contrasting data about adiponectin levels have been reported for SGA infants and chil-
dren (61-64). Some found positive correlations with birth weight (61, 63, 65-67), but oth-
ers did not (62, 68-70). Importantly, birth weight was not adjusted for gestational age in 
all of these studies, whereas adiponectin has been shown to increase impressively with 
gestational age (71). Compared with AGA children, previous studies reported lower (61, 
63), similar (64) or higher (62) levels in SGA children. This might be explained by the 
fact that the studied SGA groups for which lower adiponectin levels were reported, all 
consisted of a mixture of short SGA children and SGA children with catch-up growth 
(61, 63).
Data on inflammatory markers in SGA children are very scarce. One study reported 
IL-6 levels in short SGA children (64), which were comparable with normal AGA chil-
dren. Unfortunately, they did not provide any information on recent infections, surgery 
or trauma, which obviously can influence inflammatory markers.
Resistin, CRP and MMP-9 levels have not been described in SGA children before.
Glucose homeostasis and conventional cardiovascular risk factors
In a group of prepubertal short SGA children with a mean age of 8 years, we previ-
ously showed that 8% had an impaired oral glucose tolerance test (72). Further studies 
indicated that short SGA children were more insulin resistant than children born AGA 
(73, 74). Notably, there was a compensatory increase in insulin secretion in short SGA 
children (73, 74). The relationship between insulin sensitivity and insulin secretion is 
best described by a hyperbolic function (Figure 6). When insulin sensitivity varies, a 
proportionate and reciprocal alteration in insulin secretion is required to maintain 
a constant glucose tolerance (75). If insulin secretion does not change appropriately, 
impaired glucose tolerance and ultimately diabetes mellitus type 2 will develop (76). 
In addition to reduced insulin sensitivity, it was also reported that SGA children and 
adolescents had a higher systolic blood pressure (77, 78) and more often hypercholes-
terolemia (79).
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Figure 7. Hyperbolic association between insulin secretion and insulin sensitivity. Adapted from Kahn et 
al. (80). IGT: impaired glucose tolerance; T2DM: type 2 diabetes mellitus  
Body composition
It is well known that obesity is an important risk factor for the development of cardio-
vascular disease and diabetes mellitus type 2 (22). In children born SGA with spon-
taneous catch-up in weight, early development of adiposity has been reported (81). 
However, short children born SGA have a different phenotype. They have a typical lean 
appearance, which is confirmed by a low body mass index (BMI) SDS and a low sum 
of skinfolds SDS (77). Short SGA children also have lower IGF-I levels (82-84), and be-
cause abnormalities in body composition in GH deficient children have previously been 
demonstrated (85), it might well be that body composition in short SGA children is also 
altered. However, data on detailed body composition in short SGA children are very 
scarce (86, 87).
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3. Growth hormone (GH) treatment in SGA children
3.1 Effects on linear growth
A significant number of short SGA children exhibit alterations in the GH-IGF-IGFBP 
axis (82, 84, 88-92). These observations have led to the first GH studies in short SGA 
children. In 1991, the first Dutch multi-centre randomized double-blind dose-response 
GH trial was started to investigate the efficacy of GH treatment on growth (84, 93). 
Children were treated with either 1 or 2 mg GH/m2/day. In this study, 85% of the chil-
dren reached a normal adult height above –2 SDS and 98% reached an adult height with-
in their target height range (93). Interestingly, adult height SDS was not significantly 
different between the two GH dosage groups. In 1996, the second Dutch GH trial was 
started with a randomized control group for 3 years. After 3 years, GH treatment with 
a dose of 1mg GH/m2/day resulted in a normalization of height, whereas children in 
the control group remained short (94). In addition to the Dutch GH trials, several other 
studies have also demonstrated that GH treatment is an effective and safe therapy for 
short SGA children. Table 2 summarizes the findings of long-term GH studies in short 
SGA children and data on adult height.
Table 2. Long-term GH trials in short SGA children.
 
Definitions 
SGA/ short stature 
GH dose At start ! Height SDS Adult Height  
  N Age (yr) Height SDS 5 y N Height SDS  
<–1.88 SDS Untreated 29 7.8 –2.6  15 –2.3 
 0.033 mg/kg/d 41 7.3 –3.0 2.2 28 –1.1 
 0.067 mg/kg/d 38 7.2 –3.1 2.6 26 –0.9 
Sas et al. (84) and van 
Pareren et al. (93) 
         
<–2 SDS/ <–2.5 SDS Untreated 47 12.8 –3.2  33 –2.7 Carel et al. (95) 
 0.067 mg/kg/d 102 12.7 –3.2  91 –2.1  
         
<–2 SDS Untreated 34 8.3 -2.2  34 -2.0 Dahlgren et al. (96) 
 0.033 mg/kg/d 36 8.9 -3.1  36 -1.2  
 0.033 mg/kg/d 41 12.3 -2.5  41 -1.6  
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3.2 Effects on the GH-IGF-IGFBP-axis
Previous reports have shown that GH treatment of short SGA children leads to increas-
es in serum IGF-I and IGFBP-3 levels, which are positively related to the GH dose (84, 
89, 97). Boguszewski et al. reported a rise of 90% in IGF-I levels after one year and of 
123% after 2 years of GH treatment with a dose of 1 mg/m2/day (89). Sas et al. reported 
a rise in IGF-I and IGFBP-3 levels up to 1.2 SDS and 0.2 SDS, respectively, during GH 
treatment with 1 mg GH/m2/day for one year, whereas treatment with 2 mg GH/m2/
day resulted in IGF-I and IGFBP-3 levels of 1.9 SDS and 0.5 SDS, respectively. After 5 
years of GH treatment, the IGF-I SDS and IGFBP-3 SDS were 1.7 and 1.0 in the 1 mg GH 
dose group and 2.0 and 1.2 in the 2 mg GH dose group, respectively (84). Van Dijk et 
al. performed overnight GH profiles in short prepubertal SGA children (83). Mean and 
maximum GH levels during an overnight GH profile were 34.8 and 104 mU/l respec-
tively during treatment with 1 mg GH/m2/day, and 64.4 and 161 mU/l during treatment 
with 2 mg GH/m2/day (83).
3.3 Effects on novel cardiovascular risk markers
Data regarding the effect on novel cardiovascular risk markers, such as adiponectin, 
resistin, IL-6, CRP and MMP-9 are very limited. Ibañez et al. reported a reduction in 
adiponectin and an increase in IL-6 levels in a small group of SGA children after 6 
months of high-dose GH treatment (64). However, no information was given on recent 
infections, surgery or trauma. Given the important antidiabetic and anti-inflammatory 
properties of adiponectin, we hypothesized that adiponectin might be involved in the 
reduction in insulin sensitivity induced by GH treatment. At start of this study, reports 
describing the effects of GH treatment on resistin, CRP and MMP-9 levels did not ex-
ist.
3.4 Effects on insulin sensitivity and conventional cardiovascular      
           risk factors
GH has well-documented insulin-antagonistic effects and its use has been associated 
with a reduction in insulin sensitivity and an increase in insulin levels (98-100). There-
fore, concern has been expressed regarding the long-term effects of GH-treatment on 
the insulin-glucose homeostasis in short SGA children. It has previously been shown 
that insulin sensitivity is reduced in short SGA children before start of GH treatment 
(74, 101). GH treatment resulted in a further decline of insulin sensitivity and a com-
pensatory increase in insulin secretion (73, 102). 
Previous studies reported conflicting results regarding the change in insulin sensi-
tivity after GH was stopped. De Zegher et al. observed a decrease in insulin sensitivity 
in 9 short SGA children during GH treatment (using a very high dose of ~3 mg GH/
m2/day), which was reversible after stop of GH treatment (102). Cutfield et al. measured 
insulin sensitivity in 5 short SGA children and reported that insulin sensitivity did not 
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recover after stop of GH treatment (73). Both groups investigated insulin sensitivity 
after stop of GH treatment, but still before adult height had been achieved. Besides, in 
one study it remained unclear if some of the children had already entered puberty (102), 
which can reduce insulin sensitivity as well (103, 104). Furthermore, it is questionable 
if the number of subjects was sufficient to draw definitive conclusions. Up to date, it is 
not known how insulin sensitivity and secretion change longitudinally in SGA adoles-
cents after adult height has been attained and GH treatment has been stopped. 
With respect to other cardiovascular risk factors, GH treatment has been associ-
ated with a reduction in systolic blood pressure as well as a reduction in cholesterol 
levels which remained so until 6.5 years after discontinuation (105, 106). In the same 
study, at an age of 22 years, insulin sensitivity and secretion, body mass index and waist 
circumference in previously GH-treated SGA subjects were comparable with those of 
untreated SGA subjects. 
Reassuringly, the results of the follow-up studies which have been performed until 
now in previously GH-treated SGA subjects do not indicate that GH treatment increas-
es the risk for diabetes mellitus type 2 and metabolic syndrome (105, 106). However, 
long-term surveillance of insulin sensitivity and cardiovascular parameters in previ-
ously GH-treated SGA subjects is important to exclude any negative effects of GH. In 
the last SGA consensus meeting in 2007 long-term follow-up of previously GH-treated 
SGA subjects was considered essential (2).
3.5 Effects on body composition
GH has well-documented anabolic effects on muscle mass and lipolytic effects on adi-
pose tissue (107, 108). GH deficiency has been associated with increased fat mass and 
truncal obesity (51, 109), whereas GH excess, as in active acromegaly, has been related 
to reduced fat mass and increased LBM (110). 
Data regarding the effect of GH on body composition in short SGA children are 
scarce. Leger et al. measured muscle and fat tissue mass of the thighs by magnetic res-
onance imaging (MRI) in 14 short SGA children during GH therapy (86). They reported 
a progressive increase in muscle tissue cross-sectional area and a transient decline in 
adipose tissue cross-sectional area following 3 years of GH treatment (86). However, 
they did not measure total body fat and muscle mass. Besides, there are no data on 
the long-term consequences of GH treatment on body composition beyond the initial 
phase of catch-up growth during the first 2-3 years of GH treatment in SGA children. 
From a methodological point of view, it is remarkable that most studies investigat-
ing body composition in children receiving GH therapy did not adjust for the GH-as-
sociated catch-up in height (85-87, 109, 111). Consequently, these studies might have 
reported an underestimation of lean and fat mass for height and an overestimation of 
the effect of GH treatment on these parameters.
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3.6 Safety aspects
The National Cooperative Growth Study (NGCS) monitored the safety of GH treatment 
from 1984 until 1995 in children with various diagnoses. Reported adverse events in-
cluded idiopathic intracranial hypertension, edema and lymphedema, carpal tunnel 
syndrome, slipped capital femoral epiphysis, diabetes mellitus and glucose intoler-
ance (112). However, the authors concluded that major adverse events in relation to GH 
treatment were rare and their frequency may be affected by preexisting medical condi-
tions. 
In SGA children, several studies have shown that GH treatment was well tolerated 
and that side effects were uncommon (72, 77, 105). Nevertheless, all SGA children re-
ceiving GH therapy should be monitored regularly for changes in glucose homeostasis, 
lipid profile, blood pressure and serum IGF-I levels to exclude any possible adverse ef-
fects of GH (2, 113).
4. Aims of the study
Novel cardiovascular risk markers
We compared adiponectin, resistin, IL-6 and CRP levels in short SGA children with 
those in healthy normal-statured children. Besides, we evaluated the short-term effect 
(2 years) of GH treatment on adiponectin and resistin levels compared with untreated 
SGA controls. Also, we assessed the long-term effects (7 years) of GH treatment in 2 
different dosages (1 and 2 mg GH/m2/day) and the effect of discontinuation of GH 
treatment on adiponectin, resistin, IL-6 and CRP-levels. 
We investigated whether GH treatment affects plasma MMP-9 levels and blood pres-
sure in short SGA children compared with sex- and age-matched untreated SGA con-
trols. Because MMP-9 levels are thought to play a role in remodelling the arterial wall 
we also investigated whether these levels are related to blood pressure.
Body composition and bone mineral density
We measured body composition and bone mineral density by Dual Energy X-ray Ab-
sorptiometry during 6 years in short SGA children participating in a GH study with 
a randomized controlled part of 3 years. Besides, we investigated in a larger group of 
short SGA children whether there were differences in body composition between pre-
mature and term short SGA children. At last, we investigated longitudinal changes in 
body composition after discontinuation of GH due to attainment of adult height.
Insulin sensitivity and secretion
We evaluated longitudinal changes in insulin sensitivity and secretion, as measured 
with a frequently sampled intravenous glucose tolerance test (FSIGT) with tolbuta-
mide, in GH-treated SGA subjects at near adult height and 6 months after GH treat-
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ment was stopped. Besides, we investigated whether insulin sensitivity and secretion 
were different between preterm and term short SGA children. 
Prematurity
Since both SGA and preterm birth have been associated with increased incidence of 
adult cardiovascular disease and diabetes mellitus type 2, we investigated in short chil-
dren born SGA if preterm birth had an independent effect on insulin sensitivity and se-
cretion, body composition, blood pressure and lipid levels. In addition, we investigated 
the relative contributions of prematurity and SGA on insulin sensitivity and secretion 
in young adulthood as well as the effect of adult body composition and early postnatal 
growth on these parameters.
5. Outline of the thesis
Chapter 1 gives an introduction in the topics described in this thesis.
Chapter 2 describes adiponectin and resistin levels before and during 2 years of GH 
treatment in comparison with healthy AGA controls and untreated SGA controls, and 
reports the associations of these adipocytokines with cardiovascular risk factors.
Chapter 3 describes longitudinal changes in adiponectin, resistin, IL-6 and CRP levels 
during and after discontinuation of long-term GH treatment with either 1 or 2 mg 
GH/m2/day in comparison with healthy AGA controls. 
Chapter 4 reports on MMP-9 levels and blood pressure in short SGA children during 3 
years of GH treatment in comparison with untreated SGA controls.
Chapter 5 describes the long-term effects of GH treatment on body composition and 
bone mineral density during 6 years of GH treatment in short SGA children with a 
randomized controlled part of 3 years.
Chapter 6 reports on serial measurements of insulin sensitivity, insulin secretion and 
body composition in GH-treated SGA adolescents at discontinuation of GH due to 
attainment of adult height and 6 months after stop of GH. 
Chapter 7 describes differences between preterm and term short prepubertal SGA 
children in insulin sensitivity, insulin secretion, body composition, blood pressure 
and lipid levels.
Chapter 8 reports on insulin sensitivity, insulin secretion and body composition in 
young adults that were born premature and/or SGA. 
Chapter 9 discusses our data in relation to current literature and comments on the 
clinical implications and conclusions of our study results
Chapter 10 summarizes our findings in English
Chapter 11 presents a Dutch summary
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Abstract
Background: Adiponectin and resistin are fat-cell derived hormones, which are 
thought to be respectively protective and disadvantageous with regard to the develop-
ment of cardiovascular disease (CVD) and diabetes mellitus type II (DM II). Low birth 
weight has been associated with increased risks for the development of these diseases. 
In short SGA children, GH therapy has several positive effects regarding cardiovascu-
lar risk factors. On the other hand concern has been expressed about the effects of GH 
therapy on insulin sensitivity.
Methods: We measured adiponectin and resistin levels in 136 short prepubertal chil-
dren born SGA and their association with cardiovascular risk parameters and growth 
factors. Also, we compared the levels with normal-statured controls. The effect of GH 
treatment was evaluated in 50 short SGA children versus baseline and versus an un-
treated sex- and age-matched SGA control group. 
Results: Short SGA children had similar adiponectin and lower resistin levels com-
pared to normal-statured controls. In GH-treated SGA children, neither adiponectin 
nor resistin levels changed significantly during 2 years of GH treatment. Compared to 
untreated sex- and age-matched SGA controls, GH-treated SGA children had similar 
adiponectin and lower resistin levels. Adiponectin correlated inversely with age, but 
not with any cardiovascular risk parameter or growth factor. Higher IGF-1 levels in GH-
treated children were associated with lower resistin levels.
Conclusions: Compared to normal-statured controls, short prepubertal SGA chil-
dren had similar adiponectin and lower resistin levels. Two years of GH treatment had 
no effect on their adiponectin and resistin levels. 
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Introduction
The identification of so-called ‘adipocytokines’ has brought challenging opportunities 
in metabolic research. Adipocytokines are fat-cell derived hormones, which are thought 
to have an influence on metabolism and might predict susceptibility to cardiovascular 
disease. 
Adiponectin was first described in 1995 as a novel adipocytokine, synthesized exclu-
sively by adipocytes and secreted in relatively large amounts into plasma (1). Adiponec-
tin has been inversely associated with insulin resistance and parameters of obesity in 
both animal models and human studies (2-9). Adiponectin knock-out mice developed 
insulin resistance, when fed a high fat/high sucrose diet (8), whereas in obese children, 
weight loss resulted in an increase of serum adiponectin levels (2). Though its mecha-
nism of action is largely unknown, adiponectin is regarded as one of the factors related 
to the metabolic syndrome (9).
Resistin was recently discovered as an adipocytokine that was downregulated by thi-
azolidinediones (TZDs, a class of Peroxisome Proliferator Activated Receptor gamma 
(PPARγ) agonists) (10). TZDs are used in the treatment of type 2 diabetes mellitus and 
are known to enhance insulin sensitivity in vivo. Increased resistin levels were found in 
genetically and diet-induced animal models of obesity (10). In animals, inverse associa-
tions were described between resistin levels and glucose tolerance and positive correla-
tions with obesity (10). In humans, however, the associations with insulin resistance 
and obesity are less clear and often cannot be reproduced (7, 11-14). Data on resistin 
levels in children and adolescents are very scarce (13, 14).
Low birth weight has been associated with increased risk for the development of 
adult cardiovascular disease and type 2 diabetes mellitus (15). Since growth hormone 
(GH) therapy has effects on insulin sensitivity, concern has been expressed about the 
long-term effects of GH therapy in short children born small for gestational age (SGA). 
GH therapy has various positive effects on cardiovascular risk factors, such as a reduc-
tion in blood pressure SD-score, the atherogenic index and a more favourable body 
composition with particularly more lean body mass (16). On the other hand, lower 
insulin sensitivity with higher insulin levels has been described during GH therapy 
(17, 18), which appeared to normalize after discontinuation of GH (19). Contrasting 
data about adiponectin levels have been reported for SGA infants and children (20-23). 
Some found positive correlations with birth weight (20, 22, 24-26), but others did not 
(21, 27-29). Importantly, birth weight was not adjusted for gestational age in all of these 
studies, whereas adiponectin has been shown to increase impressively with gestational 
age (30).
To the best of our knowledge resistin levels haven’t been described in SGA children. 
Besides, adiponectin and resistin levels have not been described in relation to cardio-
vascular risk parameters in short SGA children.
The aims of the present study were (i) to evaluate adiponectin and resistin levels 
in prepubertal short SGA children before and after 24 months of GH-therapy, (ii) to 
compare the levels of the GH-treated short SGA children with a sex- and age-matched 
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untreated short SGA control group and (iii) to describe the relation between adipocy-
tokine levels and parameters of obesity, blood lipids, glucose, insulin, blood pressure 
and growth factors.
Subjects and methods
Subjects
The study group comprised 136 prepubertal short children born SGA. All children 
fulfilled the same inclusion criteria: 1) birth length and/or birth weight standard 
deviation score (SDS) below –2 for gestational age (31), 2) height SDS below –2 according 
to Dutch standards (32), 3) height velocity SDS below zero to exclude children with 
spontaneous catch-up growth (32), 4) prepubertal stage, defined as Tanner breast 
stage 1 for girls and testicular volume less than 4 ml for boys (33), 5) an uncomplicated 
neonatal period without signs of severe asphyxia (defined as Apgar score below 3 
after 5 minutes), sepsis or long-term complications of respiratory ventilation such 
as bronchopulmonary dysplasia. Children with endocrine or metabolic disorders, 
chromosomal defects, syndromes and growth failure caused by other conditions (e.g. 
emotional deprivation, severe chronic illness, chondrodysplasia) were excluded, with 
the exception of Silver-Russell syndrome. In 50 of the 136 children, adiponectin and 
resistin levels were tested before and after 24 months GH-therapy (while still receiving 
GH therapy). Baseline cardiovascular data and GH effects on height SDS, IGF-1 SDS 
and IGFBP-3 SDS of 28 of these 50 children have been published before(34, 35). In 
order to study the effect of GH, the GH-treated children were also compared with 27 
untreated short prepubertal SGA-children. These 27 children were selected from the 86 
children at baseline, which did not have a repeat measurement, to match in age and sex 
with the 50 GH-treated children. Biosynthetic GH (r-hGH Norditropin®, Novo Nordisk 
A/S, Denmark) was given subcutaneously once daily at bedtime. Three-monthly, the 
GH dose was adjusted to the calculated body surface area (BSA). GH dose was 1 mg/
m2 BSA for all children, except for a subgroup of 19 children, who received 2 mg/m2 
BSA for the first 6 months of treatment followed by 1 mg/m2 BSA thereafter. Since the 
2-year change in adiponectin and resistin was similar for children receiving 1 or 2 mg/
m2 BSA in the first 6 months of GH treatment (data not shown), they were analysed 
together. The study was approved by the Ethics Committees. Written informed consent 
was obtained from the parents or custodians of each child. 
Anthropometry
Standing height was measured using a Harpenden stadiometer and was expressed as 
SD-score for sex and chronological age using Dutch references (32). Body mass index 
(BMI) was calculated according to the formula weight/(height)2 and was expressed as 
SD-score for sex and age (36). Biceps, triceps, subscapular and suprailiacal skinfold 
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thickness were measured using a Holtain skinfold calliper, the sum of four skinfolds 
was calculated and these were expressed as SDS using references for healthy Dutch 
children (37). Systolic and diastolic blood pressure (BP) was measured twice on the 
left arm. The mean of 2 measurements was used for analysis. BP was expressed as 
SDS adjusted for age and sex (38). Since height is an important determinant of BP in 
childhood and adolescence, BP was also expressed as SDS adjusted for height and 
sex(38).
Hormone and biochemical assays
All blood samples were taken after an overnight fast. Serum glucose and total cholesterol 
levels were measured as described previously (19). Insulin levels were all measured in 
one laboratory using the same method (IRMA; Medgenix, Biosource Europe). The 
intra-assay coefficient of variation (CV) was 2 % to 4.7 % (19-405 pmol/l) and the inter-
assay CV was 4.2 % to 11.3% (32-375 pmol/l). Triglycerides (TG) were measured on the 
Chem-1 analyser according to the manufacturer’s instructions (Technicon Instruments, 
Tarrytown, New York) and after 1998 on the Hitachi 917 analyser according to the 
manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany). Both methods 
were comparable (y = x-0.030). 
DHEAS levels were measured in 79 consecutive children recruited between 1991 and 
2000 using a chemiluminescence-based competitive immunoassay (Immulite1, Diag-
nostic Products Corporation, Los Angeles, CA.) The interassay coefficient was 8 %. The 
limit of detection was 0.2 µmol/liter. Values below this limit of detection were consid-
ered to be 0.2 µmol/liter.
Insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 
(IGFBP-3) serum levels were measured as described previously (39). IGF-I and IGFBP-3 
levels were adjusted for age and sex as SDS (40, 41).
Adiponectin and resistin levels were measured before and after 2 years of GH thera-
py, after an overnight fast. All samples were assayed in duplicate and the mean of these 
two measures used for analysis. Serum adiponectin levels were determined by ELISA 
(R&D Systems Inc., Minneapolis, MN; intra-assay coefficient of variation (CV) < 7 %; 
inter-assay CV < 7 %). Serum resistin levels were determined by ELISA (R&D Systems 
Inc., Minneapolis, MN; intra- and inter-assay coefficient of variation < 6% and <7 %, 
respectively). Adiponectin and resistin reference values were obtained from 40 healthy 
normal statured prepubertal children (23 boys and 17 girls), aged 5.0-10.1 years, attend-
ing the outpatient clinic for a minor surgical procedure. Children suffering from any 
systemic illness, syndrome or dysmorpic features were excluded. Normal stature was 
defined as a height SDS above –2 and below +2 according to Dutch standards (32).
Statistical analysis
All data are presented as mean ± SD, except for serum adiponectin and resistin levels, 
which are presented as median and interquartile range. The non-normally distributed 
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levels of adiponectin and resistin were logarithmically transformed. Differences 
between groups were tested using the independent Student’s t-test. Differences 
in time within the same subjects (i.e. before and after 2 years of GH therapy) were 
calculated using a paired Student’s t-test. Correlations were analysed using Spearman’s 
correlation coefficient in the total group at baseline and in 55 children (50 GH-
treated and 5 untreated) with a repeat measurement after 2 years. Backward multiple 
regression analyses with logarithmically transformed adiponectin and resistin as the 
dependent variable were used to assess multivariate relationships. Factors showing a 
linear correlation with adiponectin or resistin were entered in the model together with 
age and sex. Level of significance was determined at p<0.05. Statistics were performed 
using SPSS for Windows version 11.0.1.
Results
Baseline data
Table 1 shows the clinical and laboratory parameters of the total study population. 
Adiponectin did not significantly differ from the normal statured control group of 
the same age. Resistin levels were significantly lower in SGA children (p<0.001), 
when compared to normal statured controls. BMI SDS and sum of skinfolds SDS were 
significantly lower than zero SDS. Also, IGF-1 SDS and IGFBP-3 SDS were significantly 
lower than zero SDS. Whereas diastolic BP SDS was in the normal range, systolic BP 
SDS was significantly higher than zero SDS. Lipid, fasting glucose and insulin levels 
were in the normal range. Adiponectin and resistin levels at baseline were not different 
for girls and boys (data not shown). Table 2 shows anthropometric and laboratory 
parameters for the GH-treated SGA children versus the sex- and age-matched untreated 
SGA controls. Gestational age, birth weight SDS, birth length SDS, height SDS at 
baseline, age and sex were similar for the GH-treated SGA children and the untreated 
SGA controls.  
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Table 1 Baseline clinical and fasting laboratory parameters in 136 short SGA-children
 
  Reference values 
N 136 40 
Sex (m/f) 87/49 23/17 
Gestational age (wks) 37.0 (3.6) b 39.0 (2.3) 
Birth weight SDS -2.3 (1.1) ab 0.1 (1.2) 
Birth length SDS -3.2 (1.4) ab -0.3 (1.2) 
Age (yr) 8.0 (2.3) 7.5 (1.5) 
Height SDS -3.0 (0.6) a  
BMI SDS -1.3 (1.0) a   
Sum of 4 skinfolds SDS -1.0 (1.2) a   
Systolic BPheight SDS 0.9 (1.0) 
a   
Diastolic BPheight SDS 0.1 (1.0)  
   
Adiponectin (µg/ml) 10.9 (6.8-15.0) 10.7 (8.3-13.0) 
Resistin (ng/ml) 9.7 (7.5-11.9) b 14.7 (9.9-19.4) 
Cholesterol (mmol/l)  4.2 (0.9) 2.8-5.4 
Triglycerides (mmol/l)  0.8 (0.4) 0.3-1.4 
Insulin (mU/l) 6.0 (2.8) < 16 
Glucose (mmol/l)  4.6 (0.8) 2.6-6.0 
IGF-1 SDS -1.0 (1.0) a   
IGFBP-3 SDS -1.2 (0.9) a   
   
All values expressed as mean (SD), except for adiponectin and resistin, 
which are median (interquartile range).  
BPheight SDS = blood pressure SD-scores adjusted for height and sex 
a = significantly different from 0 SDS (p<0.001) 
b = significantly different from reference group (p<0.001) 
 
 
 
 
Correlations at baseline
At baseline, serum adiponectin levels in 136 short SGA children did not correlate with 
BMI SDS or sum of four skinfolds SDS. There was no correlation between adiponectin 
levels and systolic and diastolic blood pressure SDS (either corrected for age and sex or 
for height and sex). There was a weak, but significant negative correlation between age 
and adiponectin (r = -0.229, p<0.01). Adiponectin levels did not correlate with height 
SDS, fasting insulin, glucose, insulin/glucose-ratio, IGF-1 SDS, IGFBP-3 SDS, DHEAS, 
total cholesterol, triglyceride levels, birth weight SDS, birth length SDS and birth head 
circumference SDS. Resistin levels in all SGA children at baseline did not correlate with 
BMI SDS, sum of skinfolds SDS, systolic or diastolic blood pressure SDS, age, height 
SDS, fasting insulin and glucose, IGF-1 SDS, IGFBP-3 SDS, DHEAS, total cholesterol, 
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triglyceride levels, birth weight SDS, birth length SDS and birth head circumference 
SDS. 
Adiponectin and resistin levels during 2 years of GH therapy
In the 50 GH-treated children, neither adiponectin nor resistin levels changed 
significantly during 2 years of GH treatment (Figure 1 and 2; Table 2). Height and BMI 
SDS increased significantly compared to baseline in the GH-treated children, whereas 
the sum of skinfolds SDS decreased significantly. IGF-1 SDS, IGFBP-3 SDS and fasting 
insulin increased significantly compared to baseline. 27 SGA children were selected 
from the remaining 86 untreated on the basis of matching sex and age with the treated 
group. Compared to these untreated sex- and age-matched SGA controls, the GH-
treated SGA children had similar levels of adiponectin and lower resistin levels (Figure 
2). Compared to the untreated SGA controls they had a significantly higher height SDS, 
systolic BP SDS, IGF-1 SDS and IGFBP-3 SDS, but lower cholesterol levels and sum of 
skinfolds SDS. 
In the 5 untreated children with a repeat measurement after 2 years, adiponectin lev-
els did also not change, but resistin levels tended to increase (8.6 (0.8) ng/ml at baseline 
to 13.0 (3.5) ng/ml after 2 years; p=0.08).
Correlations after 2 years 
In the 55 children with a second measurement after 2 years (50 GH-treated and 5 
untreated), adiponectin correlated weakly with fasting glucose (r = -0.278; p<0.05) but 
did not correlate with age, height SDS, IGF-1 SDS and IGFBP-3 SDS. There were also no 
correlations with BMI SDS, sum of skinfolds SDS, systolic and diastolic blood pressure 
SDS, fasting insulin, insulin/glucose-ratio, total cholesterol and triglyceride levels. 
Resistin levels correlated inversely with IGF-1 SDS (r = -0.291; p<0.05), but not with 
age and IGFBP-3 SDS. Resistin levels did not correlate with height SDS, BMI SDS, sum 
of skinfolds SDS, blood pressure SDS, fasting glucose, insulin, insulin/glucose ratio, 
total cholesterol and triglyceride levels. 
 
Multiple regression analysis
In multiple regression analyses on the data of 55 children, with a repeat measurement 
after 2 years (50 GH-treated and 5 untreated) the correlation between serum adiponectin 
levels and fasting glucose lost significance after adjustment for GH therapy (coded as 
yes/no), age and sex.
For serum resistin levels, a model containing IGF-1 SDS (β= -0.123; p<0.01) explained 
14.7 % of the variance in resistin levels, after adjustment for GH therapy, age and sex. 
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Figure 1. Adiponectin levels of GH-treated children vs. baseline, untreated SGA,
and normal-statured controls.
Figure 2. Resistin levels of GH-treated children vs. baseline, untreated SGA, 
and normal-statured controls.
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Table 2. GH effects on anthropometric and laboratory parameters
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Discussion
Our study reports serum adiponectin and resistin levels in 136 short prepubertal SGA 
children. The effect of 2 years of GH treatment was evaluated by testing fifty children 
before and after 24 months of GH treatment. In addition, we compared the GH-treated 
children with an untreated sex- and age-matched SGA control group and a normal 
statured reference group. At baseline, no strong relations were present between either 
adiponectin or resistin levels and known cardiovascular parameters, such as BMI and 
sum of four skinfolds SDS, blood pressure, lipids, fasting glucose and insulin. There 
was a weak inverse correlation between age and adiponectin levels. Compared to 
normal statured controls, SGA children had similar levels of adiponectin, but lower 
resistin levels. Compared to baseline neither serum adiponectin nor resistin levels 
changed significantly in 50 SGA children during 2 years of GH-treatment. Compared to 
untreated sex- and age- matched SGA controls, the GH-treated children had comparable 
levels of adiponectin and lower resistin levels. In multivariable analyses in the children 
which were also measured after 2 years, higher IGF-1 levels were associated with lower 
resistin levels after adjustment for age, sex and GH treatment. 
At baseline, we did not find correlations between serum adiponectin levels and vari-
ables, such as BMI SDS, sum of skinfolds SDS, blood lipids, fasting glucose, insulin and 
blood pressure. Martin et al. investigated relationships between adiponectin, fasting 
insulin and lipids (42) and found that the association between adiponectin and fast-
ing insulin could only be demonstrated in obese individuals, whereas the associations 
between adiponectin and lipid levels were very weak in lean children. Also, Knobler et 
al. found the association between adiponectin and measures of insulin sensitivity to 
be not present in non-obese coronary artery disease (CAD) patients when stratifying 
the total group by their BMI (43). Since short SGA children typically have a very lean 
appearance with a low muscle mass and fat mass (44), it is very plausible that associa-
tions between adiponectin and fasting insulin and blood lipids were not present in our 
study group. 
We found adiponectin levels in short SGA children not to be different from those in 
normal statured controls. Some authors reported adiponectin levels in SGA children 
and found lower (20, 22), similar (23) or higher (21) levels when compared to AGA chil-
dren. However, the studied SGA groups for which lower adiponectin levels were report-
ed, all consisted of a mixture of short SGA children and SGA children with catch-up 
growth (20, 22). Ibanez et al. reported adiponectin levels in a group of exclusively short 
SGA children and also found normal levels (23). Lopez-Bermejo et al. found higher 
levels in lean SGA children and lower levels in overweight SGA children (21). Our SGA 
children were all short. More recent data indicate that SGA children with spontane-
ous catch-up growth, particularly those who become overweight, are probably more 
at risk than those who remain short (45). We did not find reduced adiponectin levels 
in our population of exclusively short SGA children, which is in agreement with this 
hypothesis.
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Our study showed that 2 years of GH treatment in a group of short SGA children did 
not affect adiponectin levels. A previous study reported a decline in adiponectin levels 
during GH treatment of 16 short SGA children (46). However, numbers were smaller, 
the study period lasted 6 months instead of 2 years and the study population had a dif-
ferent ethnicity. Since the decline of adiponectin levels in the latter study was accompa-
nied by an increase of DHEAS levels, as opposed to our population (47), we wanted to 
investigate whether DHEAS levels were associated with adiponectin levels. We could, 
however, not detect such a correlation. The longer duration of GH treatment in our 
study might also be important, due to possible time-dependent effects of GH on insu-
lin sensitivity and growth factors, resulting in a different net outcome of adiponectin 
levels. 
Data on the effects of GH and IGF-1 on adiponectin levels, as reported in the litera-
ture up to date, have been inconclusive. Acromegalic patients have been reported to 
have increased, similar as well as decreased levels when compared to healthy controls 
(48-51). In growth hormone deficient (GHD) patients substitution therapy led to either 
an increase in adiponectin levels or no change (52-56). In accordance with the reports 
in GHD patients, GH therapy in our SGA patients did not affect adiponectin levels.
The first reports on resistin levels in animals suggested that resistin could be a mark-
er of insulin resistance (8, 10). In accordance with other reports in humans, we did not 
find positive correlations between resistin and fasting glucose and insulin levels (12, 
13, 57, 58). Strikingly, short SGA children had reduced resistin levels. One of the expla-
nations might be that short SGA children typically have a very lean appearance and low 
fat mass (44, 59). GH therapy, which has been reported to attenuate insulin sensitivity 
(17, 18), did not change resistin levels in the GH-treated group. The untreated SGA con-
trol group, which is expected to be less insulin resistant, showed even higher resistin 
levels. After 2 years, resistin levels correlated inversely with  IGF-1 SDS. In multiple 
regression analysis with resistin levels as the dependent variable IGF-1 SDS had a nega-
tive association with resistin, independently of GH therapy, age and sex. This is in line 
with a report showing that in vitro IGF-1 downregulates resistin gene expression and 
protein secretion (60). The IGF-1/IGFBP-3 axis has been repeatedly linked with insulin 
sensitivity as well as with the pathogenesis of atherosclerosis (61, 62). Underlying as-
sociations between IGF-1 and resistin might have confounded the reported, yet incon-
clusive associations in the literature. On the other hand, we did not find significant 
changes in resistin levels during 2 years of GH treatment, suggesting that there are 
also other factors influencing resistin levels. Recent reports on resistin levels indicate 
that, instead of being a marker for insulin resistance, it might have proinflammatory 
properties, as it is a member of the cytokine family (63, 64). Our data do not support 
that resistin is a marker for insulin resistance.
A limitation of our study is the absence of a large untreated control group with a re-
peat measurement after 2 years. We had only 5 untreated children with a repeat meas-
urement after 2 years. Therefore, we chose to compare the GH-treated children with a 
sex- and age-matched untreated SGA control group, with the same in- and exclusion 
criteria as the GH-treated children. We cannot exclude the possibility that this sex- and 
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age-matched group had already higher resistin levels 2 years prior to the measurement 
for this study. However, in our small group of untreated children a rise in resistin levels 
was observed, which is in agreement with the higher resistin levels in the sex- and age-
matched control group when compared with the GH-treated group.   
In conclusion, our study shows that short prepubertal SGA children have normal 
adiponectin and lower resistin levels, when compared to normal statured controls of 
the same age. Because of known associations between low birth weight and the de-
velopment of cardiovascular disease and diabetes mellitus type II, concern has been 
expressed about the effects of GH treatment in short SGA children. Our data demon-
strate that two years of GH treatment had no effect on their adiponectin and resistin 
levels. This is reassuring as it shows that GH treatment does not induce disadvanta-
geous changes in these adipocytokines, which have emerged as one of the markers for 
the development of cardiovascular disease and diabetes mellitus type II.   
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Abstract
Context: Low birth weight is associated with increased risks for adult cardiovascular 
disease (CVD) and diabetes mellitus type 2 (DM2). Adiponectin and resistin are hor-
mones, considered respectively protective and disadvantageous regarding these risks. 
No data exist on the effect of long-term GH treatment on these hormones and inflam-
matory markers in children born small for gestational age (SGA). 
Objective: To describe longitudinal changes in inflammatory markers and adipocy-
tokines during and after a long-term dose-response GH study. 
Design: Longitudinal dose-response study (group A: 1 mg/m2 body surface area 
(BSA) (~0.033 mg/kg·day) vs. group B: 2 mg/m2 BSA (~0.067 mg/kg·day)) and compari-
son with age-related controls
Patients: 103 SGA children
Measurements: We measured adiponectin, resistin, interleukin-6 (IL-6) and C-Reac-
tive Protein (CRP) levels at baseline, after 1 and 7 years of GH treatment and 6 months 
after discontinuation of GH. 
Results: Adiponectin levels decreased over time, but remained comparable with con-
trols. Resistin levels increased and remained lower or comparable with controls. There 
were no significant differences between the GH dosage groups. After stop of GH, adi-
ponectin decreased in group B and resistin increased in group A. GH therapy did not 
affect IL-6 and CRP levels at any time point. An increase in BMI SDS over time was 
associated with a decrease in adiponectin levels. None of the markers were associated 
with insulin sensitivity.
Conclusion: Long-term GH treatment is not associated with disadvantageous 
changes in adiponectin, resistin, IL-6 and CRP levels, neither during nor after GH 
treatment.
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Introduction
Approximately 10 % of children born small for gestational age (SGA) fail to show 
sufficient catch-up growth (1, 2). Growth hormone (GH) therapy accelerates childhood 
growth and increases adult height (3-5). GH treatment for short children born SGA has 
recently been licensed and is increasingly applied as a growth promoting therapy in 
short SGA children. 
However, low birth weight has been associated with increased risks for the devel-
opment of adult cardiovascular disease (CVD) and type 2 diabetes mellitus (DM2)(6). 
Risk factors for the development of these diseases, such as a reduced insulin sensitivity 
and an increased systolic blood pressure, are present during childhood in short SGA 
children (7, 8). Since GH therapy has effects on insulin sensitivity, concern has been 
expressed about the long-term effects of GH treatment in short SGA-children. On one 
hand, GH therapy has various positive effects on cardiovascular risk factors, such as a 
decrease in blood pressure SD-score and the atherogenic index, and a more favourable 
body composition with particularly more lean body mass (8, 9). On the other hand, GH 
therapy decreases insulin sensitivity (10, 11). 
Adiponectin was first described in 1995 as a novel adipocytokine, synthesized exclu-
sively by adipocytes and secreted in relatively large amounts into serum (12). Decreased 
levels were described in obesity in both animal models and human studies and also in 
DM2 (13). Adiponectin knock-out mice developed insulin resistance, when fed a high 
fat/high sucrose diet (14). Weight loss in obese children resulted in an increase in adi-
ponectin levels (15). Adiponectin has been inversely associated with insulin resistance 
and parameters of obesity (16-19). Though its mechanism of action is largely unknown, 
longitudinal studies have shown that low adiponectin is a risk factor for developing 
DM2 (20).
Resistin was discovered a few years later as an adipokine that was down regulated by 
thiazolidinediones (TZDs, a class of Peroxisome Proliferator Activated Receptor gam-
ma (PPARγ) agonists) (21). TZDs are used in the treatment of DM2 and enhance insulin 
sensitivity in vivo. Increased resistin levels were found in genetically and diet-induced 
animal models of obesity (21). In animals, inverse associations were described between 
resistin levels and glucose tolerance and positive correlations with obesity (21). In hu-
mans, however, the associations with insulin resistance and obesity are less clear cut 
and often cannot be reproduced (13, 22-25). Data on resistin levels in children and ado-
lescents are very scarce (24, 25).
There is increasing evidence that the innate immune system in combination with 
nutritional factors is involved in the pathogenesis of DM2 (26). IL-6 is an inflammatory 
cytokine and a primary determinant of the production of CRP. Both increased CRP 
and IL-6 levels have been associated with increased incidence of cardiovascular dis-
ease, obesity and diabetes mellitus type 2 in adults(27-33). In children, CRP levels were 
positively associated with BMI, systolic blood pressure and triglycerides and inversely 
with HDL-C levels (34). To the best of our knowledge, there are no data on CRP levels 
in short SGA children. 
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In this paper we present the effect of long-term GH treatment with an average dura-
tion of 7 years and the effect of GH discontinuation after reaching adult height (AH) on 
adiponectin, resistin, IL-6 and CRP levels for 103 short SGA individuals. For all markers 
we report the effect of two different doses of GH (1 vs. 2 mg/BSA·day) and compare the 
levels with those in age-related controls.
Subjects and methods
Subjects
The study group comprised 103 short children born SGA. Inclusion criteria have 
previously been described (3). In short, the children were prepubertal, had a birth 
length and height standard deviation score (SDS) below –1.88, did not show catch-up 
growth in height and had no growth failure caused by other disorders. The study was 
approved by the Medical Ethics Committees. Written informed consent was obtained 
from the parents or custodians of each child. 90 children participated in a double-
blind dose-response trial and were randomly assigned to either 1 or 2 mg GH/m2 body 
surface area (BSA)·day (~0.033 vs. 0.067 mg GH/kg·day) (4). 11 of these children were 
not randomized due to their advanced age at start of GH treatment; they received 2 mg 
GH/BSA·day. Thirteen children participated in another GH trial and received 1 mg GH/
BSA·day (35). Due to ethical considerations the ethics committees did not allow for 
a control group until AH. Biosynthetic GH (r-hGH Norditropin®, Novo Nordisk A/S, 
Bagsværd, Denmark) was given subcutaneously once daily at bedtime. Three-monthly, 
the GH dose was adjusted to the calculated BSA. GH treatment was discontinued when 
height velocity dropped below 0.5 cm over the last 6 months and/or bone age was ≥ 15 
years for girls and ≥ 16.5 years for boys. 
40 healthy normal statured prepubertal children, attending the outpatient clinic for 
elective minor surgery were used as a control group for adiponectin and resistin levels 
at baseline and after 1 year of GH treatment. Children suffering from any systemic ill-
ness, syndrome or dysmorphic features were excluded. Since adiponectin levels change 
during puberty (36, 37) we compared adiponectin, resistin and IL-6 levels at near AH 
and 6 months after discontinuation of GH with a post-pubertal control group of 34 
healthy normal statured adolescents. The collection and use of blood samples from the 
control groups was approved by the Medical Ethics Committee and written informed 
consent was obtained from all adolescents and the parents or custodians of each child. 
Normal stature was defined as a height SDS between –2 and +2 according to Dutch 
standards(38).
Anthropometry
Before start of treatment and subsequently every three months, height, weight and 
Tanner stage were recorded, as described previously (3). Height, body mass index (BMI) 
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and sum of four skinfolds were expressed as SD-score using references for healthy 
Dutch children, as described previously (3,8).
Parameters of insulin sensitivity
In a subgroup of 79 children a 2 hr oral glucose tolerance test (OGTT) was performed, 
as previously described (10). For these children, the whole body insulin sensitivity 
index (WBISI) was calculated (39) as an estimate for insulin sensitivity according to 
the formula (10,000/square root of [fasting glucose x fasting insulin] x [mean glucose 
x mean insulin during OGTT]). The WBISI has been shown to be highly correlated 
(r=0.73; p<0.0001) with the rate of whole-body glucose disposal during the euglycemic 
hyperinsulinemic clamp (39). For the total study group, the fasting glucose to insulin 
(G/I) ratio was calculated, which is another estimate of insulin sensitivity.
Hormone and biochemical assays
At baseline, after 1 year of GH treatment, at near AH (defined as 1.5 years or less before 
discontinuation of GH) and 6 months after discontinuation of GH treatment, a fasting 
blood sample was taken. After centrifugation all samples were frozen (-80 ˚C) until 
assayed. For the analyses of IL-6 and CRP levels, samples of children with reported 
infection, trauma or surgery in the month before blood sampling were excluded. 
Because values of CRP above 10 mg/l are suggestive of macro inflammation, these were 
also excluded from analysis. For the  analyses of correlations between the markers, all 
available samples were used. 
Serum glucose and insulin levels were measured as described previously (10). Serum 
adiponectin was determined by ELISA (R&D Systems Inc., Minneapolis, MN; intra-
assay coefficient of variation (CV) < 7 %; inter-assay CV < 7 %). Serum resistin was 
determined by ELISA (R&D Systems Inc., Minneapolis, MN; intra- and inter-assay coef-
ficient of variation < 6% and <7 %, respectively). Serum IL-6 levels were measured with 
a high sensitivity ELISA kit (R&D Systems Inc., Minneapolis, MN; intra- and inter-assay 
coefficient of variation < 12.3 % and 7.2 %, respectively).  Serum CRP levels were deter-
mined with a sensitive method (high-sensitive CRP) on the Immage analyser (Beckman 
Coulter, Mijdrecht, the Netherlands) according to the manufacturer’s instructions. The 
lower limit of detection was 0.2 mg/liter. Values below this limit were considered as 
0.2 mg/liter. Since CRP values were very skewed, even after logarithmic transforma-
tion, the values were recoded as either <0.999 mg/l or ≥ 1 mg/l. Thus, the percentages 
of individuals with a CRP ≥ 1 mg/l in the 2 dosage groups at the different study times 
were calculated.
Statistical analysis
To test the time effect (0, 1 year of GH treatment, near AH and 6 months after 
discontinuation of GH treatment) and dose effect of 1 mg versus 2 mg GH/BSA·day on 
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adiponectin, resistin and IL-6, mixed model analyses of variance were performed. In 
these models, sex and pubertal status (coded as either prepubertal or pubertal) were 
entered as covariates. Besides, we tested whether there were interactions between sex 
and time as well as dose and time. Clinical data are presented as mean (SD), model 
estimates as mean (95% CI). Non-normally distributed levels of adiponectin, resistin, 
IL-6, WBISI and the fasting G/I ratio were logarithmically transformed before analysis. 
Differences between SGA individuals and controls were tested by one-way analysis of 
variance (ANOVA) with Dunnett’s post-hoc test (several experimental groups versus 
one control group). Differences between groups at baseline were tested by one-way 
analysis of variance (ANOVA) with Bonferroni’s post-hoc test. To test time and dose 
effects on the percentage of individuals having a CRP > 1 mg/ml, a logistic regression 
was performed using the GEE (Generalized Estimating Equations) method in order to 
account for repeated measurements. Correlations were analysed using Spearman’s rank 
correlation coefficient. The significance level was set at 0.05. Statistics were performed 
using SPSS for Windows (version 11.0.1, Chicago, Illinois, USA) and SAS (SAS Institute 
Inc., Cary, NC, USA, release 8.2).
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Results
Clinical characteristics at baseline
Gestational age, birth weight SDS, birth length SDS, height SDS, BMI SDS, sum of 
skinfolds SDS, age and sex were not significantly different for both GH dosage groups 
(Table 1). Sex distribution and pubertal status were comparable between the 2 GH-
dosage groups at the various time points (data not shown). At baseline and after 1 year 
of GH treatment the SGA children were compared with a group of age-related  children. 
For comparison at near AH and 6 months after discontinuation of GH, a group of 
postpubertal controls was used. As expected, the controls had a significantly higher 
birth weight SDS, birth length SDS and gestational age.
 
Table 1 Clinical characteristics at baseline
 
 Group A Group B Controls (children) Controls 
(adolescents) 
N 54 49 40 34 
Sex (m/f) 35/19 28/21 23/17 17/17 
Gestational age (wks) 37.3 (3.1) a 36.4 (4.1) a 39.0 (2.3) 39.3 (1.7) 
Birth weight SDS -2.6 (1.1) b -2.7 (1.0) b 0.1 (1.2)  0.0 (1.3) 
Birth length SDS -3.5 (1.5) b -3.8 (1.6) b -0.3 (1.2)  0.1 (0.9) 
Age (yr) 8.0 (2.4) 8.2 (2.8) 7.5 (1.5) 20.9 (1.5) 
Height SDS -3.0 (0.7) -3.0 (0.8)   
BMI SDS -1.2 (1.2) -1.3 (1.0)   
Sum of skinfolds SDS -0.7 (1.7) -0.8 (1.3)   
 
Group A: 1 mg GH/BSA·day (~0.033 mg GH/kg·day); Group B: 2 mg GH/BSA·day (~0.067 mg GH/kg·day); SDS= 
standard deviation score 
Data are presented as mean (SD) 
a p<0.05 vs. controls; b p<0.001 vs. controls  
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Adiponectin
Adiponectin decreased in both dosage groups over time, but the decrease in group B 
was less marked than in group A (Table 2). The adiponectin level in group A  decreased 
already significantly after 1 year of GH treatment, whereas in group B, adiponectin 
became only significantly lower than baseline at near AH. After discontinuation of GH 
treatment, adiponectin levels did not significantly change in group A, but decreased 
in group B (p<0.01). Compared with age-related controls, adiponectin levels remained 
normal during the entire course of GH treatment. Adiponectin levels did not significantly 
differ between the two GH-dosage groups at all time points, even after correction for 
sex. After adjustment for GH dosage, girls showed higher levels of adiponectin than 
boys, but this gender difference was only significant at near AH (baseline: p=0.433; 1 
year GHRx: p=0.190; near AH: p<0.01; after discontinuation: p=0.074). In the mixed 
model, we assessed the influence of puberty on serum adiponectin levels. Puberty was 
associated with an 18.2 % decrease in adiponectin levels, though this did not reach 
statistical significance (p=0.07).
Resistin
After 1 year of GH treatment, resistin levels remained comparable to baseline (Table 
2). At near AH after approximately 7 years of GH treatment, only group A had higher 
levels of resistin than at baseline (p<0.01). After discontinuation of GH, both dosage 
groups showed higher resistin levels than at baseline (p<0.01 for group A; p<0.05 for 
group B), but only group A had higher levels after discontinuation of GH treatment 
than at near AH (p<0.05). Resistin levels before, during and after stop of GH treatment 
were either lower or comparable to those of age-related controls. After adjustment for 
GH dosage, resistin levels were not significantly different for girls and boys at all time 
points. Resistin levels did not significantly differ between the two dosage groups at all 
time points, even after correction for sex. Puberty had no effect on resistin levels.
Interleukin-6
IL-6 levels remained similar before, during and after stop of GH treatment and were 
not significantly different between both GH-dosage groups (Table2). After adjustment 
for GH dosage, IL-6 levels were not significantly different for girls and boys at all time 
points. Compared with age-related controls, SGA individuals had similar IL-6 levels. 
This remained so after correction for sex. Puberty did not affect IL-6 levels.  
High sensitivity CRP
The percentage of SGA individuals with CRP values above 1 mg/ml was comparable 
before, during and after stop of GH treatment and was not significantly different 
between both GH dosage groups (Table 2). 
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Table 2. Adipocytokines and parameters of insulin sensitivity before, during and after stop of GH treat-
ment in SGA individuals
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Parameters of insulin sensitivity
The fasting glucose/insulin (G/I) ratio decreased significantly after 1 year of GH 
treatment in group B and in both groups at near AH (Table 2). After adjustment for 
sex, there were no significant differences between the two dosage groups, except 
after 1 year of GH treatment (group B lower than group A; p<0.05). In both groups, 
the fasting G/I ratio increased after discontinuation of GH treatment, though this did 
not reach statistical significance in group B. After adjustment for GH dose, girls had a 
lower fasting G/I ratio than boys, both at near AH (p<0.02) and at 6 months after GH 
discontinuation (p<0.05). 
The whole body insulin sensitivity index (WBISI) decreased significantly in both 
groups during GH treatment (Table 2). After discontinuation of GH, the WBISI in-
creased significantly in group A only. After adjustment for sex, there were no signifi-
cant differences between the two dosage groups. After adjustment for GH dose, girls 
had a lower WBISI at near AH (p<0.05).
The G/I ratio correlated significantly with WBISI at all time points (r=0.59-0.91; 
p<0.001). Also, the changes in G/I ratio correlated significantly with the changes in 
WBISI at all time points (r=0.47-0.79; p-values <0.001-0.04). 
Correlations between the adipocytokines
At all time points, IL-6 levels correlated with CRP levels (r=0.342; p<0.05; r=0.467; 
p<0.001; r=0.470; p<0.01; r=0.499; p<0.001, respectively). Adiponectin did not correlate 
with resistin, IL-6 and CRP levels. After 1 year of GH treatment and 6 months after 
discontinuation, resistin correlated with IL-6 and CRP levels (r=0.225; p<0.05 and 
r=0.313; p<0.01 after 1 year of GH; r=0.431; p<0.01 and  r=0.347; p<0.05 6 months after 
discontinuation of GH).
Correlations between changes in adipokines and inflammatory markers and changes in BMI 
SDS, height SDS, sum of skinfolds SDS and parameters of insulin sensitivity
The changes in adiponectin levels from baseline to 1 yr of GH and from baseline to near 
AH were inversely correlated with the corresponding changes in BMI SDS (r=-0.399; 
p<0.01 and r=-0.478; p<0.05, respectively). The change in adiponectin levels from 
baseline to post-GH was inversely associated with the change in sum of skinfolds 
SDS, but this association failed to reach statistical significance (r=-0.350; p=0.08). 
Changes in resistin and IL-6 levels did not correlate with changes in BMI SDS and sum 
of skinfolds SDS. 
Changes in adiponectin, resistin and IL-6 levels from baseline to 1 yr GH, from base-
line to near AH and from baseline to post-GH did not correlate with the corresponding 
changes in the WBISI, fasting G/I ratio and height SDS.
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Discussion
In this paper we report the long-term effects of 7 years GH treatment in 2 different 
doses and the effect of discontinuation of GH in short SGA individuals on adiponectin, 
resistin, IL-6 and CRP levels. Also, we compared the levels with age-related controls. 
We observed a decrease in adiponectin levels and an increase in resistin levels over time, 
which was less marked in group B (2 mg GH/BSA·day) compared to group A (1 mg GH/
BSA·day). GH therapy did not affect IL-6 and CRP levels at any time point. At all time 
points, adiponectin and IL-6 levels were comparable with controls, whereas resistin 
levels were either lower or comparable. Our results indicate that long-term GH therapy 
of SGA individuals is not associated with disadvantageous changes in adipocytokine 
levels over time. 
During the course of GH treatment, adiponectin levels decreased, but were not dif-
ferent from age-related controls at any time point. Previous studies reported decreas-
ing adiponectin levels with increasing age and pubertal status (36, 37). In our study 
population, we found puberty to be associated with a decrease in adiponectin levels 
of 18.2 %, though this did just not reach statistical significance. After adjustment for 
dosage, we also found girls to have higher adiponectin levels than boys, which became 
significant during GH therapy at near AH. Besides, adiponectin levels did not increase 
during the 6 months after discontinuation of GH in both GH-dosage groups. So, the 
observed decrease in adiponectin levels during the course of GH treatment as well as 
the emerging gender difference are most likely the effect of sex steroids in puberty. 
Ibañez et al. reported 6 months of GH treatment in short SGA children to be associ-
ated with a decrease of serum adiponectin levels (40). Our long-term longitudinal study 
shows, however, that 7 years of GH treatment of 103 SGA individuals is not associated 
with disadvantageous changes in adiponectin levels.
In our study, changes in adiponectin over time did not correlate with GH-induced 
changes in parameters of insulin sensitivity. Previously, no associations were found 
between adiponectin and fasting insulin or measures of insulin sensitivity in lean indi-
viduals as opposed to obese individuals (41, 42). Since the SGA individuals investigated 
in our study all were relatively lean (8), the lack of any association between adiponectin 
and parameters of insulin sensitivity is in line with these previous observations. 
Notably, at most study times we found significantly lower resistin levels in SGA in-
dividuals than in controls. The lower resistin levels in SGA individuals might be ex-
plained by their typical body composition, with a reduced fat mass SDS (9). Resistin 
correlated with IL-6 and CRP levels, though this was not consistent at all time points. 
There were no correlations between changes in resistin levels and changes in any of the 
parameters of insulin sensitivity. The role of resistin as a marker for insulin resistance 
in humans has been questioned (24, 43). Recent reports suggest that, instead of being 
a marker for insulin resistance, resistin might have proinflammatory properties as it 
is a member of the cytokine family (44, 45). Jung et al. showed that resistin is secreted 
from macrophages in atheromas and may contribute to atherogenesis because of its 
effects on vascular endothelial cells and smooth muscle cells (46). So, resistin might 
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rather be considered as a parameter for inflammation and atherosclerosis than for in-
sulin resistance. The correlations between resistin and IL-6 and CRP levels and the lack 
of any correlation between resistin and parameters of insulin sensitivity in our study 
support this.
Of note, the decrease in adiponectin levels and the increase in resistin levels over 
time in group B (2 mg/BSA·day) were less pronounced than in group A (1 mg/BSA·day). 
From this, one may argue that a GH dose of 2 mg/BSA·day might be favourable with 
regard to adipocytokine levels. However, the observed differences between both dos-
age groups were quite small and not significantly different at all time points. Besides, 
it has been shown that the 2 mg dose results in high GH and IGF-I levels in the major-
ity of short SGA children and the long-term risks of GH and IGF-I levels in the higher 
quartile in SGA children are yet unknown (47).
Growing evidence indicates that the GH-IGF-I system and the immune system are 
correlated and several bidirectional interactions have been described (48). The recep-
tors and signalling cascades activated by GH and IL-6 appear to be very similar (49). 
Hypopituitary adults have higher CRP and IL-6 levels (50). Conflicting results exist re-
garding the effect of GH therapy in GHD patients. Some authors found CRP levels to 
decrease during GH treatment in GHD adults (51), whereas others reported no change 
(52). In GHD children, increased IL-6 and TNF-α levels were measured 6 hours after 
administration of GH, but not after 24 hours or 3 months (53). Another study report-
ed increased levels of several cytokines (measured 12 hours after injection) in normal 
short statured children after 4 days of GH in a GH generation test protocol (54). Data 
on inflammatory markers in SGA children are very scarce. Ibañez et al. reported a sig-
nificant increase of IL-6 levels in short SGA children after 6 months of GH treatment 
(40), but no information was given on recent infections, surgery or trauma. Our study 
shows that long-term GH treatment in 2 different doses does not affect IL-6 and CRP 
levels in SGA individuals who were free of recent infections, surgery and trauma. 
Previously, we reported the results of our pilot study on short term effects of GH 
treatment on adiponectin and resistin levels in comparison with untreated SGA con-
trols (55). In this other, smaller group of SGA children, the effect of 2 years of GH treat-
ment in a single dose (1 mg GH/BSA·day) was studied. Our present paper is the only one 
describing the longitudinal effects of long-term continuous GH treatment during 7 
years with 2 different GH doses and the effect of GH discontinuation on inflammatory 
markers and adipocytokines in a large cohort of SGA individuals.
We found that an increase in BMI SDS in SGA individuals during childhood and ado-
lescence was associated with a decrease in serum adiponectin levels. The same trend 
was observed for the sum of skinfolds SDS, but this association failed to reach statisti-
cal significance. Our data suggest that gaining more fat mass during childhood and 
puberty is associated with a greater decrease in serum adiponectin levels. Recent data 
indicate that low birthweight children that exhibit rapid weight gain might be more at 
risk than those who remain lean (56). The GH-treated children in our SGA cohort re-
mained relatively lean during treatment and puberty with an average sum of skinfolds 
of –1 SDS which remained significantly lower than 0 SDS during 6 years of GH treat-
CHAPTER 3
71
ment (8). This could be one of the reasons why adiponectin levels remained comparable 
with the controls.
In conclusion, our data show that long-term GH treatment in SGA individuals does 
not induce unfavourable changes in serum adiponectin, resistin and IL-6 levels, be-
cause all levels remained normal compared with age-related controls. Adiponectin lev-
els decreased over time, but this is most likely the effect of sex steroids in puberty. Re-
sistin levels increased, but remained lower or comparable than the controls at all time 
points. Serum IL-6 en CRP levels remained the same during and after discontinuation 
of GH treatment. Thus, our results are reassuring, because they indicate that long-term 
GH treatment does not disadvantageously change these adipocytokines, which have 
been suggested as determinants of the development of diabetes mellitus type 2 and 
cardiovascular disease in later life.
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Abstract
Context: Short SGA children have an increased systolic blood pressure, which de-
creases during long-term GH treatment. The underlying mechanism is still unknown. 
Matrix metalloproteinases (MMPs) are zinc-dependent endoproteinases, which are 
involved in the remodelling of the extracellular matrix and are thought to play a role 
in atherosclerosis. High MMP-9 levels are found in hypertensive patients and predict 
cardiovascular mortality. 
Objectives: To investigate whether GH treatment affects plasma MMP-9 levels in 
short SGA children and whether these are related to blood pressure (BP)
Design: Case-control study 
Intervention: GH treatment versus no treatment during 36 months
Patients: 38 short SGA children receiving GH treatment versus 17 sex- and age-
matched untreated short SGA controls
Outcome measure: Plasma MMP-9 levels and BP were measured at baseline, and af-
ter 6, 12 and 36 months of study
Results: MMP-9 decreased significantly during 3 years of GH treatment, whereas it 
remained similar in untreated SGA controls. After 3 years of GH treatment, MMP-9 
levels were significantly lower in the GH group than in untreated SGA controls. Systol-
ic BP SDS significantly decreased in the GH group, but remained unaltered in untreated 
SGA controls. MMP-9 levels did not correlate with systolic or diastolic BP. 
Conclusions: Plasma MMP-9 levels and systolic BP SDS decreased to almost 50% of 
baseline values in the GH group, whereas these remained unchanged in untreated SGA 
controls. Our data indicate that GH has a positive effect on both MMP-9 levels and 
systolic BP SDS. 
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Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent endoproteinases, which 
participate in remodelling the extracellular matrix (ECM) (1, 2). Since alterations 
in the elastic properties of the vasculature in atherosclerosis result from constant 
remodelling of the arterial wall, MMPs are thought to play a role in the development 
of atherosclerosis and cardiovascular disease (2, 3). One of the interesting MMPs with 
respect to atherosclerosis is MMP-9, which can degrade elastin. Elastin is the main 
elastic component of the arterial wall. In MMP-9 knock-out mice, MMP-9 deficiency 
resulted in less intima hyperplasia and less atherosclerosis (4). MMP-9 deficient 
smooth muscle cells had decreased migratory activity as well as a decreased capacity 
to contract collagen (4). Increased MMP-9 levels were found in hypertensive subjects 
(5, 6) and high plasma MMP-9 levels predict cardiovascular mortality in patients with 
coronary artery disease (7). 
Smaller size at birth has been associated with higher risks for the development of 
adult cardiovascular disease (8). Various studies reported that short children born 
small-for-gestational-age (SGA) had a high systolic blood pressure (BP) (9, 10), which 
declined during growth hormone (GH) therapy (9). The mechanism by which this re-
duction was achieved, is still unclear. Sixty percent of short SGA children also have ab-
normalities in the GH-insulin-like-growth factor-I (IGF-I)-axis with low normal plasma 
levels of insulin-like-growth-factor-I (IGF-I) and IGF-binding-protein-3 (IGFBP-3) (11). 
Low IGF-I levels in adulthood have been associated with increased risk of ischaemic 
heart disease (12). In GH-deficient adults, GH replacement led to a progressive decrease 
in MMP-9 and vascular endothelial growth factor (VEGF) levels and an initial decrease 
of MMP-2 reaching a plateau thereafter, in parallel to an increase in IGF-I levels (13).
In short SGA children, GH treatment increases IGF-I levels to physiological or supra-
physiological levels, depending on the GH dose (14). However, little is known about the 
vascular growth factors in short SGA children and about the effect of GH therapy on 
these parameters. To the best of our knowledge, no data have been reported on MMPs 
in short SGA children. We hypothesized that GH treatment in short SGA children af-
fects MMP-9 levels and that these are related to blood pressure.
To investigate if GH treatment affects MMP-9 levels, we measured plasma MMP-9 
levels in short SGA children during 36 months of GH treatment and compared them 
with those in an untreated sex- and age-matched short SGA control group. Further-
more, we investigated whether MMP-9 levels were associated with blood pressure. 
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Subjects and methods
Subjects
The study group consisted of 55 prepubertal short children born SGA (38 GH-treated 
and 17 sex-and age-matched untreated). All children fulfilled the same inclusion 
criteria: 1) birth length and/or birth weight standard deviation score (SDS) below –2 
for gestational age (15), 2) height SDS below –2 according to Dutch standards (16), 3) 
height velocity SDS below zero to exclude children with spontaneous catch-up growth 
(16), 4) prepubertal stage, defined as Tanner breast stage 1 for girls and testicular 
volume less than 4 ml for boys (17), 5) an uncomplicated neonatal period without signs 
of severe asphyxia (defined as Apgar score below 3 after 5 minutes), sepsis or long-
term complications of respiratory ventilation such as bronchopulmonary dysplasia. 
None of the children were growth hormone deficient. Children with endocrine or 
metabolic disorders, chromosomal defects, syndromes and growth failure caused by 
other conditions (e.g. emotional deprivation, severe chronic illness, chondrodysplasia) 
were excluded, with the exception of Silver-Russell syndrome. IGF-I levels (14, 18) and 
part of the blood pressure data (10, 19) have previously been published. The study was 
approved by the Medical Ethics Committees of the participating centers and written 
informed consent was obtained from the parents. 
GH treatment protocol
38 children were randomised to receive either 1 or 2 mg GH/m2 body surface area (BSA)/
day during the first 6 months. After the initial 6 months, all children continued with 
1 mg/BSA/day. Biosynthetic GH (Norditropin, Novo Nordisk A/S, Bagsværd, Denmark) 
was administered subcutaneously once daily at bedtime. Every three months, the GH 
dose was adjusted to the calculated BSA.
Anthropometry
Standing height and weight were measured and body mass index (BMI) was calculated 
as previously described (18). Height and BMI were expressed as SDS adjusted for sex 
and age according to Dutch reference data for children (16, 20). Systolic and diastolic 
blood pressure (BP) was measured twice in the left arm. The mean of 2 measurements 
was used for analysis. Because height is an important determinant of BP in childhood, 
BP was expressed as SDS adjusted for height and sex (21). None of the children received 
anti-hypertensive therapy. 
Assays
Insulin-like growth factor I (IGF-I) serum levels were measured in one laboratory 
as previously described (14). The intra-assay coefficient of variation (CV) was 4% 
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and the inter-assay CV was 6%. IGF-I levels were adjusted for age and sex as SDS 
(22, 23). Heparinized plasma MMP-9 levels were determined by ELISA (total MMP-9 
Immunoassay, R&D Systems Inc., Minneapolis, MN); intra-assay coefficient of variation 
(CV) < 3 %; inter-assay CV < 8 %. 
Statistics
All data are presented as mean ± SD, except for MMP-9 levels, which are presented as 
median and interquartile range. The non-normally distributed levels of MMP-9 were 
logarithmically transformed prior to analysis. Because the change in MMP-9 levels and 
blood pressure during the first 6 months was not significantly different between the 
2 GH dosage groups, the groups were combined to one GH-group. 4 children of the 
GH group and 3 children of the untreated control group had started puberty at the 36 
months visit. Exclusion of these subjects for the statistical analyses gave exactly the 
same results and therefore it was not considered to affect our results. SD-scores were 
compared with zero using Student’s one sample t-test. Differences between groups 
were tested using the independent Student’s t-test. Differences in time within the same 
subjects (i.e. before and during GH therapy) were calculated using a paired Student’s 
t-test. Multiple linear regression was used to adjust differences in outcome between the 
groups for possible baseline differences. Correlations were analysed using Spearman’s 
correlation coefficient. With respect to anthropometry at birth and in childhood and 
blood pressure, a value of 0 SDS corresponds with the mean value of the parameter in 
a child with the same age and sex (anthropometry) or with the same height and sex 
(blood pressure). Therefore, SD-scores were compared with 0. The significance level 
was set at 0.05. Statistics were performed using SPSS for Windows (version 12.0.1, SPSS 
Inc., Chicago, IL, USA). 
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Results
Clinical data
Age, sex, gestational age, anthropometric parameters at birth and at baseline, and 
baseline diastolic BP SDS were comparable for both groups (Table 1). Baseline systolic 
BP SDS was significantly higher than zero SDS in both groups, whereas birth weight 
SDS, birth length SDS, current height SDS and BMI SDS were all significantly lower 
than zero SDS. 
Table 1. Characteristics at birth and at baseline
GH-treated SGA Untreated  SGA 
controls
N 38 17
Sex (m/f) 1 8/15 1 3/7
Gestational age (wks) 36.5 (3.8) 35.1 (4.0)
Birth weight SDS -2.2 (1.2)* -2.8 (1.1)*
Birth length SDS -3.2 (1.0)* -3.1 (1.1)*
Age (yr) 6.4 (1.1) 6.2 (0.9)
Height SDS -3.1 (0.5)* -3.2 (0.5)*
BMI SDS -1.2 (1.1)§ -1.2 (1.1)*
Systolic BP SDS 1.2 (0.9)*,a 0.6(1.0)#
Diastolic BP SDS 0.3 (1.2) 0.4 (0.8)#
*= p<0.001; §= p<0.01; #= p<0.05 versus zero SDS
a= p<0.05 vs. SGA controls
SDS = standard deviation score; BP = blood pressure
Changes during GH treatment
Plasma MMP-9 levels decreased significantly and progressively during 3 years of GH 
treatment, whereas they remained at the same level in the untreated SGA controls (Figure 
1; Table 2). After 3 years of GH treatment, plasma MMP-9 levels were significantly lower 
in the GH group than in the untreated SGA controls (p=0.04), also after correction for 
baseline IGF-I SDS and systolic BP SDS (p=0.018). The change in plasma MMP-9 levels 
during 3 years of follow-up was also significantly greater in the GH-treated children 
than in the untreated SGA controls (p=0.006), and this remained so after correction 
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for baseline IGF-I SDS and systolic BP SDS (p=0.035). At all time points, MMP-9 levels 
were not different between boys and girls.
Systolic BP SDS tended to increase during the first 6 months of GH treatment. How-
ever, after 3 years of follow-up, systolic BP SDS had significantly decreased in the GH 
group, but had remained similar in the untreated SGA controls. Diastolic BP SDS de-
creased in both the GH group and the untreated SGA controls.
IGF-I SDS significantly increased in the GH group, whereas it remained unchanged 
in the untreated SGA controls.
 
Figure 1. MMP-9 levels in GH-treated SGA children vs. untreated sex- and
age-matched SGA controls. Horizontal lines represent medians.
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Table 2. Changes in blood pressure, MMP-9 and IGF-I SDS during GH treatment
GH Group P-value vs. 
baseline
Untreated
SGA controls
P-value vs. 
baseline
Age (yr) Baseline 6.4 (1.1) 6.2 (0.9)
6 mo 6.9 (1.1) 6.5 (1.2)
12 mo 7.5 (1.1) 7.2 (1.0)
36 mo 9.4 (1.1) 9.2 (1.1)
MMP-9 (ug/l) Baseline    111 (72-220) 88 (73-118)
6 mo 99 (79-141) 34 -
12 mo 85 (62-137) 53 93 (69-169) 52
36 mo    61 (47-90) §,1 <0.001 94 (60-222) 88
SBP SDSa Baseline        1.2 (0.9) § 0.6 (1.1)
6 mo        1.6 (1.1) # 30 0.7 (0.7) 79
12 mo        1.1 (0.9)  57 0.8 (1.0) 68
36 mo        0.5 (1.0) 3 0.5 (1.0) 56
DBP SDSa Baseline 0.3 (1.2)  0.4 (0.9)
6 mo 0.5 (0.9) 59  0.2 (0.9) 14
12 mo 0.0 (0.9) 32  0.2 (1.1) 66
36 mo 0.0 (0.8) 23 -0.4 (0.8) 5
IGF-I SDS Baseline -1.6 (0.9) & -0.6 (0.9)
6 mo        0.8 (1.3) <0.001 -
12 mo        0.7 (1.0) &,2 <0.001 -0.7 (1.4) 795
36 mo     0.9 (1.1) &,2 <0.001 -1.2 (1.3) 14
GH Group: n=38; Untreated SGA: n=17
SBP= systolic blood pressure; DBP= diastolic blood pressure; SDS= standard deviation score
a = corrected for height and sex
&= p<0.001; #=p<0.01; §= p<0.05 vs. untreated SGAcontrols
1= p<0.01 change in MMP-9 levels in GH-group vs. that in untreated SGA controls
2= p<0.001 change in IGF-I SDS in GH-group vs. that in untreated SGA controls
Data are presented as mean (SD), except for MMP-9, which is median (interquartile range)
Correlations
MMP-9 levels were not associated with IGF-I SDS and systolic or diastolic blood 
pressure SDS at the various time points. Changes in MMP-9 levels over time were also 
not correlated with changes in IGF-I SDS and systolic or diastolic blood pressure SDS. 
Changes in IGF-I SDS over time did not correlate with changes in systolic or diastolic 
blood pressure SDS. At the various time points, IGF-I SDS did not correlate with 
systolic BP SDS as well. There was a weak positive correlation between IGF-I SDS and 
diastolic BP SDS at baseline and at 36 months, but the correlation coefficient was <0.3 
and therefore considered not to be clinically relevant.
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Discussion
In this study, we investigated whether GH treatment affected MMP-9 levels in short 
SGA children and whether changes in MMP-9 levels were related with changes in 
blood pressure during GH treatment. Plasma MMP-9 levels decreased significantly and 
progressively during 3 years of GH treatment to almost 50% of the level at baseline, 
whereas they remained unchanged in sex- and age-matched untreated SGA controls. 
After 3 years of GH treatment, plasma MMP-9 levels were significantly lower in the 
GH group than in the untreated SGA controls. After 3 years of GH treatment, systolic 
BP SDS had significantly decreased, whereas it had remained similar in the untreated 
SGA controls. MMP-9 levels did however not correlate with systolic or diastolic BP SDS 
at the various time points; neither did the changes in MMP-9 levels correlate with the 
changes in systolic and diastolic BP SDS. 
In our study, MMP-9 levels decreased during GH treatment. Likewise, in a study 
by Randeva et al. (13), GH-replacement in GH-deficient adults was accompanied by a 
progressive decrease in MMP-9 levels. The fact that 2 independent studies observed 
a reduction of MMP-9 during GH treatment suggests that GH treatment affects this 
parameter. This finding is of interest, since SGA and GH-deficiency have both been 
linked with an increased risk for the development of cardiovascular disease. Recently, 
our group showed that systolic blood pressure measured 6.5 years after cessation of 
GH treatment in young adults born SGA had remained lower than at start of GH treat-
ment in childhood (24). The systolic BP was also significantly lower compared with un-
treated short SGA adults. The mechanism by which this reduction was achieved is still 
unclear. In this paper we show that both MMP-9 levels and systolic BP decreased dur-
ing GH treatment. We could however not detect a relation between MMP-9 and blood 
pressure. This does not necessarily imply that the MMP system is not involved in blood 
pressure. There might be several explanations for the absence of this correlation. 
Firstly, blood pressure might not be high enough in our population of healthy SGA 
children to detect a correlation. Yasmin et al. (5) investigated the association between 
MMP-9 levels and blood pressure in 2 study groups and found the association to be 
weaker in a group of healthy individuals with a normal mean blood pressure than in 
a case-control study of hypertensive subjects. Secondly, besides MMP-9, other MMPs 
might play a role in remodelling the vascular tree. MMP-1 is another metalloprotein-
ase, which degrades collagen type I (2). Collagen type I has high tensile strength and 
rigidity (25). Hypertensive patients had lower MMP-1 levels (26), and thus, more col-
lagen type I in their hearts and vascular tree, than other types of collagen. Thirdly, the 
activity of the various MMPs can be affected by tissue inhibitors of metalloproteinases 
(TIMPs) (2). Lastly, atherosclerosis has a complex multifactorial pathogenesis in which 
inflammation and lipid levels also play a prominent role and this should be taken into 
account when interpreting our data.  
In another study, short SGA children also had a significantly higher systolic BP SDS 
than healthy controls (9). It has been questioned whether the reduction in systolic BP 
SDS during 6 years of GH treatment in this study was due to a reduction of anxiety af-
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ter repeated hospital visits rather than a true effect of GH treatment (9). In the present 
study, we confirm the previous finding that systolic BP SDS decreases on the longer 
term. In addition, we show that systolic BP SDS remained similar in untreated SGA 
controls, although the initial value was lower than in the GH-group. 
An unexpected finding was that systolic BP SDS significantly increased after 6 months 
of GH treatment. Since this increase was small, we are not sure if this should be regard-
ed as a true increase. Alternatively, a transient increase in systolic BP SDS might be the 
consequence of a temporary increase in extracellular and/or plasma volume after GH 
treatment as described in GH-deficient adults (27-29), though this observation was not 
accompanied by an increase in systolic BP in all studies (27, 28). Besides, the increase in 
systolic BP is most probably only an acute effect of GH treatment (28, 29). Data regard-
ing longitudinal changes in BP in GH-deficient children are very scarce (30). 
In conclusion, our data show that MMP-9 levels decreased by approximately 50 % 
during 3 years of GH treatment. Systolic BP SDS was significantly higher than zero at 
baseline, but decreased significantly on the longer term in the GH-group. In contrast, 
both MMP-9 levels and systolic BP SDS remained unchanged in the untreated sex- and 
age-matched SGA controls. Future research should be directed at the effects of GH 
treatment on other MMPs, such as MMP-1, and TIMPs, which can inhibit the activity 
of MMPs. 
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Abstract
Context: Alterations in the GH-IGF-I axis in short SGA children might be associated 
with abnormalities in bone mineral density (BMD) and body composition. In addition, 
birth weight has been inversely associated with diabetes and cardiovascular disease in 
adult life. Data on detailed body composition in short SGA children and long-term ef-
fects of GH treatment are very scarce.
Objective: To investigate effects of long-term GH treatment on body composition 
and BMD by Dual Energy X-Ray Absorptiometry (DXA) in short SGA children
Design: Longitudinal 6-year GH study with a randomized controlled part for 3 
years
Results: At baseline, fat percentage standard deviation score (SDS) and lumbar spine 
BMD SDS corrected for height (BMAD
LS
 SDS) were significantly lower than zero. Lean 
body mass (LBM) SDS adjusted for age was also reduced, but LBM adjusted for height 
(LBM SDS
height
) was not decreased. GH treatment induced a decrease in fat percentage 
SDS and an increase in BMAD
LS
 SDS. LBM SDS
height
 remained similar in GH-treated 
children, but deteriorated in untreated controls. When these untreated controls subse-
quently started GH treatment, their LBM SDS
height
 rapidly normalized to values compa-
rable with zero.
Conclusion: During long-term GH treatment in short SGA children, fat percentage 
SDS decreased and BMAD
LS
 SDS increased. These effects of GH treatment were most 
prominent in children who started treatment at a younger age and in those with greater 
height gain during GH treatment. LBM SDS
height 
remained around 0 SDS in GH-treated 
children, but declined to low normal values in untreated controls. 
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Introduction
Approximately 10 % of children born small-for-gestational-age (SGA) fail to show 
sufficient catch-up growth (1, 2). Growth hormone (GH) therapy in short children born 
SGA improves childhood growth and increases adult height (3-5). GH treatment for 
short children born SGA has recently been licensed (Food and Drug Administation 
(FDA), 2001 and European Agency for the Evaluation of Medicinal Products (EMEA), 
2003) and will thus be increasingly applied as a growth promoting therapy in short 
SGA children. 
Birth weight has been inversely associated with risk of diabetes mellitus type 2 and 
cardiovascular disease in adult life (6). It is well known that obesity is an important 
risk factor for the development of these diseases (7). Therefore, it is relevant to monitor 
body composition in this specific population. In children born SGA with spontane-
ous catch-up in weight, early development of adiposity has been reported (8). How-
ever, short children born SGA have a different phenotype. They have a lean appearance, 
which is confirmed by a low body mass index (BMI) SDS and a low sum of skinfolds 
SDS (9). On the other hand, short SGA children have lower IGF-I levels (4, 10, 11), and 
because abnormalities in body composition in growth hormone deficient children have 
previously been demonstrated (12), it might well be that body composition in short SGA 
children is also altered. However, data on detailed body composition in short SGA chil-
dren as well as the effects of GH treatment in this population are very scarce (13, 14). 
Besides, there are no data on the long-term consequences of GH treatment on body 
composition beyond the initial phase of catch-up growth during the first 2-3 years of 
GH treatment in SGA children. From a methodological point of view, it is remarkable 
that most studies investigating body composition in children receiving GH therapy did 
not adjust for the GH-associated catch-up in height (12-16). Consequently, these studies 
might have reported an underestimation of lean and fat mass for height and an overes-
timation of the effect of GH treatment on these parameters.   
There is increasing evidence that size at birth and in childhood may affect bone min-
eral density (BMD) and the risk of osteoporotic fracture in adulthood (17). In various 
animal models, the GH-IGF-I axis appeared to be an important factor  regarding the 
regulation of bone growth and BMD (14, 18-20). Since short SGA children have lower 
IGF-I levels (4, 10, 11), it is interesting to investigate their BMD, and the effects of long-
term GH treatment on this parameter.
In this paper, we report the 6-year longitudinal data of short SGA children partici-
pating in a randomized controlled GH study investigating body composition and BMD 
by Dual Energy X-Ray Absorptiometry (DXA). After the first 3 years, the untreated con-
trol group started GH treatment as well. In our study we expressed lean and fat mass as 
SD-scores adjusted for age and sex, and also as SD-scores adjusted for height and sex.  
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Subjects and methods
Subjects
The study group comprised 25 short prepubertal children born SGA. Inclusion criteria 
have previously been described (21). In short, the children were prepubertal, had a 
birth length and current height standard deviation score (SDS) below –2, did not show 
catch-up growth in height and had no growth failure caused by other disorders. None 
of the children were growth hormone deficient, which was defined as a GH peak <10 
µg/l during two GH stimulation tests. During the first 3 years of the study, all children 
remained prepubertal. Puberty was defined as Tanner breast stage > 2 for girls and a 
testicular volume > 4 ml for boys (22). The study was approved by the Medical Ethics 
Committees. Written informed consent was obtained from the parents or custodians 
of each child. 
Study design
This study was an open-labelled study with a randomized control group for 3 years. 
After 3 years, the initially untreated SGA controls started GH treatment as well. Before 
randomisation, the children were stratified according to chronological age of the 
children (3.00-5.50 years versus 5.50-7.99 years) and height of the parents (height of 
both parents above –2.00 SDS versus height of at least one parent below –2.00 SDS). 
Subsequently, the patients were randomly assigned to either the GH-group (2/3 of 
children) or the control group (1/3 of children). The GH-group started immediately 
with GH treatment at a dose of 1 mg/m2  body surface area (BSA)·day. The control 
group remained untreated for 3 years followed by GH treatment with the same dose as 
the GH-group. Biosynthetic GH (r-hGH Norditropin®, Novo Nordisk A/S, Bagsværd, 
Denmark) was given subcutaneously once daily at bedtime. Three-monthly, the GH 
dose was adjusted to the calculated BSA. 
DXA measurements
During 6 years, a Dual-Energy X-ray Absorptiometry scan (DXA, type Lunar DPX-L, GE 
Healthcare) was yearly performed in a group of 30 SGA children living near Rotterdam 
(20 of the GH-group and 10 of the control group). Lean body mass (LBM), total fat 
mass (FM), fat percentage (% fat) and lumbar spine bone mineral density (BMD
LS
) 
were measured. To correct for bone size, we calculated bone mineral apparent density 
(BMAD) of lumbar spine (gram/cm3) with the model BMAD
LS
= BMD
LS
 x [4/(π x width)] 
(23). All values were transformed into SD-scores for sex and chronological age using 
Dutch reference values for children (24, 25). 
Since body composition, particularly LBM, is strongly related to height, LBM and FM 
expressed as SD-score for age and sex might result in an underestimation in short stat-
ure. Besides, we were interested to know whether GH had an additional effect on LBM 
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and FM beyond the effects due to catch-up in height. For these reasons, LBM and FM 
were also expressed as SD-score for height and sex. These height-adjusted SD-scores 
were calculated as follows. Heights of the children of the reference group (24) were 
plotted against the corresponding DXA parameters (LBM, FM). The SD
height
-scores, that 
were computed using these reference values, compared the DXA parameters of the SGA 
children with those of children with the same height and sex.  Reference values were 
obtained using the same instrumentation and software (24, 25). 
This paper presents 6-year data of this randomized controlled study. The prelimi-
nary findings on 1-year changes in body composition and 3-year changes in BMD were 
previously published (14, 21). 
Statistics
Five children were excluded from analysis. These children received gonadotropin 
releasing hormone agonist (GnRHa) treatment because of relative early puberty and 
an adult height prognosis < -2 SDS (4 of the GH-group and 1 of the control group). 
During the total duration of the study there were only 3 missing values (1 at 6 years in 
the GH-group; 1 at 3 years and 1 at 5 years in the control group). Because the group for 
which DXA scans were available was a part of the original cohort, we tested whether 
there was any selection bias. Gestational age, birth weight SDS, birth length SDS, age, 
sex, height SDS, BMI SDS, IGF-I SDS and IGFBP-3 SDS were comparable for children 
who had DXA scans compared with children who had not (data not shown). Data 
are expressed as mean (SD). SD-scores were compared with zero using Student’s one 
sample t-test. Differences between groups at the various time points, differences in 
changes during the first 3 years of the study (0-3 yr for both groups) and differences 
in changes during the first 3 years of GH treatment (0-3 yr for GH-group vs. 3-6 yr 
for control group) were tested using independent Student’s t-test. Differences between 
points in time were tested by paired Student’s t-tests. Correlations were analysed using 
Spearman’s correlation coefficient. Backward multiple regression analysis was used to 
assess predictors for the changes in various parameters during 3 years of GH treatment. 
Level of significance was determined at p<0.05. Statistics were performed using the 
computer statistical package SPSS (version 11.0.1; SPSS Inc. Chicago, IL) for Windows.
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Results
Baseline characteristics
Table 1 shows the baseline characteristics of the study groups. Gestational age, 
anthropometric parameters at birth and before entering the study, age, sex, IGF-I and 
IGFBP-3 levels were not significantly different between groups.   
Table 1. Clinical characteristics at baseline
SGA GH 
group
SGA Control group
N 16 9
Sex (m/f) 7/9 2
Gestational age (wks) 35.6 (3.1) 35.9 (2.5)
Birth weight SDS -2.2 (1.4) -2.9 (0.9)
Birth length SDS -3.3 (1.3) -3.3 (1.3)
Age (yr) 6.1 (1.5) 5.9 (1.7)
Height SDS -3.0 (0.7) -3.2 (0.5)
BMI SDS -1.0 (1.0) -1.2 (0.9)
IGF-1 SDS -0.4 (1.1) -0.1 (1.2)
IGFBP-3 SDS -1.2 (1.1) -0.9 (1.4)
SDS= standard deviation score
BMI= body mass index
IGF-1= insulin-like growth factor 1
IGFBP-3= insulin-like growth factor binding protein 3
Body composition
At baseline, both groups had a significantly reduced mean LBM SDS adjusted for age 
and sex (LBM SDS
age
; Table 2). LBM SDS
age
 increased rapidly after start of GH treatment 
but remained significantly lower than zero up to 6 years after start of GH treatment. 
The untreated randomized control group showed a further decline in LBM SDS
age
 
(p<0.01), whereas height SDS did not decrease. After start of GH treatment, the initially 
untreated control group showed a catch-up in LBM SDS
age
, which was comparable in 
magnitude with the catch-up in LBM SDS
age
 during the first 3 years of treatment in the 
GH-group (p=0.209). 
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Table 2. Six year changes in LBM SDSage, body fat % SDSage and height SDS of the GH- and control 
group
Because either of the groups SGA children were short for age at baseline (Table 2), LBM 
expressed as SD-score for age and sex might result in an underestimation. We therefore 
expressed LBM also as SD-score adjusted for height and sex (LBM SDS
height
; Table 3). 
Importantly, LBM SDS
height
 at baseline was not significantly reduced for all groups. 
 
 SGA GH 
group 
SGA Control group 
  Untreated 0-3 yr GH 3-6 yr 
LBM SDSage    
Baseline -2.0 (0.3) 3 -2.2 (0.4) 3  
1 year -1.4 (0.4) 3, ¶, c -2.3 (0.3) 3  
2 year -1.1 (0.5) 3, ¶, c -2.6 (0.4) 3, #  
3 year -1.1 (0.5) 3, ¶, c -2.8 (0.4) 3, #  -2.8 (0.4) 3, # 
4 year -1.1 (0.5) 3, ¶, c  -2.3 (0.5) 3 
5 year -1.0 (0.6) 3, ¶, b  -2.0 (0.5) 3 
6 year -0.9 (0.7) 3, ¶, a  -1.6 (0.7) 3, # 
    
% Body fat SDS    
Baseline -1.0 (0.8) 3 -0.9 (1.0) 1  
1 year -1.7 (0.8) 3, #, a -0.8 (0.8) 1  
2 year -1.4 (0.8) 3, *, a -0.5 (1.1)  
3 year -1.5 (0.7) 3, # -0.7 (1.3)  -0.7 (1.3) 
4 year -1.5 (0.6) 3, *  -1.1 (0.9) 2 
5 year -1.6 (0.7) 3, #  -1.2 (1.2) 1 
6 year -1.6 (0.7) 3, *  -1.1 (1.1) 1 
    
Height SDS    
Baseline -3.0 (0.7) 3 -3.2 (0.5) 3  
1 year -2.0 (0.8) 3, ¶, b -3.2 (0.4) 3  
2 year -1.5 (0.9) 3, ¶, c -3.1 (0.4) 3  
3 year -1.3 (0.9) 3, ¶, c -3.1 (0.4) 3  -3.1 (0.4) 3 
4 year -1.2 (0.9) 3, ¶, c  -2.6 (0.5) 3, # 
5 year -1.1 (1.0) 3, ¶, a  -2.2 (0.7) 3, # 
6 year -1.0 (1.1) 2, ¶, a   -1.9 (0.7) 3, ¶ 
   
All values expressed as mean (SD) 
1 = p<0.05 compared to zero 
2 = p<0.01 compared to zero  
3 = p<0.001 compared to zero 
* = p<0.05 versus baseline 
# = p<0.01 versus baseline 
¶ = p<0.001 versus baseline 
a = p<0.05 compared to control group 
b = p<0.01 compared to control group  
c = p<0.001 compared to control group 
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Whereas LBM SDS
height
 did not significantly change for the GH-treated children up to 6 
years, it tended to decrease in the untreated ones and became significantly lower than 
zero after 2 years. As a result, LBM SDS
height
 of the GH-group was significantly higher 
than that of the untreated control group after 2 and 3 years of GH treatment (p<0.05 and 
p<0.01, respectively). When the initially untreated SGA controls started GH treatment, 
they showed a rapid increase in their LBM SDS
height
, resulting in a similar LBM SDS
height
 
as the GH-group. 
Table 3. Six year changes in LBM SDSheight and fat mass SDSheight of the GH- and control group
 
 SGA GH 
group 
SGA Control group 
  Untreated 0-3 yr GH 3-6 yr 
LBM SDSheight    
Baseline 0.5 (2.1)  -1.1 (2.5)  
1 year 0.2 (1.3) -1.1 (2.0)  
2 year -0.1 (0.9) a -1.9 (1.7) 1  
3 year -0.3 (0.9) a -2.0 (1.4) 2  -2.0 (1.4) 2 
4 year -0.5 (0.9) 1  -1.0 (0.8) 2 
5 year -0.4 (0.9)  -0.5 (0.8) 
6 year -0.3 (0.9)  -0.4 (0.8) 
    
Fat mass SDSheight    
Baseline -1.3 (1.3) 2 -1.5 (1.6) 1  
1 year -2.1 (1.1) 3, # -1.4 (1.4) 1  
2 year -1.6 (1.0) 3 -1.1 (1.4)   
3 year -1.7 (1.0) 3 -1.2 (1.7)  -1.2 (1.7) 
4 year -1.7 (0.8) 3  -1.5 (1.2) 2 
5 year -1.7 (0.9) 3  -1.4 (1.4) 1 
6 year -1.8 (0.6) 3  -1.3 (1.3) 1 
   
All values expressed as mean (SD) 
1 = p<0.05 compared to zero 
2 = p<0.01 compared to zero  
3 = p<0.001 compared to zero 
# = p<0.01 versus baseline 
a = p<0.01 compared to control group 
 
Before GH treatment, all children had a body fat percentage SDS significantly below 
zero (Table 2). During the first 3 years of GH treatment, the GH-group showed a 
significant decrease in % body fat SDS, which remained at the same level up to 6 years 
of GH treatment. When GH treatment was started in the initially untreated control 
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children, these children also showed a reduction in their % body fat SDS, which was 
comparable with the reduction during the first 3 years of the GH-group.
At baseline, fat mass adjusted for height and sex (fat mass SDS
height
) was significantly 
lower than zero in all children (Table 3). Fat mass SDS
height 
decreased significantly dur-
ing the first year of GH treatment in the GH-group. After 6 years of GH treatment, fat 
mass SDS
height
 was still significantly lower than zero. 
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Bone mineral density 
To correct for short stature, we calculated lumbar spine bone mineral apparent density 
SDS (BMAD
LS
 SDS). At baseline, BMAD
LS
 SDS was significantly lower than zero (Table 
4). Compared to BMD
LS
 SDS, BMAD
LS
 SDS was only moderately reduced. The GH-group 
showed a significant increase in their BMAD
LS
 SDS after 2 years of GH treatment, 
which was maintained up to 6 years after start of GH treatment. The initially untreated 
control group showed no increase in their BMAD
LS
 SDS after start of GH treatment.
Table 4. Six year changes in lumbar spine bone mineral density (BMDLS) and bone mineral apparent 
density (BMADLS) SDS of the GH- and control group
 
 SGA GH 
group 
SGA Control group 
  Untreated 0-3 yr GH 3-6 yr 
BMDLS SDS    
Baseline -1.5 (1.0) 3 -1.4 (0.8) 2  
1 year -0.8 (0.8) 2, ¶ -1.3 (0.8) 2  
2 year -0.4 (0.8) ¶, a -1.3 (0.8) 2  
3 year -0.1 (0.6) ¶, b -1.0 (0.7) 2, *  -1.0 (0.7) 2, * 
4 year -0.2 (0.7) ¶, a  -0.9 (0.6) 2, * 
5 year -0.3 (0.6) ¶  -0.8 (0.4) 2, * 
6 year -0.3 (0.7) ¶, a  -0.9 (0.5) 2, # 
    
BMADLS SDS    
Baseline -0.7 (1.3) 1 -0.6 (0.7) 1  
1 year -0.4 (1.0) -0.6 (0.8)  
2 year -0.3 (1.0) # -0.3 (1.0)  
3 year 0.1 (0.9) ¶ -0.3 (0.8)  -0.3 (0.8) 
4 year 0.0 (1.1) ¶  -0.5 (0.6) 1 
5 year -0.2 (0.9)  -0.1 (0.7) 
6 year -0.2 (1.0) *  -0.5 (0.8) 
   
All values expressed as mean (SD) 
1 = p<0.05 compared to zero 
2 = p<0.01 compared to zero  
3 = p<0.001 compared to zero 
* = p<0.05 versus baseline 
# = p<0.01 versus baseline 
¶ = p<0.001 versus baseline 
a = p<0.05 compared to control group 
b = p<0.01 compared to control group  
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Changes during the first 3 years of the study
We also compared the changes in the DXA parameters during the first 3 years of the 
study between the 2 study groups. GH-treated children had a significantly higher gain 
in LBM SDS
age
 (p<0.001) and BMD
LS
 SDS (p<0.001), and a larger reduction in fat % SDS 
(p<0.01) and fat mass SDS
height 
(p<0.05) than untreated controls. The changes in LBM 
SDS
height
 during the first 3 years of the study were not significantly different between 
both groups. The increase in BMAD SDS during the first 3 years of the study tended to 
be higher in the GH-group than the control group (p=0.084).
Correlations
During 3 years of GH treatment, the gain in BMD
LS
 SDS (r=0.71; p<0.001), the gain 
in BMAD
LS
 SDS (r=0.63; p<0.01), the reduction in body fat percentage SDS (r=-0.41; 
p<0.05) and the gain in LBM SDS
age
 (r=0.42; p<0.05) were all strongly correlated with 
the gain in height SDS. As expected, the gain in LBM corrected for height and sex (LBM 
SDS
height
) was not correlated with the gain in height SDS. The association between the 
reduction in fat mass SDS
height
 and the gain in height SDS was comparable with the 
association between the change in body fat percentage SDS and the gain in height SDS, 
but did not reach statistical significance (r= -0.35; p=0.098).
Multiple regression analysis
The gain in height SDS during 3 years of GH treatment was associated with age at start 
of GH treatment (β= -0.10; p=0.012), height at start of GH treatment (β=0.22; p=0.083) 
and sex (β= -0.27; p=0.078), regardless of puberty. This model explained 41% of the 
variance of the gain in height SDS during 3 years of GH treatment.
The gain in LBM SDS
height
 during 3 years of GH treatment was associated with age at 
start of GH treatment (β= 0.26; p<0.01) and LBM SDS
height
 at start of GH treatment (β= 
-0.72; p<0.001), regardless of sex and puberty. This model explained 91% of the vari-
ance of the gain in LBM SDS
height
 during 3 years of GH treatment.
The reduction in fat mass SDS
height
 during 3 years of GH treatment was associated 
with age at start of GH treatment (β= -0.24; p<0.01), fat mass SDS
height
 at start of GH 
treatment (β= 0.50; p<0.001), regardless of sex and puberty. The explained variance of 
the reduction in fat mass SDS
height
 of this model was 57%. A regression model with body 
fat percentage SDS instead of fat mass SDS
height
 showed comparable results.
The gain in BMAD
LS
 SDS during 3 years of GH treatment was associated with age 
at start of GH treatment (β= -0.16; p<0.05), BMAD
LS
 SDS at start of GH treatment (β= 
-0.30; p<0.05), regardless of sex and puberty. This model explained 52% of the variance 
of the gain in BMADLS SDS during 3 years of GH treatment.
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Discussion
This paper shows 6-year longitudinal results of GH treatment on body composition 
and BMD measured by DXA in short SGA children during a study with a randomized 
controlled part for 3 years. Our longitudinal cohort is the only group of short SGA 
children in which these parameters have been studied by DXA over the long term. We 
show that short SGA children have a significantly reduced body fat % SDS and BMD at 
baseline. Lean mass adjusted for age and sex was also reduced, but when it was adjusted 
for height and sex (LBM SDS
height
), it was not. GH treatment induced a decrease in body 
fat % SDS and an increase in BMAD
LS
 SDS during the first years of treatment, which was 
maintained at the same level up to 6 years after start of GH treatment. LBM SDS
height
 
remained at the same level in GH-treated children, but deteriorated in the untreated 
control group. When the initially untreated control group started GH treatment, their 
LBM SDS
height
 rapidly normalized to values comparable with zero. Children, who grew 
better during 3 years of GH treatment, also had higher gains in their BMAD
LS
 SDS and 
larger reductions in body fat % SDS. Finally, a younger age at start of GH treatment was 
associated with a larger decline in body fat % SDS and a higher gain in height SDS and 
BMAD
LS
 SDS during GH treatment. 
At baseline, both lean mass and body fat % were significantly lower compared with 
normal children of the same age and sex. The reduced LBM at baseline appeared to 
be caused by short stature, since lean mass adjusted for height and sex (LBM
height
 SDS) 
was not reduced. On the other hand, short SGA children did have a reduced fat mass 
for their short stature, which was indicated by their reduced body fat % SDS and the 
reduced fat mass adjusted for height and sex (fat mass SDS
height
). Therefore, it seems 
unlikely that development of childhood obesity in short SGA children is responsible 
for the association between low birth weight and adult cardiovascular disease and dia-
betes. It might be that SGA children with spontaneous catch-up in weight are the ones 
at risk, rather than SGA children that remain short (26). On the other hand, we cannot 
rule out that  other mechanisms are responsible for the negative association between 
birth weight and CVD and diabetes in adult life, such as insulin resistance or low IGF-I 
levels levels (27, 28). Although the short SGA children in our study were not growth 
hormone deficient, they did have relatively low IGF-I levels (21). Another important as-
pect is the distribution of fat mass in the body, which we did not analyze in this study. 
It has been demonstrated that central obesity, as opposed to peripheral obesity, confers 
the highest risk for cardiovascular disease (7). Future studies should be directed at this 
issue.
During GH treatment, both body fat % SDS and fat mass SDS
height
 declined. The great-
est reduction was seen during the first year of GH treatment causing a significant dif-
ference compared with the untreated controls after 1 year. Children, who were younger 
and had a higher fat mass SDS
height
 at start of GH treatment, showed a greater reduction 
in their fat mass SDS
height
 during 3 years of GH treatment. The same associations were 
seen when we used body fat % SDS as the dependent variable. Thus, it might be more 
favourable to start GH treatment at a younger age to obtain a larger reduction in body 
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fat %, although most SGA children already had a low body fat % SDS at baseline. 
Most studies investigating the effects of GH treatment on body composition in chil-
dren did not adjust for the increased height which accompanies GH therapy and thus, 
were unable to study the effects of GH treatment beyond the increases of muscle and 
fat mass as a consequence of catching-up in height (12-16). In contrast to lean mass 
adjusted for age and sex (LBM SDS
age
), lean mass adjusted for height and sex (LBM SD-
S
height
) did not increase during GH treatment. Thus, GH did not result in an increase of 
lean mass beyond the normal increase as consequence of a gain in height. 
Notably, the untreated children had a further decline of their LBM SDS
age
 to almost 
–3 SDS, without significant changes in their height SDS. Also, lean mass  adjusted for 
height and sex (LBM SDS
height
) tended to decrease over time in the untreated controls 
resulting in a significantly lower LBM SDS
height
 after 3 years compared with GH-treated 
children. Thus, lean mass in the untreated SGA children declined, whereas it was pre-
served in the GH-treated children. A possible explanation for this decline might be 
that short SGA children have a reduced food intake, which improves during GH treat-
ment (14). Singhal et al. reported an inverse association between birth weight and lean 
mass, which was stronger in older children (29). Our data are in line with this report as 
they show that older SGA children have indeed a lower lean mass SDS compared with 
younger SGA children. The reduced muscle mass might also have played a role in the 
reduced insulin sensitivity which has been found in a comparable group of short SGA 
children with  the same age (27, 30).
When lean mass was adjusted for age and sex only, the initially untreated children 
tended to have a lower lean mass after 3 years of GH treatment compared to the GH-
group after 3 years of GH treatment. However, when lean mass was adjusted for height 
and sex (LBM SDS
height
), it appeared that the initially untreated children showed a rapid 
catch–up in their LBM SDS
height
 during 3 years of GH treatment, resulting in levels com-
parable with the GH-group after 3 as well as 6 years of GH treatment. The difference 
between LBM corrected for age and LBM corrected for height is explained by the fact 
that the control children also gained less height, because they were older at start of GH 
treatment. LBM SDS
height
 increased in the initially untreated children during GH treat-
ment, whereas no change was observed during the first 3 years in the GH-group. This 
might be explained by the fact that the increase in LBM SDS
height
 during GH treatment 
is higher when the baseline level was lower, as was shown in the multiple regression 
analysis.
Bone mineral density SDS at baseline was significantly lower than zero. However, 
DXA measures an areal density (g/cm2), which is obtained by dividing bone mineral 
content (BMC, gram) by the projected bone image (area, cm2). Therefore, DXA may 
underestimate BMD in children with short stature. A widely used and validated model 
to correct for bone size is BMAD (23). This is a better parameter for assessing bone 
mineralization in short children. In contrast to BMD
LS
 SDS, BMAD
LS
 SDS was only 
moderately reduced at baseline. In our study, GH treatment resulted in an increase in 
BMAD
LS
 SDS after 3 years of GH treatment. The change in BMAD
LS
 SDS during 3 years 
of GH treatment correlated strongly with the increase in height SDS. Thus, the chil-
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dren with the best growth response also had the highest gain in their bone mineral 
density SDS. Multiple regression analysis showed that children who were older at start 
of GH treatment gained less BMAD
LS
 SDS than children who started GH therapy at an 
earlier age. Our data suggest that starting GH at an earlier age is more favourable, be-
cause it is accompanied by a higher gain in BMAD
LS
 SDS. Since lean mass adjusted for 
height (LBM SDS
height
) did not increase during GH treatment, it seems that the increase 
in BMAD cannot be regarded as a consequence of gaining more muscle mass. IGF-I, 
ALS (Acid Labile Subunit) and IGFBP-3 play a prominent role in the regulation of bone 
growth and density(18-20). In short SGA children, IGF-I and IGFBP-3 levels are low and 
increase during GH treatment (4, 11, 21). In addition, a better nutritional intake and in-
creased physical activity during GH treatment, as was reported by parents, might have 
played a role in the increase in BMD (14). 
In conclusion, short SGA children have a low body fat percentage and BMD. Long-
term GH treatment in short children born SGA causes a decrease in body fat percentage 
and body fat adjusted for height as well as an increase in BMD. Lean mass increased 
along with height in GH-treated children but GH treatment did not result in an incre-
ment of lean mass beyond the normal growth-related increase. Lean mass adjusted 
for height and sex remained around 0 SDS in GH-treated children, but declined to low 
normal values in untreated controls. The effects of GH treatment on body fat and BMD 
were most prominent in children who started GH treatment at a younger age with a 
higher gain in height SDS during 3 years of GH treatment. Our  study shows that it is 
necessary to correct DXA parameters for height in order to obtain a good interpretation 
of body composition and bone mineral density in short SGA children at baseline as well 
as during GH treatment.
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Abstract
Context: Growth hormone (GH) treatment reduces insulin sensitivity (Si). For small-
for-gestational-age (SGA) subjects, who might have an increased risk to develop car-
diovascular disease and type 2 diabetes, it is still uncertain how Si, ß-cell function and 
body composition change over time after stop of GH treatment.
Objective: To investigate longitudinal changes in Si, ß-cell function and body com-
position after stop of long-term GH treatment
Design: Longitudinal study
Patients: 48 SGA adolescents were studied at adult height, while still on GH, and 6 
months after GH stop, and compared with 38 AGA controls 
Outcome measure: Paired measurements of Si and ß-cell function, assessed by fre-
quently sampled intravenous glucose tolerance tests (FSIGT), and body composition, 
measured by dual energy x-ray absorptiometry (DXA). 
Results: After stop of GH, Si (p=0.006), glucose effectiveness (Sg; p=0.009) and ß-
cell function (disposition index= DI; p=0.024) increased, whereas insulin secretion 
(AIR; NS) decreased. Fat percentage increased (p<0.0005), and lean body mass (LBM) 
decreased (p<0.0005), but fat distribution remained unaltered and body composition 
remained within the normal range. Compared with AGA controls, Si was lower during 
GH and became similar after GH stop, AIR was higher at both time points, and Sg and 
DI became higher. 
Conclusions: The GH-induced lower insulin sensitivity in SGA adolescents increases 
after stop of long-term GH treatment and becomes similar to that of AGA controls. 
Discontinuation of GH treatment is, however, also associated with an increase in per-
cent body fat and a decrease in LBM, without changes in fat distribution.  
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Introduction
It is well known that growth hormone (GH) treatment reduces insulin sensitivity. Since 
short children born small-for-gestational-age (SGA) have a lower insulin sensitivity 
than normal children prior to start of GH treatment, concern has been expressed 
regarding the long-term effects of GH-treatment on the insulin-glucose homeostasis 
of SGA children (1-3).  
Previously, we showed that the insulin response during an oral glucose tolerance test 
(OGTT) normalized after stop of GH treatment (4). An OGTT is, however, dependent 
on the uptake of glucose in the digestive system and does not provide any information 
regarding changes in insulin sensitivity and ß-cell function. 
Two studies reported conflicting results regarding the change of insulin sensitivity 
after discontinuation of GH treatment (5, 6). In the first study in 9 short SGA children, 
the observed decrease in insulin sensitivity during GH treatment was reversible (5). 
In the second study in 12 children, insulin sensitivity did not recover after stop of GH 
treatment (6). Both studies investigated insulin sensitivity after stop of GH treatment, 
but before adult height was achieved. Besides, in one study it was unclear whether some 
children had already entered puberty (5), which can reduce insulin sensitivity as well 
(7, 8). Furthermore, it is questionable if the number of subjects was sufficient to draw 
definite conclusions. Thus, up to date, it is not known how insulin sensitivity and se-
cretion change longitudinally in SGA adolescents after adult height has been attained 
and GH treatment has been stopped. Regarding body composition, there are no data 
on changes after stop of GH treatment.
We hypothesized that the GH-induced reduction in insulin sensitivity recovers after 
stop of GH treatment and that the changes in body composition, if any, would be lim-
ited. We performed paired measurements of insulin sensitivity and ß-cell function, us-
ing the frequently sampled intravenous glucose tolerance test (FSIGT) in 48 GH-treated 
SGA adolescents, at near adult height (AH) and 6 months after cessation of GH. Be-
sides, we measured body composition by dual energy x-ray absorptiometry (DXA) at the 
same time points. In addition, we compared their data with those of 38 AGA controls.
Subjects and methods
Subjects
The study group comprised 48 adolescents born SGA, who participated in a GH-trial, 
of which the inclusion criteria have previously been described (9). In short, the children 
were prepubertal, had a birth length and height standard deviation score (SDS) below 
–2.0, did not show catch-up growth in height and had no growth failure caused by 
other disorders. Once daily at bedtime, 1 mg biosynthetic GH (r-hGH Norditropin®, 
Novo Nordisk A/S, Bagsværd, Denmark) per square meter body surface area (BSA) was 
given subcutaneously. Every three months, the GH dose was adjusted to the calculated 
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BSA. GH treatment was discontinued when height velocity dropped below 0.5 cm over 
the last 6 months and/or bone age was ≥ 15 years for girls and ≥ 16.5 years for boys. 
SGA subjects were compared with 38 healthy normal-statured AGA (defined as birth 
length and height >-2 SDS (10, 11)) controls, which were matched for gestational age 
and sex. The GH trial and the current follow-up study were approved by the Medical 
Ethics Committees. Written informed consent was obtained from all controls and 
subjects and, if they were younger than 18 years, also from the parents or custodians 
of each adolescent.
Study design
Subjects were studied twice after an overnight fast: (i) at near adult height, while still 
on GH, and (ii) 6 months thereafter, without GH. Standing height and weight were 
measured and body mass index (BMI) was calculated. Height and BMI were expressed 
as SDS adjusting for sex and age according to Dutch reference data (10, 12). A modified 
frequently sampled iv glucose tolerance test (FSIGT) with tolbutamide was performed, 
as previously described (13, 14). Insulin sensitivity (Si), glucose effectiveness (Sg), acute 
insulin response (AIR) and disposition index (DI) were calculated using Bergman’s 
MINMOD MILLENNIUM software (15). Insulin sensitivity quantifies the capacity of 
insulin to promote glucose disposal and glucose effectiveness reflects the capacity of 
glucose to mediate its own disposal. The acute insulin response, an estimate of insulin 
secretory capacity, was measured as the area under the curve from zero to ten minutes 
corrected for baseline insulin levels. Disposition index equals AIR*Si and indicates the 
degree of glucose homeostasis. 
Body composition was measured with dual-energy x-ray absorptiometry scans on 
one machine (DXA, type Lunar Prodigy, GE Healthcare, Chalfont St Giles, UK). Lean 
body mass (LBM), fat mass (FM) and fat percentage (% fat) were determined. Fat per-
centage was transformed into SD-scores for sex and age using Dutch reference values 
(16, 17). Since body composition is strongly related to height, LBM and FM expressed 
as SD-score for age and sex might result in an underestimation in case of short stature. 
Therefore, LBM and FM were expressed as SD-score for height and sex. Height-adjusted 
SD-scores were calculated as previously described (18).
Assays
All serum glucose levels were determined on a VITROS analyser 750 (Orthoclinical 
Diagnostics, Johnson&Johnson Company, Beerse, Belgium). All serum insulin levels 
were measured by IRMA (Medgenix, Biosource Europe, Nivelles, Belgium). The 
intra-assay coefficient of variation (CV) was 2% to 4.7% (19-405 pmol/l) and the inter-
assay CV was 4.2% to 11.3% (32-375 pmol/l). All assays were performed in one central 
laboratory. 
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Statistics
To normalize the distribution, all FSIGT parameters were logarithmically transformed 
prior to analyses. With respect to body composition data, a value of –2 to 2 SDS 
corresponds with a normal body composition corrected for age and sex (SDS
age
) or 
height and sex (SDS
height
). To test the time effect of discontinuation of GH treatment 
on FSIGT and body composition parameters, mixed model analyses of variance were 
performed. There were no interactions between sex and time and oral contraceptive 
use and time. Therefore, these data were not entered in the model. Differences between 
SGA subjects and controls were tested by one-way analysis of variance (ANOVA) with 
an LSD post-hoc test. Clinical data are presented as mean (SD), model estimates as 
geometric mean (95% confidence interval) for FSIGT parameters, and mean (95% 
confidence interval) for body composition data. Level of significance was determined at 
p<0.05. Statistics were performed using the computer statistical package SPSS (11.0.1; 
SPSS Inc., Chicago, IL).
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Results
Clinical characteristics
Table 1 shows the clinical characteristics of the SGA subjects and AGA controls at 
various time points. SGA subjects had a mean age of 8.6 years at start of GH treatment 
and 16.1 years at stop of GH treatment. After a mean duration of 7.5 years of GH 
treatment, height had increased from –2.8 SDS at start of GH treatment to –1.3 SDS at 
adult height (AH).  
Table 1. Characteristics at birth, at start and at stop of GH treatment
 
 
  
SGA AGA controls P-value 
SGA vs AGA 
    
N 48 38  
Sex (m/f) 18/30 14/24 0.950 
Gestational age (wks) 36.6 (3.3) 35.5 (3.5) 0.132 
Birth weight SDS -2.4 (1.0)* -0.1(1.2) <0.0005 
Birth length SDS -3.0 (1.5)* -0.3 (1.0) <0.0005 
    
Age at start of GH treatment (yrs) 8.6 (2.4) N/A  
Height SDS at start of GH treatment -2.8 (0.7)* N/A  
Age at current study (yrs) 16.1 (1.3) 19.2 (0.9) <0.0005 
Adult height SDS -1.3 (0.8)* -0.3 (1.1) <0.0005 
GH duration (yrs) 7.5 (1.7) N/A  
    
SDS = standard deviation score  
*= p<0.0005 versus zero SDS 
N/A = not applicable 
 
Longitudinal changes in insulin sensitivity and ß-cell function
Figure 1 shows the data of the serial FSIGT tests at stop of GH treatment (SGA at stop 
GH) and 6 months thereafter (SGA after stop GH) in comparison with AGA controls. Si 
increased significantly after stop of GH treatment (Fig. 1A: 3.8 (3.3-4.4) to 5.1 (4.2-6.3) x 
10-4/min-1 (mU/l); p=0.006). Si was significantly lower in SGA subjects at stop of GH than 
in AGA controls (p=0.001), but became comparable after GH treatment was stopped. 
Also, Sg improved significantly after stop of GH treatment (Fig. 1C: 1.5 (1.3-1.8) to 1.9 
(1.8-2.1) x 10-2/min-1 (mg/d); p=0.009), and became significantly higher than Sg in AGA 
controls (p=0.024). After stop of GH treatment, insulin secretion decreased (Fig. 1B: 699 
(577-848) to 623 (514-754) mU/l; p=0.130) and disposition index increased significantly 
CHAPTER 6
123
(Fig. 1D: 2561 (2063-3178) to 3258 (2768-3835); p=0.024). Compared with AGA controls, 
SGA subjects had a significantly higher insulin secretion at and 6 months after stop of 
GH (p<0.0005), and a significantly higher DI 6 months after stop of GH (p=0.004). 
 
Figure 1. Longitudinal changes in FSIGT parameters of SGA adolescents from stop of GH treatment to 
6 months thereafter in comparison with AGA controls. A: Insulin sensitivity; B: Insulin secretion; C: 
Glucose effectiveness; D: Disposition index. 
Si= insulin sensitivity. AIRg= acute insulin response to glucose. Sg= glucose effectiveness. DI= dispo-
sition index. NS= not significant
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Longitudinal changes in body composition
 
Table 2 shows the changes in body composition from stop (SGA at stop GH) to 6 months 
after stop of GH treatment (SGA after stop GH). There was a significant increase in fat 
percentage SDS and fat mass corrected for height and sex (p<0.0005), and a significant 
decrease in lean body mass corrected for height and sex (p<0.0005). Trunk to total 
fat mass ratio did not significantly change and remained within the normal range at 
both time points. Body composition was comparable with the AGA controls, with the 
exception of a higher trunk to total fat mass ratio in SGA subjects at stop of GH. Body 
mass index (BMI) SDS did not change after discontinuation of GH. 
Table 2. Longitudinal changes in body composition after stop of GH treatment 
 
 SGA at stop GH SGA after stop GH P-value 
at vs. after 
stop GH 
AGA 
     
Fat percentage SDS -0.20 
(-0.53  –  0.12) 
0.14 
(-0.16  –  0.44) 
<0.0005 0.26 
(-0.06 – 0.58) 
Fat mass SDSheight -0.04 
(-0.32  –  0.23) 
0.25 
(-0.01  –  0.49) 
<0.0005 0.30 
(0.01 – 0.60) 
Lean body mass SDSheight 0.06 
(-0.27 –  0.39) 
-0.21 
(-0.53  –  0.12) 
<0.0005 -0.41 
(-0.80 – -0.03) 
Trunk fat/total fat ratio 0.50# 
(0.48  -  0.51) 
0.49 
(0.48  -  0.50) 
0.158 0.47 
(0.45 – 0.49) 
BMI SDS 0.05 
(-0.20  –  0.29) 
0.03 
(-0.22  –  0.27) 
0.648 -0.01 
(-0.40 – 0.38) 
     
Values are represented as mean (95 percent confidence interval) 
# = p<0.01 vs. AGA 
SDS= standard deviation score adjusted for age and sex 
SDSheight= standard deviation score adjusted for height and sex 
 
Discussion
In this paper we report longitudinal changes in insulin sensitivity, ß-cell function and 
body composition in SGA adolescents from stop to 6 months after stop of GH treatment 
in comparison with AGA controls. Insulin sensitivity was significantly reduced in SGA 
subjects at stop of GH, but increased significantly after stop of GH treatment to a 
similar value as in AGA controls. Insulin secretion decreased compensatory after stop 
of GH, but remained significantly higher than in AGA controls. Glucose effectiveness 
increased significantly after stop of GH treatment and became higher than that of 
controls. Disposition index, which indicates how well the ß-cells compensate for 
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lower values of insulin sensitivity, improved after stop of GH treatment, reaching a 
higher value than controls. Regarding body composition, fat percentage SDS and fat 
mass adjusted for height and sex increased significantly after stop of GH, whereas lean 
body mass adjusted for height and sex decreased significantly, but the values remained 
within the normal range.  
This is the first study describing serial measurements of insulin sensitivity and se-
cretion in SGA subjects at stop and 6 months after stop of GH treatment at attainment 
of adult height. Our data are in contrast to those of Cutfield et al. (6), who reported 
that the decrease of insulin sensitivity during GH treatment was irreversible after its 
discontinuation. However, they only studied 5 children after stop of GH treatment. 
De Zegher et al. (5) reported a reversible decrease of insulin sensitivity after stop of 
GH treatment in 9 children, but in this study it was unclear if the children had become 
pubertal. Finally, both studies investigated insulin sensitivity before adult height had 
been attained.
Previously, we investigated glucose tolerance with OGTT in another group of GH-
treated SGA subjects and showed that the glucose and insulin response during OGTT 
normalized after stop of GH treatment (4). Unfortunately, OGTT do not provide infor-
mation on insulin sensitivity and ß-cell function. Our current data show that the de-
crease in insulin sensitivity during GH treatment is reversible after discontinuation of 
GH. Van Dijk et al. (19) investigated insulin sensitivity in previously GH-treated young 
adults who had discontinued GH treatment for 6.5 years, and found that their insulin 
sensitivity and ß-cell function were similar to those of untreated SGA controls. How-
ever, insulin sensitivity and ß-cell function were not measured in these subjects during 
GH treatment. Therefore, that study was unable to study longitudinal changes in insu-
lin sensitivity and ß-cell function.
To the best of our knowledge, this is the first study investigating changes in body 
composition in SGA after stop of GH. Interestingly, we found significant changes in 
body composition after stop of GH treatment, which could not be detected with BMI 
SDS. Fat percentage SDS and fat mass SDS increased, whereas lean body mass SDS 
decreased. These changes are opposite to those which occur when GH treatment is 
started in SGA children (18). At this moment, the clinical relevance of the observed 
changes is unclear. It remains to be elucidated how body composition changes on the 
longer term after GH has been discontinued. 
Insulin sensitivity is known to have a strong correlation with fat percentage. Despite 
the increase in fat percentage SDS after stop of GH, insulin sensitivity increased. This 
indicates that discontinuation of GH treatment has a beneficial effect on insulin sen-
sitivity, which is greater than the opposite effect on insulin sensitivity due to gaining 
more fat mass.
An unexpected finding was the increase in Sg after stop of GH treatment. Sg is a 
measure for insulin-independent glucose disposal. In previous studies, Sg was not sig-
nificantly different, albeit lower in short SGA than in normal AGA children (1). During 
GH treatment, Sg did not change on the short-term (6), but the long-term effects are 
not known. In first-degree relatives of type 2 diabetic individuals, who were followed 
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longitudinally, Sg was lower at the first assessment in those subjects, who progressed 
from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) (20). In an-
other follow-up study on first degree relatives of type 2 diabetics, Sg was found to be an 
independent predictor for the development of type 2 diabetes (DM2) (21). The combina-
tion of a low Si and a low Sg was associated with the highest cumulative risk of DM2 
(21). Importantly, in our study Sg was similar for GH-treated SGA subjects and AGA 
controls and improved significantly when GH treatment was stopped, indicating that 
Sg in SGA subjects, both on and off GH, is not worse than that in AGA controls.
Interestingly, insulin secretion remained significantly higher in SGA subjects, also 
after GH was discontinued. One could argue that the ß-cells need to secrete relatively 
large amounts of insulin to maintain glucose homeostasis, leading to a possible ex-
haustion of the ß-cells and thus DM2 on the longer term. However, there is no support 
for this view in the available literature on the development of DM2 in persons at risk, 
because published data indicate that low rather than high first-phase insulin secretion 
is associated with progression from NGT to IGT as well as progression from IGT to 
DM2 (22, 23). Moreover, the decline in glucose tolerance over time in relatives of type 
2 diabetic individuals was strongly related to the loss of ß-cell function, measured by 
DI (20). In our study DI was even higher in SGA subjects than in controls. Nevertheless, 
our data cannot guarantee that glucose homeostasis remains unaffected on the longer 
term. Therefore, long-term follow-up of previously GH-treated SGA subjects remains 
important.    
In conclusion, the GH-induced reduction in Si in SGA adolescents is reversible after 
stop of long-term GH-treatment and Si becomes similar to that of AGA controls, which 
is reassuring. Discontinuation of GH treatment was, however, also associated with 
a significant increase in percent body fat and a decrease in lean body mass, without 
changes in fat distribution. It remains to be elucidated how body composition changes 
on the longer term after GH has been discontinued. Our data underscore the impor-
tance of follow-up studies after discontinuation of GH treatment. 
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Abstract
Context: Both small-for-gestational-age (SGA) and preterm birth have been asso-
ciated with increased incidence of adult cardiovascular disease and diabetes mellitus 
type 2. It is however unclear if preterm birth has an additional effect on cardiovascular 
risk factors in short children born SGA.
Objective: To investigate if prematurity has an independent influence on several car-
diovascular risk factors within a population of short SGA children.
Design: Cross-sectional observational study
Patients: 479 short SGA children (mean age 6.8 years), divided in preterm (< 36 
weeks) and term (≥ 36 weeks) children.
Outcome measure: Insulin sensitivity, beta cell function, body composition and li-
pid levels were studied in subgroups; blood pressure, anthropometry at birth and dur-
ing childhood in the total group
Results: Preterm SGA children were significantly lighter and shorter at birth after 
correction for gestational age than term SGA children (p<0.001), but had a comparable 
head circumference. In preterm SGA children, we found a significantly higher systolic 
(p=0.003) and diastolic blood pressure SDS (p=0.026), lower body fat % SDS (p=0.011), 
and higher insulin secretion (p=0.033) and disposition index (p=0.021), independently 
of the degree of SGA. Insulin sensitivity, serum lipid levels, muscle mass and body fat 
distribution were comparable for preterm and term SGA children.
Conclusions: Within a population of short SGA children, preterm birth has diver-
gent effects on several cardiovascular risk factors. Whereas preterm SGA children had 
a higher systolic and diastolic blood pressure, they also had a lower body fat % and a 
higher insulin secretion and disposition index than term SGA children.
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Introduction
A small size at birth has been associated with adult diseases, such as cardiovascular 
disease and diabetes mellitus type 2 (1-3). However, size at birth is determined by 2 
factors: intrauterine growth and duration of pregnancy. 
We and others have previously shown that short small-for-gestational-age (SGA) 
children have a lower insulin sensitivity (4, 5) and a higher systolic blood pressure (4, 
6). Recent reports indicate that also prematurity itself might have adverse consequenc-
es with regard to cardiovascular risk factors. Compared with controls born at term, 
premature born young adults had higher blood pressure and fasting glucose levels, 
irrespective of being SGA (7). In a cohort of young adult Swedish men, prematurity was 
recognized as a risk factor for high blood pressure, independent of birth weight stand-
ard deviation score (SDS) (8). 
In contrast, others reported that among children born preterm, only those who were 
born SGA had an increased systolic blood pressure and pulse wave velocity, which is a 
measure for arterial stiffness (9). Singhal et al. found comparable levels of fasting glu-
cose, insulin and lipids between preterm SGA and AGA adolescents (10). 
Most aforementioned studies investigated the influence of SGA within a population 
of preterm born or ‘low birth weight’ subjects. However, because only a minority of 
all preterm children is born SGA (~2-3 %), these studies may not have been suitable to 
investigate whether a combination of SGA and preterm birth is worse with regard to 
cardiovascular risk parameters than being born SGA at term.  
The aim of our study was to investigate if prematurity has an independent influence 
on insulin sensitivity, beta cell function and other cardiovascular risk factors within a 
large population of short SGA children. We hypothesized that being born both preterm 
and SGA is associated with a worse cardiovascular risk profile than being born SGA at 
term. To test our hypothesis, we compared preterm short SGA children with term short 
SGA children. 
Subjects and methods
Subjects
The study group comprised 479 prepubertal short children born SGA. All children 
fulfilled the same inclusion criteria: 1) birth length and/or birth weight standard 
deviation score (SDS) below –2 for gestational age(11), 2) height SDS below –2 according 
to Dutch standards(12), 3) height velocity SDS below zero to exclude children with 
spontaneous catch-up growth(12), 4) prepubertal stage, defined as Tanner breast 
stage 1 for girls and testicular volume less than 4 ml for boys(13), 5) an uncomplicated 
neonatal period without signs of severe asphyxia (defined as Apgar score below 3 
after 5 minutes), sepsis or long-term complications of respiratory ventilation such 
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as bronchopulmonary dysplasia. Children with endocrine or metabolic disorders, 
chromosomal defects, syndromes and growth failure caused by other conditions 
(e.g. emotional deprivation, severe chronic illness, chondrodysplasia) were excluded, 
with the exception of Silver-Russell syndrome. When we performed the analyses after 
exclusion of the Silver-Russell subjects, the results were the same. The following 
data have been published before: insulin sensitivity and secretion data from 28 of 77 
children (4), body composition from 30 of 149 children (14, 15), blood pressure, total 
cholesterol, HDL-c, LDL-c and triglyceride levels of 159 children (4, 6, 16) and FFA levels 
of 28 children (4). However, these papers had another objective and did not focus on the 
influence of prematurity. The study was approved by the Medical Ethics Committees. 
Written informed consent was obtained from the parents or custodians of each child.
Study design
Children were divided into 2 groups on the basis of their gestational age: (i) preterm 
(gestational age <36 wks) and (ii) at term (gestational age ≥36 wks). The gestational 
age of the subjects was determined by ultrasound in the first trimester, if available, and 
otherwise calculated from the date of the last menstruation.
Anthropometry
Standing height was measured using a Harpenden stadiometer and was expressed as 
SD-score for sex and chronological age using Dutch references (12). Body mass index 
(BMI) was calculated according to the formula weight/(height)2 and was expressed as 
SD-score for sex and age (17). Systolic and diastolic blood pressure (BP) was measured 
twice on the left arm with an automated device and appropriate cuff size (Dinamap 
Critikon, Southern Medical Corp., Baton Rouge, LA, USA). The mean of 2 measurements 
was used for analysis. Since height is an important determinant of BP in childhood and 
adolescence, BP was expressed as SDS adjusted for height and sex (18).
Body composition
Dual-Energy X-ray Absorptiometry scans (DXA, type Lunar DPX-L, GE Healthcare, 
Madison, Wisconsin, USA) were performed in a subgroup of 149 children. Lean body 
mass (LBM) and fat percentage (% fat) were determined. All values were transformed 
into SD-scores for sex and chronological age using Dutch reference values for children, 
which were obtained using the same instrumentation and software (19, 20). Since body 
composition, particularly LBM, is strongly related to height, LBM expressed as SD-
score for age and sex might result in an underestimation in short stature. Therefore, 
LBM was also expressed as SD-score for height and sex. Height-adjusted SD-scores 
were calculated as previously described (15). 
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Insulin sensitivity and secretion
In a subgroup of 77 children, a modified frequently sampled intravenous glucose 
tolerance test (FSIGT) with tolbutamide was performed, as previously described (21, 
22). Glucose and insulin levels were measured in all samples and insulin sensitivity 
(Si), glucose effectiveness (Sg), acute insulin response (AIR) and disposition index 
(DI) were calculated using Bergman’s MINMOD MILLENNIUM software (23). Insulin 
sensitivity quantifies the capacity of insulin to promote glucose disposal and glucose 
effectiveness reflects the capacity of glucose to mediate its own disposal. The acute 
insulin response, an estimate of insulin secretory capacity, was measured as the 
area under the curve from zero to ten minutes corrected for baseline insulin levels. 
Disposition index equals AIR*Si and indicates the degree of glucose homeostasis. Sex 
and ethnic distribution, gestational age, birth weight SDS, birth length SDS, birth head 
circumference SDS, height SDS and BMI SDS were not significantly different between 
children who underwent an FSIGT and those who did not. Only age was slightly higher 
in the FSIGT group (7.3 vs. 6.7 years).
Hormone and biochemical assays
All blood samples were taken after an overnight fast. Serum glucose and total cholesterol 
levels were measured as previously described (24). Insulin levels were all measured in 
one laboratory using the same method (IRMA; Medgenix, Biosource Europe, Nivelles, 
Belgium). The intra-assay coefficient of variation (CV) was 2 % to 4.7 % and the inter-
assay CV was 4.2 % to 11.3%. Triglycerides (TG) were measured on the Chem-1 analyser 
according to the manufacturer’s instructions (Technicon Instruments, Tarrytown, 
New York) and after 1998 on the Hitachi 917 analyser according to the manufacturer’s 
instructions (Roche Diagnostics, Mannheim, Germany). Both methods were 
comparable (y = x-0.030).
Non-esterified fatty acids (FFA) were measured in serum using an enzymatic colori-
metric method (WAKO Chemicals, Germany). Apolipoprotein A-1, Apolipoprotein 
B and lipoprotein (a) were determined by rate nephelometry on the Immage Immu-
nochemistry system, according to the manufacturers’ instructions (Beckman Coulter, 
Mijdrecht, Netherlands). Between-run coefficients of variation were 4.2%, 2.8% and 
6.9% for these lipoproteins at levels of 0.94, 0.53 and 0.35 g/l respectively.
Statistical analysis
FSIGT parameters, triglycerides, free fatty acids, limb fat and trunk fat were 
logarithmically transformed prior to analysis because of a skewed distribution. 
Because Lp(a) levels were very skewed, also after logarithmic transformation, we tested 
whether the percentage of individuals having a value ≥ 0.3 g/l was different between 
the groups. All data are presented as mean ± SD, except for the skewed parameters 
mentioned above, which are presented as median and interquartile range. Differences 
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between groups were tested using Student’s t test for continuous variables and χ2 test for 
categorical variables. Multiple linear regression (for continuous variables) and binary 
logistic regression analyses (for dichotomous variables) were used to adjust differences 
in outcome between the groups for possible baseline differences. Correlations were 
analysed using Spearman’s correlation coefficient. With respect to body composition 
and blood pressure data, a value of –2 to 2 SDS corresponds with a normal body 
composition corrected for age and sex and a normal blood pressure corrected for height 
and sex. Level of significance was determined at p<0.05. Statistics were performed 
using the computer statistical package SPSS (12.0; SPSS Inc., Chicago, IL). 
Results
Clinical characteristics
Table 1 lists the clinical data of the total study group and the preterm and term 
subgroups. Birth weight SDS, birth length SDS, current height SDS and BMI SDS were 
significantly lower than zero for both groups. Compared with term SGA children, 
preterm SGA children were significantly lighter and shorter at birth after correction for 
gestational age. Age and BMI SDS were significantly lower in preterm than term SGA 
children. Current height SDS was slightly higher in preterm SGA children than in term 
SGA children. Sex distribution and birth head circumference SDS were comparable.
Table 1. Clinical characteristics at birth and at baseline
 
 All SGA born 
Preterm < 36 wks 
SGA born 
Term ! 36 wks 
P-value 
     
N 479 164 315  
Age (yr) 6.8 (2.4) 6.3 (2.2) 7.0 (2.5) <0.01 
Sex (m/f) 259/220 93/71 166/149 NS 
Ethnicity (% caucasian) 87.5 93.3 84.4 <0.01 
     
Gestational age (wks) 36.4 (3.7) 32.1 (2.5) 38.7 (1.6) <0.001 
Birth weight SDS -2.3 (1.1)a -2.8 (1.3)a -2.1 (1.0)a <0.001 
Birth length SDS -3.2 (1.6)a -3.9 (2.0)a -2.9 (1.2)a <0.001 
Birth head circumference 
SDS 
-2.0 (1.3)a -2.2 (1.4)a -1.8 (1.2)a NS 
     
Height SDS -3.1 (0.6)a -3.0 (0.6)a -3.1 (0.7)a <0.05 
BMI SDS -1.3 (1.0)a -1.6 (1.0)a -1.2 (1.0) <0.0005 
     
Data expressed as mean (SD) 
SDS: standard deviation score 
a p<0.001 compared with zero 
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Body composition
Because preterm SGA children had a significantly lower BMI SDS, we were interested 
whether this was due to a lower fat or a lower muscle mass. Preterm SGA children had 
a significantly lower body fat % SDS than term SGA children, also after adjustment for 
possible confounding factors (age, sex, ethnicity, birth weight SDS and birth length 
SDS) (Table 2). Both trunk fat and limb fat were significantly lower in preterm SGA 
children, though the difference for limb fat did not reach significance anymore after 
adjustment for possible confounding factors (age, sex, ethnicity, birth weight SDS, 
birth length SDS and total body weight). Fat distribution, defined as trunk fat/total fat-
ratio, was comparable between preterm and term SGA children. Lean mass SDS was 
comparable, also when height-adjusted instead of age-adjusted SD-scores were used.
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Table 2. Body composition and fat distribution by DXA
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Insulin sensitivity and secretion
Table 3 shows the results of the FSIGT tests. Insulin sensitivity (Si) was comparable 
for preterm and term SGA children. Insulin secretion (AIR) tended to be higher and 
glucose effectiveness (Sg) tended to be lower in preterm than term SGA children, but 
the difference was not statistically significant. Disposition index (DI) was significantly 
higher in preterm than in term SGA children. After adjustment for possible confounding 
factors (age, sex, ethnicity, birth weight SDS and birth length SDS), Si, Sg and AIR were 
comparable for both groups, but DI was still higher for preterm SGA children, though 
this did not reach significance (p=0.066). After additional adjustment for body fat % 
SDS and height SDS, both AIR and DI were significantly higher in preterm than in term 
SGA children. 
Fasting glucose and insulin levels and HOMA insulin resistance index (HOMA-IR) 
were comparable for preterm and term SGA children. This remained so after adjust-
ment for potential confounding factors (age, sex, ethnicity, birth weight SDS, birth 
length SDS, fat % SDS and height SDS).
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Table 3. Insulin sensitivity, beta cell function, fasting glucose and insulin and HOMA-IR
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Blood pressure
Preterm SGA children had a significantly higher systolic (p=0.010) and diastolic 
(p<0.0005) blood pressure SDS than term SGA children (Table 4). This remained so 
after adjustment for possible confounding factors (age, sex, ethnicity, birth weight 
SDS, birth length SDS, BMI SDS and height SDS). Also, the percentage of children with 
a high systolic blood pressure was higher in preterm SGA children (26.3 %) compared 
with term SGA children (16.8 %). 
Lipids
Preterm SGA children had significantly lower total cholesterol levels than term SGA 
children, but the difference was small and disappeared after adjustment for possible 
confounding factors (age, sex, ethnicity, birth weight SDS, birth length SDS, BMI SDS 
and height SDS) (Table 4). Serum levels of HDL-c, LDL-c, triglyceride, FFA, apo-A1, 
apo-B, the apo-B/apo-A1 ratio and the percentage children with a Lp(a) level ≥ 0.3 g/l 
were similar for both groups, also after adjustment for possible confounding factors 
(age, sex, ethnicity, birth weight SDS, birth length SDS, BMI SDS and height SDS). 
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Table 4. Systolic and diastolic blood pressure SDS and serum lipid levels
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Multiple regression analyses
Because we were also interested in the relative contribution of several parameters, 
such as anthropometry at birth and gestational age, to the various cardiovascular risk 
parameters, we performed backward multiple regression analyses on the total study 
group (Table 5). The multiple regression analyses indicated that gestational age was 
indeed a significant contributor to the variance in body fat % SDS, insulin secretion, 
disposition index, and systolic and diastolic blood pressure SDS. Gestational age was 
not a significant determinant of insulin sensitivity. 
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Table 5. Multiple linear regression analyses
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Discussion
In this study we investigated whether preterm birth had an independent influence on 
several cardiovascular risk factors in short children born SGA. Preterm SGA children 
were significantly lighter and shorter at birth after correction for gestational age than 
term SGA children, but had a comparable head circumference. In preterm SGA children, 
we found a significantly higher systolic and diastolic blood pressure, lower body fat % 
SDS and higher disposition index, also after adjustment for the degree of SGA. Insulin 
sensitivity, serum lipid levels, muscle mass and body fat distribution were comparable 
for preterm and term SGA children.
Our study shows that premature SGA children had a more severe degree of growth 
retardation. Previously, we showed that SGA children with a more severe phenotype 
were more likely to be delivered by an elective caesarean section (25). It is likely that 
the preterm elective delivery of these SGA children was prompted by the severe growth 
retardation. Preterm SGA children had a lower body fat % SDS than term SGA children. 
Because preterm SGA children also had a more severe degree of SGA, as indicated by 
their lower birth weight SDS and birth length SDS, we adjusted for these possible con-
founding factors. After adjustment for anthropometry at birth, premature SGA chil-
dren still had a lower body fat % SDS than term SGA children. As the postnatal period 
of children born preterm is often characterized by nutritional problems (26), this might 
be held responsible for the reduced percentage of body fat in preterm SGA children. 
Insulin sensitivity was comparable between preterm and term SGA children, but 
body fat % SDS, which is known to strongly correlate with insulin sensitivity, was lower 
in preterm SGA children. Also, insulin secretion tended to be higher in preterm SGA 
children. Both findings might indicate a relative insulin resistance in preterm SGA 
children. However, after adjustment for body fat % SDS, insulin sensitivity remained 
comparable between preterm and term SGA children. Therefore, we cannot conclude 
that preterm SGA children have a relative insulin resistance.
An unexpected finding was that the disposition index was higher in preterm than 
in term SGA children. The disposition index reflects the capacity of pancreatic islets 
to compensate for a lower insulin sensitivity (27). Our data are in line with those of 
the Dutch famine studies. Ravelli et al. (29) showed that glucose tolerance was worse 
in those that were exposed to famine during mid or late gestation. Hofman et al. (5, 
30) also reported a higher insulin secretion and disposition index in preterm SGA chil-
dren than in term SGA children, but unfortunately they did not provide statistical com-
parisons. The difference in disposition index between preterm and term SGA children 
might be explained by the timing of prenatal growth retardation. All children in our 
study were born SGA. Therefore, the children that were born prematurely must have 
had retarded growth before the third trimester. Of the children born at term, it is not 
known when they had their growth retardation, but it seems likely that if growth was 
impaired early in pregnancy, these children would not have been born at term. The 
higher disposition index in preterm SGA children indicates that their insulin secretion 
is higher than would be expected from their level of insulin sensitivity. This could be 
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due to either a greater insulin secretion or a lower hepatic insulin extraction (28). It has 
been suggested that a lower liver mass might disadvantageously affect hepatic insulin 
extraction and it is not unthinkable that this is the case in preterm SGA subjects. Due 
to the wide range and the modest difference in disposition index between preterm and 
term SGA children, the clinical relevance is questionable. Nevertheless, our data show 
that short preterm SGA children had a glucose homeostasis that was not worse than 
that of term SGA children. 
Preterm SGA children had a significantly higher systolic and diastolic blood pres-
sure. Notably, more than 25% of all premature SGA children had high systolic BP ac-
cording to the modified ATP (Adult Treatment Panel) III criteria for children(31). An 
elevated blood pressure in childhood is known to be associated with an increased risk 
for the development of hypertension in adulthood (32). In previous studies, prematu-
rity itself has been associated with increased blood pressure (7, 8), irrespective of the 
degree of SGA. However, other reports suggested that among preterms only those born 
SGA had abnormalities in their blood pressure and vascular function (9, 10). The etiolo-
gy of the relationship between small size at birth and an elevated blood pressure is still 
unclear, but there are several hypotheses. According to Brenner et al. (33) intra-uterine 
growth retardation leads to a reduced number of nephrons. This may lead to a reduced 
filtration surface area, renal sodium retention and ultimately hypertension. Rodríguez 
et al. (34) demonstrated in renal autopsy tissue that glomerulogenesis continues after 
preterm birth, but stops after 40 days. Preterm infants had less glomeruli than infants 
born at term (34). So, both intra-uterine growth retardation and prematurity may lead 
to a reduced number of nephrons. In our study, we demonstrate that both preterm and 
term SGA children have an increased systolic and diastolic blood pressure, but that 
preterm SGA children are more affected than term SGA children.
The multiple regression analyses indicated that gestational age was indeed a sig-
nificant contributor to the variance in body fat % SDS, insulin secretion, disposition 
index, and systolic and diastolic BP SDS. The regression models for insulin secretion 
and disposition index resulted in an explained variance of approximately 30%. Since 
the models for systolic and diastolic BP SDS explained not more than 7.0% of the to-
tal variation, we must, however, conclude that gestational age is not a major factor in 
determining childhood blood pressure levels. A limitation is that we measured blood 
pressure by two measurements and this might not reflect the 24-hour blood pressure. 
Other parameters were measured in a subgroup, which means that the results might 
not be applicable to the total study population. However, subjects of the subgroups 
were recruited randomly and consecutively and there was no evidence that these were 
different from the others. 
In conclusion, within a population of short SGA children, preterm birth has diver-
gent effects on several cardiovascular risk factors. Whereas preterm SGA children had 
a higher systolic and diastolic blood pressure, they had a lower body fat % and a higher 
insulin secretion and disposition index than term SGA children.
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Abstract
Background: In 2005, 12.7% of all babies was born preterm, and the incidence is 
rising. Nowadays, due to improved survival, an increasing number of children born 
premature reach young adulthood. A recent report suggested a lower insulin sensitivity 
in children born premature, which may put them at risk for the development of type 2 
diabetes. It is, however, still unknown whether this reduced insulin sensitivity persists 
into adulthood.
Methods: We determined insulin sensitivity and ß-cell function with frequently 
sampled intravenous glucose tolerance tests, in 305 young adults (aged 18-24; 169 
preterm and 136 term). We investigated the effect of gestational age, size at birth and 
adult body composition on insulin sensitivity. In a more detailed analysis, we studied 
the same parameters in clinically relevant subgroups: small-for-gestational-age (SGA) 
without catch-up growth, SGA with catch-up growth and appropriate-for-gestational-
age (AGA) subjects, either born preterm or term. 
Results: In contrast to previous reports, we found no evidence that preterm birth has 
deleterious effects on insulin sensitivity in young adulthood. Trunk fat was the most 
important determinant of insulin sensitivity, independently of size at birth and du-
ration of pregnancy. Subgroup comparison showed that only term SGA subjects with 
spontaneous catch-up growth to a normal height had significantly lower insulin sen-
sitivity than term AGA controls. However, taking insulin secretion into account, glu-
cose homeostasis in all clinically relevant subgroups was comparable with term AGA 
controls. 
Conclusion: Contrary to our hypothesis, preterm birth was not associated with re-
duced insulin sensitivity in young adulthood.
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Introduction
Small size at birth has been associated with an increased incidence of adult cardiovascular 
disease and diabetes mellitus type 2 (1-4). However, size at birth is determined by 2 
factors: intrauterine growth and duration of pregnancy. Most epidemiologic studies 
focused on subjects who were born with a lower weight. Unfortunately, size at birth 
was often not adjusted for gestational age. Therefore, it has been difficult to interpret 
whether the negative effect of a small size at birth on cardiovascular risk factors was 
due to a small size for gestational age (SGA) or due to prematurity. 
Because of advances in neonatal intensive care, survival of preterm infants has im-
proved and most children are now reaching young adulthood. In 2005, the preterm 
birth rate in the United States was 12.7%, which corresponds with approximately 
500,000 preterm births per year (5). Moreover, this percentage is 20% higher than the 
preterm birth rate in 1990 (5). There has been quite some attention to the late effects of 
prematurity on intellectual capacities and psychomotor development, but data regard-
ing risk factors for cardiovascular disease and diabetes are scarce.
A previous study in prepubertal children indicated that preterm children, either 
born SGA or appropriate-for-gestational-age (AGA), had lower insulin sensitivity than 
those born at term (6). It is, however, still unknown whether this difference persists 
into adulthood. In a group of young adults with low birth weight, glucose homeostasis 
was studied with oral glucose tolerance tests (OGTT) (7). This study showed higher 
indexes of glucose intolerance in those born premature (7). Unfortunately, OGTT are 
dependent upon the uptake of glucose in the digestive system and are therefore less 
accurate than intravenous tests for the assessment of glucose homeostasis. Besides, no 
information regarding insulin sensitivity and secretion is obtained. 
The aim of our study was to determine insulin sensitivity in young adults with very 
low birth weight and to examine the influence of prematurity and SGA on insulin sen-
sitivity. As a secondary aim, we investigated the effect of adult body composition and 
early postnatal growth on the same outcome parameters. We hypothesized that pre-
term birth is associated with a lower insulin sensitivity in young adulthood, independ-
ently of size at birth.
Subjects and methods
Subjects
The study population consisted of 305 healthy subjects with an age between 18 and 
24 years. Premature subjects (n=169) were born before 36 weeks of gestation and had 
been admitted to the neonatal intensive care unit shortly after birth. Term subjects 
(n=136) were born after at least 36 weeks of gestation and randomly selected from 
hospitals in the Netherlands, where they had been registered because of 1) being small 
at birth (SGA with a birth length <-2 SD) (8), 2) showing short stature in childhood, 
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either after being born SGA or AGA (defined as a birth length >-2 SD) or 3) having 
a minor accidental health problem, but otherwise having a normal size at birth and 
in adulthood. All subjects fulfilled the same inclusion criteria: 1) age 18-24 years; 
2) Caucasian; 3) singleton; 4) a neonatal period without signs of severe asphyxia 
(defined as an Apgar score below 3 after 5 minutes) or long-term complications of 
respiratory ventilation, such as broncho-pulmonary dysplasia; 5) maximum duration 
of respiratory ventilation and/or oxygen supply in the neonatal period of 2 weeks. 
The following subjects were excluded: those with a serious complication (including 
necrotizing enterocolitis, intraventricular haemorrhage with a degree of 3 or more, 
spastic hemiplegia or quadriplegia), endocrine or metabolic disorders, chromosomal 
defects, syndromes, dysmorphic symptoms suggestive for a yet unknown syndrome or 
a condition known to interfere with growth (e.g. growth hormone deficiency, severe 
chronic illness, emotional deprivation, growth hormone treatment, treatment with 
glucocorticosteroids, radiotherapy). Birth data were taken from records of hospitals, 
community health services and general practitioners. The Medical Ethics Committee 
of Erasmus Medical Centre, Rotterdam, the Netherlands, approved this study. Written 
informed consent was obtained from all the participants.
Based on SD-scores of birth length (8) and adult height (9), the study population was 
also subdivided into six groups: short SGA (birth length and adult height <-2 SDS), SGA 
with catch-up growth (birth length <-2 SDS and adult height >-1 SDS) and AGA (birth 
length and adult height > -1 SDS), either born premature (<36 weeks) or at term (≥36 
weeks). In order to increase the statistical power for subgroup comparison, the cut-off 
values for these subgroups were set at -2 SDS and -1 SDS (+/- 0.1 SDS). Of the 305 sub-
jects, 182 could be included in one of the subgroups. 
Anthropometry
Height was measured using a Harpenden stadiometer and expressed as SD-score for sex 
and age using Dutch references (9). Body mass index (BMI) was calculated according to 
the formula weight/(height)2 and expressed as SD-score for sex and age (10). 
Body composition
Body composition was assessed by Dual-Energy X-ray Absorptiometry (DXA, type 
Lunar-Prodigy, GE Healthcare, Chalfont St Giles, UK). All scans were made on the 
same machine and quality assurance was performed daily.
Insulin sensitivity and secretion
After an overnight fast, a modified frequently sampled intravenous glucose tolerance 
test (FSIGT) with Tolbutamide was performed, as previously described (11, 12). Glucose 
and insulin levels were measured in all samples, and insulin sensitivity (Si), glucose 
effectiveness (Sg), acute insulin response (AIR) and disposition index (DI) were 
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calculated using Bergman’s MINMOD MILLENNIUM software (13). Insulin sensitivity 
quantifies the capacity of insulin to promote glucose disposal and glucose effectiveness 
reflects the capacity of glucose to mediate its own disposal. The acute insulin response, 
an estimate of insulin secretory capacity, was measured as the area under the curve 
from zero to ten minutes corrected for baseline insulin levels. Disposition index equals 
AIR*Si and indicates the degree of glucose homeostasis.
Assays
All blood samples were taken after an overnight fast. Serum glucose levels were 
determined on a VITROS analyser 750 (Orthoclinical Diagnostics, Johnson&Johnson 
Company, Beerse, Belgium). Insulin levels were measured using the same method 
(IRMA; Medgenix, Biosource Europe, Nivelles, Belgium). The intra-assay coefficient 
of variation (CV) was 2.0-4.7% and the inter-assay CV was 4.2-11.3%. All assays were 
performed in one central laboratory.
Statistical analysis
To normalize the distribution, total fat mass, Si, Sg and AIR were logarithmically 
transformed and for DI the square root was taken prior to analyses. Differences between 
groups were tested by one-way analysis of variance (ANOVA) with Bonferroni’s post-
hoc test. Differences in categorical variables were tested with Chi square test. Multiple 
regression analyses with logarithmically transformed Si and the square root of DI as 
the dependent variable were used to assess multivariate relationships. The interaction 
term birth length SDS x adult height SDS was added to all MR models because the study 
group had been selected on birth length and adult height, in order to ensure that the 
effect of these variables was modeled correctly. Level of significance was set at p<0.05. 
Statistics were performed using the computer statistical package SPSS (version 12.0; 
SPSS Inc., Chicago, IL).
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Results
Table 1 shows the baseline characteristics. The total group of 305 subjects had a mean 
age of 20.9 years. Figure 1 depicts insulin sensitivity on the x-axis and insulin secretion 
on the y-axis, in the total study population. Markers indicate the preterm and term 
subjects. The hyperbolic relation between insulin sensitivity (Si) and insulin secretion 
(AIR) is evident as well as the overlapping pattern of measurements in preterm and 
term subjec
 
Figure 1. Insulin sensitivity and insulin secretion of preterm and term subjects
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Table 1 Baseline characteristics of the total group and the subgroups
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To investigate the most important determinants for insulin sensitivity, we made several 
regression models (Table 2). The initial multiple regression model had insulin sensitivity 
as dependent variable, and age, sex, oral contraceptive use (OC-use), gestational age, 
adult height SDS, birth length SDS, the interaction term adult height SDS x birth length 
SDS and birth weight SDS as independent variables. In Model A, birth weight SDS 
and OC-use were significant determinants of insulin sensitivity (adjusted R2= 0.10). 
Addition of adult weight SDS to the model resulted in a model with OC-use, adult height 
SDS and adult weight SDS as significant determinants of insulin sensitivity (Model 
B). Specifying adult weight SDS into adult fat mass and lean mass, measured by DXA, 
showed that adult fat mass was the most important determinant of insulin sensitivity 
(p<0.0005; adjusted R2= 0.33; Model C). In our final model D, we specified adult fat 
mass into trunk and limbs fat mass, and it appeared that trunk fat had a negative effect 
on insulin sensitivity, whereas limbs fat was not a significant determinant. 
In none of the models, gestational age was a significant determinant of insulin sen-
sitivity. There were no significant interactions between birth weight SDS, birth length 
SDS or gestational age and adult fat mass, indicating that the effect of adult fat mass on 
insulin sensitivity was not modified by size at birth or gestational age.
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Table 2. Multiple regression analyses for insulin sensitivity in the total group
 
 
Natural logarithm of Si  
Model A Model B Model C Model D 
Variables ß p-value ß p-value ß p-value ß p-value 
         
Gestational age (wks) 0.004 0.953 0.004 0.945 -0.001 0.987 -0.009 0.878 
Birth length SDS -0.019 0.855 0.040 0.679 0.057 0.533 0.050 0.583 
Birth weight SDS 0.234 0.018 0.168 0.065 0.115 0.180 0.112 0.191 
Age (yrs) 0.019 0.740 0.028 0.595 0.071 0.159 0.079 0.116 
Gender*  0.061 0.489 0.089 0.278 -0.066 0.613 0.031 0.823 
Oral contraceptive use# -0.213 0.017 -0.180 0.030 -0.174 0.025 -0.174 0.024 
Height SDS 0.126 0.119 0.367 <0.0005 0.203 0.022 0.201 0.022 
BL*AH (SDS) 0.176 0.052 0.177 0.035 0.148 0.059 0.150 0.055 
Weight SDS   -0.438 <0.0005     
Fat mass (kg)     -0.523 <0.0005   
Trunk fat mass (kg)       -0.571 <0.0005 
Limbs fat mass (kg)       0.069 0.660 
Lean body mass (kg)     -0.030 0.807 -0.037 0.763 
         
Overall  <0.0005  <0.0005  <0.0005  <0.0005 
R2  0.12  0.26  0.35  0.36 
R2  adjusted  0.10  0.23  0.33  0.34 
         
Beta’s represent standardized regression coefficients 
SDS= standard deviation score 
*= coded as 1=male; 0= female 
#= coded as 1= OC-use; 0= no OC-use 
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Subgroup analysis
For a more detailed analysis, we also investigated differences in insulin sensitivity and 
ß-cell function between 6 clinically relevant subgroups: SGA subjects with persistent 
short stature (SGA-S), SGA subjects with spontaneous catch-up growth (SGA-CU) and 
normal AGA subjects, divided in term and preterm subgroups. Sex distribution, age, 
BMI SDS, fat percentage, total fat mass and trunk fat/total fat ratio were comparable in 
all the subgroups (Table 1). Next to differences due to the selection criteria, lean body 
mass in term SGA-S subjects was significantly lower than AGA controls, in line with 
their reduced height SDS. 
Table 3 shows the unadjusted results of the FSIGT-tests in the various subgroups. 
Insulin sensitivity, glucose effectiveness, insulin secretion and disposition index were 
comparable in all the subgroups. Insulin sensitivity was lowest in term SGA-CU sub-
jects. The difference with the other subgroups reached significance in preterm AGA 
subjects only (p<0.05).
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Table 3. FSIGT results*
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Table 4 shows differences in insulin sensitivity in the clinically relevant subgroups 
compared with term AGA controls, after adjustment for several confounding factors. 
Using term AGA subjects as the reference group, only term SGA-CU subjects had 
a significantly reduced insulin sensitivity (Model 1; Table 4). This remained so after 
adjustment for age, sex, and parameters known to influence insulin sensitivity (Models 
2-4; Table 4). Disposition index, which indicates how well the ß-cells compensate for 
lower values of insulin sensitivity, was not different between the clinically relevant 
subgroups and term AGA controls in all models (data not shown). Thus, taking insulin 
secretion into account, glucose homeostasis was comparable with term AGA controls 
in all subgroups.
Table 4. Differences in insulin sensitivity in clinically relevant subgroups compared with 
term AGA controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Natural logarithm of Si  
Model 1 
Unadjusted 
Model 2 
Adjusted for age, gender 
and OC-use 
Model 3 
Adjusted for age, 
gender, OC-use, total fat 
and total lean mass 
Model 4 
Adjusted for age, 
gender, OC-use, trunk & 
limbs fat mass and total 
lean mass 
         
Subgroups ß P-value ß P-value ß P-value ß P-value 
Preterm SGA-S* 0.125 0.649 0.029 0.913 0.105 0.658 0.166 0.480 
Term SGA-S* -0.327 0.086 -0.281 0.131 -0.249 0.161 -0.234 0.182 
Preterm SGA-CU* -0.153 0.393 -0.111 0.522 -0.105 0.467 -0.077 0.587 
Term SGA-CU* -0.555 0.005 -0.558 0.004 -0.403 0.011 -0.349 0.026 
Preterm AGA* -0.040 0.803 -0.060 0.696 0.034 0.790 0.040 0.751 
         
Overall  0.017  0.001  <0.0005  <0.0005 
R2  0.08  0.14  0.44  0.46 
R2  adjusted  0.05  0.10  0.40  0.42 
         
* Term AGA group is the reference group 
OC-use= oral contraceptive use 
SGA-S= small-for-gestational-age with persistent short stature 
SGA-CU= small-for-gestational-age with spontaneous catch-up growth 
AGA= appropriate-for-gestational-age 
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Effect of early postnatal growth on adult insulin sensitivity, insulin secretion
and ß-cell function
For subjects born premature, we studied the association between early postnatal 
growth and insulin sensitivity, insulin secretion and ß-cell function. There was 
a weak association between postnatal weight gain from birth until term age and 
insulin secretion (r=0.22; p=0.006), and between postnatal weight gain from birth 
until 3 months and insulin secretion (r=0.20; p<0.05), but significance was lost after 
adjustment for the parameters used in model D (gestational age, birth weight and 
length SDS, age, gender, OC-use, height SDS, BL*AH, trunk and limbs fat mass and 
lean body mass). In contrast, insulin sensitivity and ß-cell function (determined as DI) 
were not associated with postnatal growth in length or weight from birth until term 
age or from birth until 3 months. 
Discussion
In this study we investigated the relative contribution of prematurity and small size 
at birth (SGA), either with or without catch-up growth, on insulin sensitivity and 
secretion in young adulthood. Trunk fat and the use of oral contraceptives were the 
most important determinants of insulin sensitivity in young adulthood, independently 
of gestational age and size at birth. Contrary to our hypothesis, gestational age was 
not associated with reduced insulin sensitivity. From all clinically relevant subgroups, 
only term SGA subjects with spontaneous catch-up growth to a normal height had 
a significantly lower insulin sensitivity compared with normal term AGA controls. 
However, taking insulin secretion into account, glucose homeostasis in all clinically 
relevant subgroups was comparable with term AGA controls. 
 Our data are in line with a recent study in prepubertal children, comparing preterm 
and term children born either AGA or SGA (with catch-up growth) (14). Only term SGA 
children had increased fasting insulin levels and Homeostasis Model Assessment In-
sulin Resistance (HOMA-IR), whereas preterm children born AGA or SGA were not 
worse than term AGA controls. Likewise, we previously investigated insulin sensitivity 
in short SGA children, aged 6 years, and found no differences between preterm and 
term children (15). The study by Hofman et al. suggested that both AGA and SGA pre-
term children had reduced insulin sensitivity (6). We can, however, not reproduce their 
findings in our large study of 305 young adults. Our data clearly show that gestational 
age has no effect on insulin sensitivity in young adulthood. 
Adult trunk fat mass was the most important determinant of insulin sensitivity in 
young adulthood, regardless of size at birth and gestational age. Finken et al. investi-
gated surrogate measures of insulin resistance, i.e. HOMA-IR, C-peptide and fasting 
insulin, in a group of 19-year olds born before 32 weeks of gestation (16). They reported 
that adult obesity measures, such as BMI, waist circumference and fat mass, which 
was calculated from skinfolds measurements, were the strongest predictors of higher 
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HOMA-IR, insulin and C-peptide levels. 
Hovi et al. performed OGTT in a cohort of preterm born young adults with very low 
birth weight and term AGA controls and demonstrated differences in glucose regu-
lation between preterms and controls (7). We found no evidence for a worse glucose 
regulation, as measured by intravenous glucose tolerance tests, in preterm born young 
adults compared to term controls. Possible explanations for the differences between 
their and our study are the following. Firstly, Hovi et al. used OGTT, which are de-
pendent upon the uptake of glucose in the digestive system. This test is therefore less 
accurate than an intravenous test for the assessment of insulin sensitivity and ß-cell 
function. Secondly, there were some differences in the selection of subjects. We did not 
include subjects with serious complications from preterm birth, such as cerebral palsy 
and necrotizing enterocolitis or subjects with prolonged respiratory ventilation or oxy-
gen supply. Thirdly, all subjects in our cohort were Caucasian and singleton, whereas 
this was not clear in the study of Hovi et al.
We found a negative effect of the use of oral contraceptives in women. Also when we 
analyzed women only, this adverse effect remained significant. The deleterious effect 
of oral contraceptives on insulin sensitivity is well documented and most likely due to 
estrogens (17). In all previous studies on the effect of birth weight on parameters of 
glucose homeostasis, this factor was not taken into account. We feel that it is certainly 
a factor that should be included in such analyses. 
We found no evidence that preterm birth has long-lasting deleterious effects on in-
sulin sensitivity in this cohort of young adults. The fact that only term SGA subjects 
with spontaneous catch-up growth had a significantly lower insulin sensitivity than 
term AGA controls suggests that intrauterine events in the third trimester followed 
by spontaneous catch-up growth might be associated with lower insulin sensitivity. 
Notably, this subgroup had the highest fat percentage and total fat mass, which is as-
sociated with a lower insulin sensitivity (18). Our data clearly show that a large trunk 
fat mass, and not size at birth or the duration of pregnancy, is the main determinant of 
insulin resistance in young adulthood.
Our data indicate that insulin sensitivity and ß-cell function are not adversely af-
fected in survivors of preterm birth at the age of 18-24 years. This is reassuring, but 
does not guarantee that glucose homeostasis remains normal on the long term, later 
in life. Therefore, long-term follow-up is still warranted.     
In conclusion, in a cohort of 305 young adults, adult trunk fat mass was the most 
important predictor of insulin sensitivity, and birth weight, birth length and gesta-
tional age were no significant determinants. Compared with term AGA controls, only 
term SGA subjects with spontaneous catch-up growth had a significantly lower insulin 
sensitivity, whereas preterm subjects, regardless of being born AGA or SGA, with or 
without catch-up growth, had comparable insulin sensitivity. Taking insulin secretion 
into account, glucose homeostasis in all clinically relevant subgroups was comparable 
with term AGA controls, indicating that glucose homeostasis is not adversely affected 
at this age in any of the clinically relevant subgroups.
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General Discussion
The present thesis describes cardiovascular and metabolic risk factors in two conditions 
associated with a small size at birth: SGA and preterm birth. The first part consists of 
several studies in SGA children with persistent short stature. The following parameters 
for the assessment of cardiovascular risk were studied: (i) novel cardiovascular risk 
markers, (ii) body composition and (iii) insulin sensitivity and β-cell function. For 
all outcome parameters also the effect of GH treatment was studied. The second part 
focuses on long-term consequences of preterm birth on cardiovascular and metabolic 
risk parameters. We investigated the effect of prematurity on glucose homeostasis, 
blood pressure and lipid levels within a population of short SGA children. Besides, 
insulin sensitivity and β-cell function were studied in young adults born premature.
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Part 1: Short SGA children
Novel cardiovascular risk markers
Serum adiponectin and resistin levels before and during 2 years of GH treatment
In a group of short SGA children we studied serum adiponectin and resistin levels 
before and during 2 years of GH in comparison with untreated sex- and age-matched 
short SGA children and a normal-statured control group. Before treatment, serum 
adiponectin levels of short SGA children were comparable with normal-statured 
controls and resistin levels were lower. Neither adiponectin nor resistin levels changed 
significantly during 2 years of GH treatment. Compared with untreated age- and 
sex-matched short SGA children, GH-treated SGA children had similar adiponectin 
levels and lower resistin levels. This suggests an increase in resistin levels over time 
in untreated short SGA children, which could be confirmed in paired samples of 
untreated SGA children, though this group was small and the p-value did just not 
reach significance. Adiponectin correlated inversely with age, but not with systolic or 
diastolic blood pressure, fasting insulin, glucose and lipid levels or any growth factor.
The absence of associations with cardiovascular and metabolic risk factors in these 
lean SGA subjects is in line with data from Martin et al. (3), who reported that the as-
sociation between adiponectin and fasting insulin and lipids was dependent on the 
degree of adiposity, such that the association was absent or weaker in leaner subjects. 
Short SGA children have a low fat mass, as described in chapter 5 of this thesis, which 
makes it very plausible that these associations were not present. 
Previous studies on adiponectin levels in SGA reported lower (4, 5), similar (6) or 
higher (7) levels compared with AGA children. Notably, the SGA groups for which low-
er adiponectin levels were reported all consisted of a mixture of short SGA children 
and SGA children with spontaneous catch-up growth. More recent data indicate that 
SGA children with spontaneous catch-up growth, particularly those who become over-
weight, are more at risk for cardiovascular disease than those who remain short (8).
Previously, Ibañez et al. (6) reported a decrease of adiponectin levels in 16 short SGA 
children during 6 months of GH treatment. Our data demonstrate that 2 years of GH 
treatment had no effect on adiponectin and resistin levels in 50 short SGA children. 
Van Dijk et al. (9) also found a decrease in adiponectin levels during the first 6 months 
of GH treatment, but this was followed by an improvement thereafter. Taking these 
data together, we can conclude that the reducing effect of GH on adiponectin is only 
temporary. This is reassuring because it shows that GH treatment is not associated 
with disadvantageous changes on the longer term in these adipocytokines, which have 
emerged as possible new markers for the development of cardiovascular disease and 
diabetes mellitus type 2.   
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Long-term dose effects of GH treatment and GH discontinuation on serum adiponectin, resistin, 
IL-6 and CRP levels
In another group of 103 short SGA children, we studied the effect of 7 years of GH 
treatment in 2 different doses and the effect of discontinuation of GH on serum 
adiponectin and resistin levels, as well as the inflammatory markers IL-6 and CRP. 
Regarding adiponectin, the GH-treated SGA children had a similar decrease over 
time as healthy controls. The reduction in adiponectin levels in SGA as well as AGA con-
trols over time is most probably a consequence of puberty (10, 11). Six months after GH 
was stopped, the levels remained comparable with controls. Resistin levels increased 
over time, but remained lower than or comparable with controls at all time points. The 
inflammatory markers IL-6 and CRP did not change during the entire duration of GH 
treatment and after its discontinuation. 
An increase of BMI SDS during childhood and adolescence was associated with a 
decrease in adiponectin levels. Our data suggest that gaining more fat mass during 
childhood and adolescence is associated with a worsening of adiponectin levels. The 
fact that most GH-treated SGA children remained relatively lean during treatment, 
might thus explain why adiponectin levels remained comparable with controls. Thus, 
our data underscore that it is important to prevent the development of adiposity, as 
holds true for every individual. 
IL-6 levels correlated with CRP levels at all time points. Also, several correlations be-
tween resistin and IL-6 and CRP were demonstrated. Initially, resistin was described as 
a marker of insulin resistance in mice (12). Since then, several authors have highlighted 
the proinflammatory properties of resistin (13-15). The associations between resistin 
and IL-6 and CRP, and the lack of any correlation between resistin and markers of insu-
lin sensitivity in our study, support this view. More and more, subclinical inflammation 
is considered an independent risk factor for the development of atherosclerosis (16-23). 
Therefore, resistin is a marker that deserves attention, although the initial ideas about 
its function as a marker for insulin resistance have changed. 
Clinical implications and conclusions
In 2 different studies in short SGA children, we have shown that GH treatment is not 
associated with disadvantageous changes in adiponectin, resistin, IL-6 and CRP levels. 
Also 6 months after discontinuation of GH treatment, these markers were comparable 
with healthy controls. In addition, van Dijk et al. (24) showed that at 6.5 years after 
stop of long-term GH treatment, adiponectin levels in previously GH-treated young 
SGA adults were similar to those of untreated young SGA adults as well as those of 
normal AGA young adults. This is in contrast to a previously reported reduction of 
adiponectin and an increase of IL-6 levels in 16 short SGA children during 6 months 
of GH treatment (6). Taking together our data and those of van Dijk et al. (9, 24), 
we can conclude that GH treatment might coincide with a temporary reduction of 
adiponectin during the first 6 months only. There are, however, no deleterious effects 
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of GH on adiponectin levels on the longer term. GH treatment does also not have any 
disadvantageous effect on IL-6, resistin and CRP levels, which is reassuring, because 
subclinical inflammation is increasingly mentioned as an independent risk factor for 
the development of cardiovascular disease and diabetes mellitus type 2.
Plasma matrixmetalloprotein-9 (MMP-9) levels and blood pressure before
and during GH treatment
Systolic blood pressure is increased in short SGA children (25, 26) and decreases during 
GH treatment (1, 26). The underlying mechanism is, however, still unknown. The 
MMP-system has previously been associated with blood pressure and the incidence of 
cardiovascular disease (27-31). Randeva et al. (32) demonstrated a decrease in MMP-9 
levels during GH replacement therapy in adult growth hormone deficient (GHD) 
patients, but they did not report data on blood pressure. We hypothesized that MMP-9 
levels would be associated with blood pressure in short SGA children. We investigated 
MMP-9 levels and blood pressure in a group of short SGA children before and during 
GH treatment in comparison with untreated sex- and age-matched SGA controls. 
Both MMP-9 levels and systolic blood pressure decreased by approximately 50% in 
GH-treated SGA children, and remained unchanged in the untreated SGA controls. 
We did, however, not detect a correlation between MMP-9 and blood pressure. This 
does not necessarily imply that the MMP system is not involved in the regulation of 
blood pressure. There might be several explanations for the absence of this correlation. 
Yasmin et al. (31) showed that the strength of the association between MMP-9 and 
blood pressure was dependent on the level of blood pressure. Blood pressure might not 
have been high enough in our group of healthy SGA children to detect a correlation. 
Moreover, the MMP-system is a complex network in which various agents, such as other 
MMP types and tissue inhibitors of metalloproteinases (TIMPs) work together in the 
remodelling of the arterial wall. Thus, future research might be directed at the effects 
of GH treatment on other MMPs, for example MMP-1, and TIMPs, which can inhibit 
the activity of MMPs. Also, investigating endothelial function by ultrasonographic 
assessment of intima media thickness (IMT), flow mediated vasodilation (FMD) and 
pulse wave velocity (PWV) in combination with parameters of the MMP-system could 
be valuable (33-37).
Clinical implications and conclusions
Matrixmetalloproteins (MMPs) levels play a role in remodelling of the arterial wall, 
which may lead to atherosclerosis. High MMP-9 levels have been found in hypertensive 
patients and predict cardiovascular mortality (38). We have shown that both MMP-9 
levels and systolic blood pressure decreased during 3 years of GH treatment in short 
SGA children, whereas no changes were observed in an untreated sex- and age-matched 
SGA control group. Our data indicate that GH treatment has a beneficial effect on these 
cardiovascular risk factors. 
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Body composition
Long-term effects of GH treatment on body composition and bone mineral density in short SGA 
children
We investigated the effect of GH treatment on body composition and bone mineral 
density (BMD) in short SGA children in a longitudinal GH study with a randomized 
controlled part for 3 years. At baseline, short SGA children had a reduced fat percentage 
SDS and a low lumbar spine bone mineral density SDS corrected for height (BMAD
LS
). 
During 6 years of GH treatment, fat percentage SDS decreased and BMAD
LS
 SDS 
increased. These effects were most prominent in children who started GH at a younger 
age and in those with a greater height gain during GH treatment. Lean body mass SDS 
adjusted for height was not reduced at baseline, remained around 0 SDS in GH-treated 
children, but deteriorated in untreated children.
Data on detailed measurements of body composition is short SGA children are very 
scarce (39, 40). From a methodological point of view, it is remarkable that most stud-
ies investigating body composition in short children did not adjust for height. There-
fore, these studies might have reported an underestimation of muscle and fat mass for 
short children, and an overestimation of the changes during GH treatment. Léger et al. 
(40) investigated fat and muscle tissue of short SGA children before, during and after 
GH treatment in a cross-sectional (cs) area by magnetic resonance imaging (MRI) of 
the thigh. During the first year of GH treatment, the data were compared with AGA 
controls, who were followed longitudinally as well. The authors reported an increase 
in muscle tissue cs area and a transient decrease in fat tissue cs area during GH treat-
ment. Even in this important study the parameters were not adjusted for height or, in 
this case, the total cs area of the thigh, which obviously increases more in GH-treated 
children than in controls due to increased height velocity. Therefore, it remains unclear 
if muscle mass had a greater increase in response to GH treatment than expected from 
the increment in height. Another limitation of that study was the fact that only the 
thigh was studied. 
Surprisingly, in our study the untreated SGA children had a further decline of their 
muscle mass over time, whereas it was preserved in GH-treated children. A possible 
explanation might be the reduced food intake in untreated short SGA children, which 
improved in GH-treated children (39). Our data are in line with those of Singhal et al. 
(41), who investigated body composition by skinfold thickness measurements. They 
showed that the association between birth weight z-score and lean mass is stronger 
in older children than in younger children, after adjustment for age, gender, socioeco-
nomic status, physical activity and height. 
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Clinical implications and conclusions
Our data show that GH treatment coincides with a reduction in fat % SDS, which is 
favourable regarding cardiovascular risk, although fat % SDS was already low at 
baseline. Furthermore, a modest increase in height-adjusted bone mineral density of 
the lumbar spine was observed. In order to adequately interpret body composition and 
bone mineral density in short children, at baseline as well as during GH treatment, it is 
necessary to correct DXA parameters for height.  
Insulin sensitivity
Longitudinal changes in insulin sensitivity, ß-cell function and body composition from stop
of GH treatment to 6 months thereafter 
It is well known that GH treatment reduces insulin sensitivity. A lower birth weight has 
been associated with an increased risk for the development of cardiovascular disease 
and diabetes mellitus type 2 (42-44). Because short SGA children appear to have a lower 
insulin sensitivity than normal children prior to start of GH treatment (25, 45), concern 
has been expressed regarding the long-term effects of GH treatment on the insulin-
glucose homeostasis in this specific population. There have been two previous studies 
on the effects of discontinuation of GH treatment on insulin sensitivity in short SGA 
subjects (46, 47), but numbers were small, the children were studied before adult height 
was attained and the various pubertal stages might have confounded the results. 
We measured insulin sensitivity and β-cell function with a frequently sampled in-
travenous glucose tolerance test (FSIGT), and body composition by dual energy x-ray 
absorptiometry (DXA) in 48 SGA adolescents and compared their data with 38 AGA 
controls. In order to study the effect of discontinuation of GH treatment, the subjects 
were measured longitudinally: at adult height, while still on GH, and 6 months after 
GH had been discontinued.
Insulin sensitivity was significantly reduced in SGA subjects on GH, but increased 
significantly after stop of GH treatment when it became similar to insulin sensitivity 
of AGA controls. There was a compensatory decrease of insulin secretion after stop of 
GH, not reaching significance. Insulin secretion was significantly higher in SGA sub-
jects, both on and off GH, than in AGA controls. Glucose effectiveness increased sig-
nificantly after stop of GH treatment and became higher than in controls. Disposition 
index, which indicates how well the ß-cells can compensate for lower values of insulin 
sensitivity, improved significantly after stop of GH treatment, reaching a higher value 
than in controls. Fat percentage SDS and fat mass adjusted for height and sex increased 
significantly after stop of GH, whereas lean body mass adjusted for height and sex de-
creased significantly. However, values remained within the normal range.
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Clinical implications and conclusions
Our data indicate that the GH-induced reduction in insulin sensitivity is reversible 
after stop of GH treatment and that insulin sensitivity becomes similar to that in 
AGA controls. In contrast, discontinuation of GH treatment was associated with a 
significant increase in percent body fat and a decrease in muscle mass, though the 
values remained within the normal range. Thus, while insulin sensitivity improves after 
discontinuation of GH treatment, body composition deteriorates. Because the values of 
body composition remained similar to those of AGA controls, the clinical relevance of 
these changes is still unclear. It remains to be elucidated how body composition and 
insulin sensitivity change on the longer term after GH has been discontinued.
Part 2: Prematurity
Effects of preterm birth on cardiovascular and metabolic risk factors in short SGA children
Both prematurity and SGA birth have been associated with increased cardiovascular and 
metabolic risk factors (25, 26, 45, 48-50). It is, however, unknown if the combination 
of SGA and preterm birth results in an additional increase of these risk factors. 
Several studies investigated the influence of birth weight SDS and gestational age on 
cardiovascular and metabolic risk factors within the general population (49, 51) or 
within a population of preterm born or “low birth weight” subjects (52-58). However, 
since only a minority of all children is born SGA (~2–3%), these studies may not have 
been suitable to investigate whether a combination of SGA and preterm birth is worse 
with regard to cardiovascular risk parameters than being born SGA at term. 
To answer this question, we investigated within a large population of short SGA 
children, if preterm birth was associated with an independent adverse risk profile. We 
measured insulin sensitivity and β-cell function, body composition, blood pressure 
and lipid levels, and compared these values between preterm and term short SGA chil-
dren, after adjustment for confounding factors.
Premature SGA children had a more severe degree of growth retardation at birth, 
as shown by their lower birth weight and length SDS. Previously, we showed that short 
SGA children with a more severe degree of growth retardation were more likely to be 
delivered by an elective caesarean section (59). Most likely, the elective preterm birth 
was prompted by the severity of the fetal growth retardation. Independently of the de-
gree of SGA, preterm children had a lower body fat % SDS, a higher systolic and diasto-
lic blood pressure, a higher insulin secretion and a higher disposition index at a mean 
age of 6.8 years. Insulin sensitivity and muscle mass were comparable for preterm and 
term children.
The neonatal period of preterm children is often complicated by nutritional prob-
lems, resulting in malnutrition (60). It might well be that this has long-lasting effects 
on body composition. There have been several hypotheses about the cause of increased 
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blood pressure associated with SGA as well as preterm birth. Regarding SGA, Brenner 
et al. (61) showed that intra-uterine growth retardation leads to a reduced number of 
nephrons. This may lead to a reduced filtration surface area, renal sodium retention 
and ultimately hypertension. With respect to preterm birth, Rodríguez et al. (62) dem-
onstrated in renal autopsy tissue that glomerulogenesis continues after preterm birth, 
but stops after 40 days. Preterm infants had less glomeruli than infants born at term 
(62). Thus, both SGA and preterm birth may lead to a reduced number of nephrons and 
ultimately hypertension. Also, the use of nephrotoxic agents in the neonatal period, 
such as antibiotics, might have caused permanent damage to the kidneys resulting in 
later hypertension (63, 64). In our study, we have demonstrated that the combination of 
SGA and preterm birth leads to a higher systolic blood pressure than being born SGA 
at term. The proportion of high systolic blood pressure according to the ATP III criteria 
for children (65) was 26.3% for preterm SGA children and 16.8% for term SGA children. 
During GH treatment, systolic blood pressure decreases (26). It would be interesting to 
investigate if preterm and term short SGA children benefit equally from the reduction 
in blood pressure during GH treatment with regard to their cardiovascular health later 
in life.   
Unexpectedly, insulin sensitivity was similar for preterm and term SGA children. 
Apparently, preterm birth is not associated with worse insulin sensitivity in short SGA 
children. However, insulin secretion and disposition index were higher in those born 
preterm. Comparing our data with the available literature, we see some similarities. 
Using the data of the Dutch famine studies, Ravelli et al. (66) reported that glucose 
tolerance was better in those that were exposed to famine early in their pregnancy as 
compared to those that had exposure during mid or late gestation. It seems reasonable 
to assume that the preterm SGA children in our study also had their growth retarda-
tion early in pregnancy. Also Hofman et al. (45, 50) showed a higher insulin secretion 
and disposition index in premature SGA children than in term SGA children, but un-
fortunately they did not provide statistical comparisons.
Clinical implications and conclusions 
We have shown that prematurity has independent and divergent effects on metabolic 
and cardiovascular risk factors in short SGA children. Preterm SGA children had a 
lower body fat percentage, a higher systolic and diastolic blood pressure and a higher 
insulin secretion than term SGA children, whereas insulin sensitivity and lipid levels 
were comparable. Thus, glucose homeostasis was not worse in preterm SGA children, 
but there was a relatively high prevalence of systolic hypertension (~26%) in preterm 
SGA children according to the ATP III criteria for children (65). Since GH treatment is 
accompanied by a decrease in systolic blood pressure (26), it would be interesting to 
study if preterm and term children benefit equally from this side effect during treatment 
with regard to their cardiovascular health later in life.   
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Insulin sensitivity in young adults born premature
In a group of 305 young adults (169 preterm and 136 term; PROGRAM study), 
we investigated insulin sensitivity and β-cell function with the frequently 
sampled intravenous glucose tolerance (FSIGT) test. In contrast to a previous 
report in children (50), we found no evidence that preterm birth has deleterious 
effects on insulin sensitivity in young adulthood. Adult trunk fat mass was the 
most important predictor of insulin sensitivity, independently of size at birth 
and duration of pregnancy. In a more detailed analysis, we studied the same 
parameters in clinically relevant subgroups: SGA without catch-up growth, 
SGA with catch-up growth and AGA subjects, either born preterm or term. This 
subgroup comparison showed that only term SGA subjects with spontaneous 
catch-up growth to a normal height had significantly lower insulin sensitivity 
than term AGA controls. Notably, this subgroup also had the highest fat 
percentage and total fat mass, which is associated with a lower insulin sensitivity 
(67). However, taking insulin secretion into account, glucose homeostasis in 
all clinically relevant subgroups was comparable with term AGA controls. This 
indicates that the lower insulin sensitivity in term SGA subjects with spontaneous 
catch-up growth is well compensated by an increased insulin secretion in young 
adulthood. Lastly, oral contraceptive use in women was found to significantly 
decrease insulin sensitivity. The deleterious effect of oral contraceptives on 
insulin sensitivity is well documented and most likely due to estrogens (68). 
In all previous studies evaluating the effect of birth weight on parameters of 
glucose homeostasis, this factor was not taken into account. We feel that it is 
certainly a factor that should be included in such analyses.
Clinical implications and conclusions
Our data clearly show that preterm birth was not associated with a reduction in insulin 
sensitivity in young adulthood. These data are reassuring and provide important 
information for the ongoing discussion on the long-term sequelae of preterm birth 
and increased survival rate due to advances in neonatal intensive care. Nevertheless, we 
feel that long-term follow-up is still warranted, because our data do not guarantee that 
glucose homeostasis will remain normal on the longer term. 
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General conclusions
Since the original observations by Barker et al. (42-44), a considerable number of 
reports has been published investigating the association between birth weight and 
cardiovascular disease. Short SGA children have an extreme phenotype. Only 2-3 % of 
all newborns are born SGA, of which approximately 10% shows insufficient catch-up 
growth and has persistent short stature (69-72). GH treatment for short SGA children 
was approved by the US Food and Drug Administration (FDA) in 2001, and by the 
European Agency of Medicinal Products (EMEA) in 2003. Therefore, the number of 
GH-treated short SGA children is expected to rise in the coming years. Because of the 
associations between low birth size and cardiovascular disease and type 2 diabetes 
and the metabolic effects of GH treatment, it is important to know cardiovascular 
and metabolic risk factors in short SGA children. In the first part of this thesis, we 
investigated several of these risk factors in short SGA children, before, during and after 
long-term GH treatment. Preterm birth is a condition with low birth weight as well, and 
in the past years it was suggested that the increased cardiovascular and metabolic risk 
might also be applicable to subjects born preterm. In the second part of this thesis, we 
describe the contribution of preterm birth to cardiovascular and metabolic risk factors 
within a large group of short SGA children and also in a cohort of young adults.
We investigated the novel cardiovascular risk markers adiponectin, resistin, IL-6 
and high sensitivity CRP in short SGA subjects before, during and after GH treatment. 
We showed that neither short-term (~2 years) nor long-term GH treatment (~7 years) 
was associated with disadvantageous changes in these markers.
Our studies show that GH treatment has a positive effect on MMP-9 levels and systo-
lic blood pressure. Both MMP-9 levels and systolic blood pressure SDS decreased by ap-
proximately 50% during 3 years of GH treatment, whereas these remained unchanged 
in a sex- and age-matched untreated SGA control group.
We also investigated long-term changes in body composition. During GH treatment 
percent body fat decreased and size-adjusted bone mineral density of the lumbar spine 
increased. After stop of GH treatment, percent body fat increased and lean body mass 
decreased significantly, but values remained well within the normal range. 
Furthermore, we showed that the GH-induced reduction of insulin sensitivity is re-
versible after stop of long-term GH treatment and the values become comparable with 
those in AGA controls.
Within a group of short SGA children, we showed that preterm birth has independ-
ent effects on cardiovascular and metabolic risk factors. Preterm SGA children had a 
higher systolic and diastolic blood pressure, a lower percent body fat and a higher in-
sulin secretion and disposition index than term SGA children. Insulin sensitivity was 
comparable between preterm and term SGA children. Finally, we showed that preterm 
birth was not associated with reduced insulin sensitivity in a group of young adults. 
Trunk fat was the most important determinant of insulin sensitivity, independently of 
size at birth and duration of pregnancy.
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Considerations and directions for future research
SGA children form a heterogeneous group with different etiologies of SGA. Although it 
is clear that preeclampsia and gestational hypertension are more common in mothers 
of SGA children, there are still a high percentage of SGA births with unknown etiology. 
Genetic research, preferably with a genome-wide approach, might give more insight 
in the etiology of persistent short stature after SGA birth as well as the association 
between low birth weight and cardiovascular disease.  
Preeclampsia and intrauterine growth restriction are thought to be vascular-related 
pregnancy complications. The presence of these pregnancy complications has been 
linked with future cardiovascular disease (73). Short SGA children have an increased 
systolic blood pressure, which decreases during GH treatment (26). Approximately 
6.5 years after discontinuation of GH treatment, blood pressure had remained lower 
than in untreated SGA subjects (2). It is unknown if this GH-induced decrease in blood 
pressure has a beneficial effect on the odds of SGA women to develop preeclampsia or 
gestational hypertension. Therefore, it would be highly interesting to study the preg-
nancies and offspring of GH-treated SGA mothers and compare the outcomes with 
untreated SGA mothers. Another related aspect that might link a small size at birth 
with adult cardiovascular disease and has not received much attention yet, is the pos-
sibility of disturbances in coagulation and/or fibrinolysis. These disturbances could be 
the cause of placental infarction and thus SGA. Future research might also be directed 
at identifying these disturbances, such as maternal and/or fetal thrombophilia as a 
cause for SGA birth. 
Growth hormone treatment has well-known anti-insulinemic effects, such as a 
reduction in insulin sensitivity. Our data demonstrate that long-term GH treatment 
was not associated with disadvantageous changes in several novel cardiovascular risk 
markers and that the GH-induced reduction in insulin sensitivity was reversible after 
GH was discontinuated. Thus, the available data regarding the safety of GH treatment 
in short SGA subjects with respect to cardiovascular and metabolic health are reas-
suring. However, it remains important to perform follow-up studies in previously GH-
treated SGA subjects at regular intervals because the development of cardiovascular 
disease and type 2 diabetes is age-dependent and might occur later in life. Figure 1 
presents an overview of the follow-up studies that have been performed by our research 
group in previously GH-treated SGA subjects. 
In the past decades, the survival rate of preterm children has dramatically increased 
due to improvements in neonatal intensive care. Several studies suggested that preterm 
subjects, like SGA subjects, might have an increased risk for the development of 
cardiovascular disease and diabetes type 2 (50, 51, 74-76). In a group of young adults 
born premature, we showed that gestational age had no effect on insulin sensitivity. It 
is, however, important to realize that we included subjects without major morbidities 
in the neonatal period, such as necrotizing enterocolitis, long-term ventilation or 
oxygen supply and bronchopulmonary dysplasia, and without major disabilities in 
young adulthood, such as hemiplegia and quadriplegia. Besides, it is important to 
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Figure 1. Follow-up studies in SGA subjects after discontinuation of GH treatment
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study other cardiovascular risk factors as well, because preterm birth has divergent 
effects on cardiovascular risk factors in short SGA children, as described in chapter 7 
of this thesis. 
Nowadays, due to improved neonatal care for preterms, an increased number of pre-
terms survive, whereas the quality of life of short SGA children has improved due to the 
availability of GH treatment. The studies described in this thesis aimed to investigate 
the cardiovascular and metabolic health of these 2 patient groups. These and future 
studies can improve our knowledge regarding cardiovascular and metabolic risk fac-
tors in preterm and SGA subjects and help to provide them with better treatment and 
counselling.
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Summary
Chapter 1
This chapter provides an introduction in the definitions, prevalence and etiology 
of SGA birth. Furthermore, clinical and endocrinological aspects associated with 
SGA are described, such as short stature and the association with cardiovascular 
disease. Several hypotheses regarding the association between a low birth weight and 
increased prevalence of cardiovascular disease and type 2 diabetes are discussed. The 
assessment of cardiovascular risk by several parameters, e.g. novel cardiovascular risk 
markers, such as adiponectin, resistin, IL-6, high sensitivity CRP and MMP-9, glucose 
homeostasis and body composition is highlighted and the previously reported data 
regarding these parameters in short SGA children are summarized. Besides, the effects 
of GH treatment on these markers as well as the effects on height and the GH-IGF-I-
IGFBP-axis are described. At the end of this chapter the aims and outline of this thesis 
are presented. 
Chapter 2
Adiponectin and resistin are fat-cell derived hormones, which are thought to be 
respectively protective and disadvantageous with regard to the development of 
cardiovascular disease and diabetes mellitus type II. Low birth weight has been 
associated with increased risks for the development of these diseases. In short SGA 
children, GH therapy has several positive effects regarding cardiovascular risk factors, 
such as a decrease in systolic blood pressure and lipid levels. On the other hand 
concern has been expressed about the effects of GH therapy on insulin sensitivity. We 
measured adiponectin and resistin levels in 136 short prepubertal children born SGA 
and their association with cardiovascular risk parameters and growth factors. Also, we 
compared the levels with those in normal-statured controls. The effect of GH treatment 
was evaluated in 50 short SGA children versus baseline and versus an untreated sex- 
and age-matched SGA control group. Compared to normal-statured controls, short 
SGA children had similar adiponectin (10.9 vs. 10.7 µg/ml) and lower resistin levels 
(9.7  vs. 14.7 ng/ml). In GH-treated SGA children, neither adiponectin nor resistin 
levels changed significantly during 2 years of GH treatment. Compared to untreated 
sex- and age-matched SGA controls, GH-treated SGA children had similar adiponectin 
(10.9 vs. 10.7 µg/l) and lower resistin levels (7.9 vs. 10.5 ng/ml). Adiponectin correlated 
inversely with age, but not with any cardiovascular risk parameter or growth factor. 
Higher IGF-1 levels in GH-treated children were associated with lower resistin levels. In 
conclusion, short prepubertal SGA children had similar adiponectin and lower resistin 
levels as normal-statured controls. Two years of GH treatment had no effect on their 
adiponectin and resistin levels.
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Chapter 3
Low birth weight is associated with increased risks for adult cardiovascular disease 
and diabetes mellitus type 2. Adiponectin and resistin are hormones, considered 
respectively protective and disadvantageous regarding these risks. No data exist on the 
effect of long-term GH treatment on these hormones and inflammatory markers in 
children born SGA. 
We investigated longitudinal changes in inflammatory markers and adipocytokines 
during and after a long-term dose-response GH study. 103 short prepubertal SGA chil-
dren received either 1 mg GH/m2 body surface area (BSA)/day (group A) or 2 mg GH/m2 
BSA/day (group B). Adiponectin, resistin, IL-6 and CRP levels were measured at base-
line, after 1 and 7 years of GH treatment and 6 months after discontinuation of GH. The 
levels in the 2 GH dosage groups were compared with age-related controls. We found 
that adiponectin levels decreased over time, but remained comparable with controls. 
Resistin levels increased over time and remained lower or comparable with controls. 
There were no significant differences between the GH dosage groups. After stop of 
GH, adiponectin decreased in group B and resistin increased in group A. GH treatment 
did not affect IL-6 and CRP levels at any time point. An increase in BMI SDS over time 
was associated with a decrease in adiponectin levels. None of the markers were associ-
ated with insulin sensitivity, which was derived from OGTT-tests by calculating the 
whole body insulin sensitivity index (WBISI). In conclusion, long-term GH treatment 
is not associated with disadvantageous changes in adiponectin, resistin, IL-6 and CRP 
levels, neither during nor after GH treatment.
Chapter 4
Short SGA children have an increased systolic blood pressure, which decreases 
during long-term GH treatment. The underlying mechanism is still unknown. 
Matrix metalloproteinases (MMPs) are zinc-dependent endoproteinases, which are 
involved in the remodelling of the extracellular matrix and are thought to play a role 
in atherosclerosis. High MMP-9 levels have been found in hypertensive patients and 
predict cardiovascular mortality. We investigated whether 3 years of GH treatment 
affects plasma MMP-9 levels in short SGA children and whether MMP-9 levels are 
related to blood pressure. MMP-9 levels and blood pressure were measured at baseline, 
and after 6, 12 and 36 months in a case-control study. The data of 38 short SGA children 
receiving GH treatment were compared with those of 17 sex- and age-matched untreated 
short SGA controls. We show that MMP-9 levels decreased significantly during 3 years 
of GH treatment, whereas they remained similar in untreated SGA controls. After 3 
years of GH treatment, MMP-9 levels were significantly lower in the GH group than 
in untreated SGA controls. Systolic BP SDS significantly decreased in the GH group, 
but remained unaltered in untreated SGA controls. MMP-9 levels did not correlate 
with systolic or diastolic BP. In conclusion, plasma MMP-9 levels and systolic BP SDS 
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decreased to almost 50% of baseline values in the GH group, whereas these remained 
unchanged in untreated SGA controls. Our data indicate that GH treatment has a 
positive effect on both MMP-9 levels and systolic BP SDS.
Chapter 5
Alterations in the GH-IGF-I axis in short SGA children might be associated with 
abnormalities in bone mineral density (BMD) and body composition. In addition, 
birth weight has been inversely associated with diabetes and cardiovascular disease 
in adult life. As body composition is an important determinant of these diseases, it is 
important to be informed about body composition in short SGA children, as well as 
the effects of GH treatment. However, data on detailed body composition in short SGA 
children and long-term effects of GH treatment are very scarce. We investigated the 
effects of long-term GH treatment on body composition and BMD by Dual Energy X-Ray 
Absorptiometry (DXA) in short SGA children in a longitudinal 6-year GH study with a 
randomized controlled part of 3 years. We found that fat percentage SDS and lumbar 
spine BMD SDS corrected for height (BMAD
LS
 SDS) at baseline were significantly lower 
than in normal children. Lean body mass (LBM) SDS adjusted for age was also lower 
than in normal children, but LBM adjusted for height (LBM SDS
height
) was comparable. 
GH treatment induced a decrease in fat percentage SDS and an increase in BMAD
LS
 SDS. 
LBM SDS
height
 remained similar in GH-treated children, but deteriorated in untreated 
controls. When these untreated controls subsequently started GH treatment, their LBM 
SDS
height
 rapidly normalized to values comparable with normal children. In conclusion, 
during long-term GH treatment in short SGA children, fat percentage SDS decreased 
and BMAD
LS
 SDS increased. These effects of GH treatment were most prominent in 
children who started treatment at a younger age and in those with greater height gain 
during GH treatment. LBM SDS
height 
remained around 0 SDS in GH-treated children, but 
declined to low normal values in untreated controls. In addition, our data demonstrate 
that it is important to adjust body composition parameters for height in short children 
to prevent an underestimation at baseline and an overestimation of the effect of GH 
treatment. 
Chapter 6
It is well known that GH treatment reduces insulin sensitivity (Si). For SGA subjects, who 
might have an increased risk to develop cardiovascular disease and type 2 diabetes, it is 
still uncertain how Si, ß-cell function and body composition change over time after stop 
of GH treatment. Therefore, we investigated longitudinal changes in Si, ß-cell function 
and body composition from stop to 6 months after stop of GH treatment. 48 SGA 
adolescents were studied at adult height, while still on GH, and 6 months after GH was 
discontinued, and compared with 38 AGA controls. We assessed Si and ß-cell function 
by frequently sampled intravenous glucose tolerance tests (FSIGT), and measured body 
composition by dual energy x-ray absorptiometry (DXA). We demonstrate that after 
stop of GH, Si (p=0.006), glucose effectiveness (Sg; p=0.009) and disposition index 
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(DI; p=0.024) increased, whereas insulin secretion (AIR; NS) decreased. Fat percentage 
increased (p<0.0005), and LBM decreased (p<0.0005), but fat distribution remained 
unaltered. Compared with AGA controls, Si was lower during GH and became similar 
after GH stop, AIR was higher at both time points, and Sg and DI became higher after 
stop of GH treatment. Body composition of SGA subjects was comparable with AGA 
controls at both time points. In conclusion, the GH-induced lower insulin sensitivity in 
SGA adolescents increases after stop of long-term GH treatment and becomes similar 
to that of AGA controls. Cessation of GH treatment is associated with a small, but 
significant increase in percent body fat and a decrease in LBM, without changes in fat 
distribution.
Chapter 7
Both small-for-gestational-age (SGA) and preterm birth have been associated with 
increased incidence of adult cardiovascular disease and diabetes mellitus type 2. It is 
however unclear if preterm birth has an additional effect on cardiovascular risk factors 
in short children born SGA. We investigated if prematurity has an independent influence 
on several cardiovascular risk factors within a population of short SGA children. 479 
short prepubertal SGA children (mean age 6.8 years) were divided in preterm (< 36 
weeks) and term (≥ 36 weeks) children. The following parameters were compared 
between preterm and term short SGA children: insulin sensitivity and ß-cell function 
(assessed with FSIGT), body composition (measured by DXA), lipid levels, systolic 
and diastolic blood pressure, and anthropometry at birth and during childhood. 
We demonstrate that preterm SGA children were significantly lighter and shorter at 
birth after correction for gestational age than term SGA children (p<0.001), but had 
a comparable head circumference. In preterm SGA children, we found a significantly 
higher systolic (p=0.003) and diastolic blood pressure SDS (p=0.026), lower body fat % 
SDS (p=0.011), and higher insulin secretion (p=0.033) and disposition index (p=0.021), 
independently of the degree of SGA. Insulin sensitivity, serum lipid levels, muscle 
mass and body fat distribution were comparable for preterm and term SGA children. 
In conclusion, within a population of short SGA children, preterm birth has divergent 
effects on several cardiovascular risk factors. Whereas preterm SGA children had a 
higher systolic and diastolic blood pressure, they also had a lower body fat % and a 
higher insulin secretion and disposition index than term SGA children.
Chapter 8
In 2005, 12.7% of all babies were born preterm, and the incidence is rising. Nowadays, 
due to improved survival, an increasing number of children that were born premature 
reach young adulthood. A recent report suggested a lower insulin sensitivity in 
children born premature, which may put them at risk for the development of type 2 
diabetes. It is, however, still unknown whether this reduced insulin sensitivity persists 
into adulthood. We determined insulin sensitivity and ß-cell function with frequently 
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sampled intravenous glucose tolerance tests, in 305 young adults (aged 18-24; 169 
preterm and 136 term). We investigated the effect of gestational age, size at birth and 
adult body composition on insulin sensitivity. In a more detailed analysis, we studied 
the same parameters in clinically relevant subgroups: small-for-gestational-age (SGA) 
without catch-up growth, SGA with catch-up growth and appropriate-for-gestational-
age (AGA) subjects, either born preterm or term. In contrast to previous reports, we 
found no evidence that preterm birth has deleterious effects on insulin sensitivity in 
young adulthood. Trunk fat was the most important determinant of insulin sensitivity, 
independently of size at birth and duration of pregnancy. Subgroup comparison showed 
that only term SGA subjects with spontaneous catch-up growth to a normal height had 
significantly lower insulin sensitivity than term AGA controls. However, taking insulin 
secretion into account, glucose homeostasis in all clinically relevant subgroups was 
comparable with term AGA controls. Contrary to our hypothesis, preterm birth was 
not associated with reduced insulin sensitivity in young adulthood.
Chapter 9
In the general discussion, we discuss our findings in relation to the current literature 
and conclude with general considerations and direction for future research. 
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Samenvatting
Hoofdstuk 1
Dit hoofdstuk beschrijft de definities, prevalentie en oorzaken van SGA. Vervolgens 
wordt een overzicht gegeven van klinische en endocrinologische aspecten van SGA, zoals 
een kleine lichaamslengte en het verband met hart- en vaatziekten. De verschillende 
hypotheses over het verband tussen een laag geboortegewicht en het vaker voorkomen 
van hart- en vaatziekten en diabetes mellitus type 2 worden genoemd. Het vaststellen van 
het risico op hart- en vaatziekten door middel van verschillende parameters, namelijk 
nieuwe cardiovasculaire risicomarkers, zoals adiponectine, resistine, IL-6, CRP and 
MMP-9 spiegels, de suikerstofwisseling en lichaamssamenstelling wordt beschreven 
en de eerder gepubliceerde gegevens over deze parameters in te kleine SGA kinderen 
worden samengevat. Daarnaast worden de beperkte hoeveelheid gepubliceerde 
gegevens over de effecten van GH behandeling op deze markers alsmede de effecten 
op lengte en de GH/IGF-I/IGFBP-as beschreven. Aan het eind van dit hoofdstuk worden 
de doelstellingen en de indeling van dit proefschrift gepresenteerd. 
Hoofdstuk 2
Adiponectine en resistine zijn hormonen geproduceerd in het vetweefsel, waarvan 
gedacht wordt dat ze respectievelijk een beschermende en nadelige rol spelen met 
betrekking tot de ontwikkeling van hart- en vaatziekten en diabetes mellitus type 2. 
Een laag geboortegewicht is geassocieerd met toegenomen risico’s op het ontwikkelen 
van deze ziektes. GH behandeling heeft verschillende gunstige effecten in kleine SGA 
kinderen, zoals een daling van de systolische bloeddruk en de vetspiegels. Aan de andere 
kant is er ook bezorgdheid uitgesproken over de effecten van GH behandeling op de 
insulinegevoeligheid. In 136 kleine prepubertaire SGA kinderen werden adiponectine 
en resistine spiegels gemeten en het verband met cardiovasculaire risicofactoren en 
groeifactoren bepaald. Ook werden de adiponectine en resistine spiegels vergeleken 
met die in controle kinderen met een normale lichaamslengte. Het effect van GH 
behandeling werd geëvalueerd in 50 kleine SGA kinderen ten opzichte van de 
uitgangswaarden bij het starten van GH behandeling en ten opzichte van onbehandelde 
SGA kinderen van vergelijkbare leeftijd en geslacht. Vergeleken met controles met een 
normale lichaamslengte, hadden kleine SGA kinderen vergelijkbare adiponectine 
(10.9 vs. 10.7 µg/ml) en lagere resistine spiegels (9.7  vs. 14.7 ng/ml). Adiponectine en 
resistine spiegels veranderden niet tijdens 2 jaar GH behandeling. GH-behandelde SGA 
kinderen hadden gelijke adiponectine (10.9 vs. 10.7 µg/l) en lagere resistine spiegels (7.9 
vs. 10.5 ng/ml) vergeleken met onbehandelde SGA kinderen van identieke leeftijd en 
geslacht. Adiponectine correleerde negatief met de leeftijd, maar niet met enige andere 
cardiovasculaire risicofactor of groeifactor. Hogere IGF-I spiegels in GH-behandelde 
kinderen waren geassocieerd met lagere resistine spiegels. Concluderend, te kleine 
prepubertaire SGA kinderen hadden vergelijkbare adiponectine en lagere resistine 
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spiegels ten opzichte van gezonde controles met een normale lengte. Twee jaar GH 
behandeling had geen effect op hun adiponectine en resistine spiegels.
Hoofdstuk 3
Er zijn geen gegevens bekend over de lange termijn effecten van GH behandeling 
op adiponectine, resistine en ontstekingsmarkers. Wij onderzochten longitudinale 
veranderingen in onstekingsmarkers en adipocytokines tijdens en na een lange termijn 
GH dosis-respons studie. 103 te kleine prepubertaire SGA kinderen kregen ofwel 1 (groep 
A) ofwel 2 mg GH/m2 lichaamsoppervlakte/dag (groep B). Adiponectine, resistine, 
IL-6 and CRP spiegels werden gemeten bij aanvang, na 1 en 7 jaar GH behandeling 
en 6 maanden na het stoppen van GH. De spiegels in de 2 GH dosis groepen werden 
vergeleken met leeftijdsgerelateerde controles. We vonden dat adiponectine spiegels 
afnamen in de tijd, maar ze bleven vergelijkbaar met de spiegels in controles. Resistine 
spiegels stegen in de tijd en bleven lager of vergelijkbaar met de spiegels in controles. 
Er waren geen significante verschillen tussen de GH dosis groepen. Na het stoppen 
van GH behandeling, daalde adiponectine in groep B en steeg resistine in groep A. GH 
behandeling had geen effect op IL-6 en CRP spiegels. Een stijging in de BMI SDS was 
geassocieerd met een daling van de adiponectine spiegels. Geen enkele marker was 
geassocieerd met insulinegevoeligheid, berekend als “whole body insulinegevoeligheid 
index” uit de data van OGTT testen. Samenvattend, lange termijn GH behandeling is 
niet geassocieerd met nadelige veranderingen in adiponectine, resistine, IL-6 en CRP 
spiegels, noch tijdens noch na GH behandeling.
Hoofdstuk 4
Te kleine SGA kinderen hebben een hoge systolische bloeddruk, welke daalt tijdens 
lange termijn GH behandeling. Het onderliggende mechanisme is nog onbekend. 
Matrix metalloproteinases (MMPs) zijn zink-afhankelijke endoproteinases, welke 
betrokken zijn bij het remodelleren van de extracellulaire matrix, waardoor ze waar-
schijnlijk een rol spelen bij atherosclerose. Hoge MMP-9 spiegels werden gevonden 
in hypertensieve patienten en voorspellen sterfte aan hart-en vaatziekten. Wij 
onderzochten of 3 jaar GH behandeling effect had op MMP-9 plasma spiegels in te 
kleine SGA kinderen en of MMP-9 spiegels gerelateerd waren aan bloeddruk. MMP-9 
spiegels en bloeddruk werden bij aanvang, na 6, 12 en 36 maanden GH-behandeling 
gemeten in een case-controle studie. De gegevens van 38 te kleine SGA kinderen 
tijdens GH behandeling werden vergeleken met die van 17 onbehandelde te kleine SGA 
controles met een identieke leeftijd en geslacht. MMP-9 spiegels namen significant af 
tijdens 3 jaar GH behandeling, terwijl ze gelijk bleven in onbehandelde SGA controles. 
Na 3 jaar GH behandeling waren MMP-9 spiegels significant lager in de GH groep dan 
in de onbehandelde SGA controles. Systolische bloeddruk SDS daalde significant in 
de GH groep, maar veranderde niet in onbehandelde SGA controles. MMP-9 spiegels 
correleerden niet met systolische of diastolische bloeddruk. Samenvattend, plasma 
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MMP-9 spiegels en systolische bloeddruk SDS daalden tot bijna 50% van de waarden bij 
aanvang in de GH groep, terwijl deze niet veranderden in onbehandelde SGA controls. 
Onze resultaten laten zien dat GH behandeling een gunstig effect heeft op zowel 
MMP-9 spiegels als systolische bloeddruk SDS.
Hoofdstuk 5
Veranderingen in de GH-IGF-I as in te kleine SGA kinderen zijn mogelijk geassocieerd 
met afwijkingen in de botdichtheid en lichaamssamenstelling. Daarnaast is een laag 
geboortegewicht geassocieerd met het vaker voorkomen van diabetes en hart- en 
vaatziekten op volwassen leeftijd. Aangezien lichaamssamenstelling een belangrijke 
determinant is van deze ziektes, is het belangrijk om geïnformeerd te zijn over de 
lichaamssamenstelling van te kleine SGA kinderen, en de effecten van GH behandeling. 
Echter, er zijn zeer weinig gegevens bekend van gedetailleerde lichaamssamenstelling 
in kleine SGA kinderen en de lange termijn effecten van GH behandeling. Wij 
onderzochten de lange termijn effecten van GH behandeling op lichaamssamenstelling 
en botdichtheid, gemeten met Dual Energy X-Ray Absorptiometry (DXA) scans in 
te kleine SGA kinderen tijdens een 6 jaar durende longitudinale GH studie met een 
gerandomiseerd gecontroleerd deel van 3 jaar. We vonden dat het vetpercentage SDS 
en de botdichtheid SDS van de lumbale wervekolom gecorrigeerd voor lengte (BMAD
LS
 
SDS) bij aanvang significant lager waren dan bij normale kinderen. Spiermassa SDS 
(gecorrigeerd voor leeftijd en geslacht) was ook lager dan bij normale kinderen, maar 
spiermassa gecorrigeerd voor lengte (LBM SDS
height
) was vergelijkbaar. GH behandeling 
induceerde een afname van het vetpercentage SDS en een toename van de BMAD
LS
 
SDS. LBM SDS
height
 bleef gelijk in GH-behandelde kinderen, maar verslechterde in 
onbehandelde controles. Waneer deze onbehandelde controles vervolgens startten met 
GH behandeling, normaliseerde hun LBM SDS
height
 snel naar waardes vergelijkbaar met 
die in normale kinderen. Concluderend, tijdens lange termijn GH behandeling van 
te kleine SGA kinderen, nam het vetpercentage SDS af en de BMAD
LS
 SDS toe. Deze 
effecten van GH behandeling waren het sterkst aanwezig in kinderen die op jongere 
leeftijd met GH behandeling startten en in de kinderen met een grotere lengtewinst 
tijdens GH behandeling. LBM SDS
height 
bleef rond de 0 SDS in GH-behandelde kinderen, 
maar daalde tot laag normale waardes in onbehandelde controles. Tenslotte laten onze 
resultaten zien dat het belangrijk is om de lichaamssamenstelling van te kleine kinderen 
te corrigeren voor lengte teneinde een onderschatting van de waardes bij aanvang en 
een overschatting van de veranderingen tijdens GH behandeling te voorkomen. 
Hoofdstuk 6
Het is algemeen bekend dat GH behandeling gepaard gaat met een daling van de 
insulinegevoeligheid. Mensen die SGA geboren werden hebben mogelijk een verhoogd 
risico op het ontwikkelen van hart- en vaatziekten en type 2 diabetes. Het is echter 
nog onbekend hoe de insulinegevoeligheid, ß-cel functie en lichaamssamenstelling 
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veranderen in de tijd na het stoppen van GH behandeling. Daarom onderzochten 
wij longitudinale veranderingen in insulinegevoeligheid, ß-cel functie en lichaams-
samenstelling vanaf het moment van stoppen van GH behandeling tot 6 maanden erna. 
48 SGA adolescenten werden onderzocht op het moment dat ze hun eindlengte hadden 
bereikt, terwijl ze nog steeds GH gebruikten, en 6 maanden nadat de GH behandeling 
was gestopt. Ze werden vergeleken met 38 gezonde controles, die zowel bij de geboorte 
als op latere leeftijd een normale lengte hadden (AGA controles). Insulinegevoeligheid en 
ß-cel functie werden gemeten met zogenaamde frequently sampled intravenous glucose 
tolerance tests (FSIGT), en lichaamssamenstelling werd gemeten met dual energy x-ray 
absorptiometry (DXA) scans. Na het stoppen van GH namen de insulinegevoeligheid 
(p=0.006), de insuline-onafhankelijke glucose opname (p=0.009) en de dispositie 
index (p=0.024) toe, terwijl de insulinesecretie (NS) afnam. Het vetpercentage steeg 
(p<0.0005), en de spiermassa nam af (p<0.0005), maar de vetverdeling bleef gelijk. 
Vergeleken met AGA controles, was de insulinegevoeligheid in SGA adolescenten 
lager tijdens GH behandeling, maar werd die na het stoppen van GH vergelijkbaar. De 
insulinesecretie was hoger op beide tijdstippen, en de insuline-onafhankelijke glucose 
opname en dispositie index werden hoger na het stoppen van de GH behandeling. 
Lichaamssamenstelling van SGA personen was op beide tijdstippen vergelijkbaar met 
die van AGA controles. Samengevat, de GH-geïnduceerde lagere insulinegevoeligheid 
in SGA adolescenten neemt weer toe na het stoppen van GH behandeling en wordt 
vergelijkbaar met die van AGA controles. Stoppen van GH behandeling is geassocieerd 
met een kleine, maar significante toename van het vetpercentage en een daling van de 
spiermassa, zonder veranderingen van de vetverdeling.
Hoofdstuk 7
Zowel SGA als prematuriteit zijn geassocieerd met hogere cardiovasculaire en metabole 
risicofactoren. Het was echter nog onduidelijk of prematuriteit een additioneel effect 
heeft op deze risicofactoren in te kleine SGA kinderen. Wij onderzochten of prematuriteit 
een onafhankelijke invloed heeft op verschillende cardiovasculaire risicofactoren 
in een groep te kleine SGA kinderen. 479 te kleine prepubertaire SGA kinderen 
(gemiddelde leeftijd 6.8 jaar) werden verdeeld in premature (< 36 weken) en aterme 
(≥ 36 weeks) kinderen. De volgende parameters werden vergeleken tussen premature 
en aterme kleine SGA kinderen: insulinegevoeligheid en ß-cel functie (bepaald met 
FSIGT), lichaamssamenstelling (gemeten met DXA), lipiden spiegels, systolische en 
diastolische bloeddruk, en anthropometrie bij geboorte en op de kinderleeftijd. We 
laten zien dat premature SGA kinderen significant lichter en korter waren bij hun 
geboorte, na correctie voor de zwangerschapsduur, dan aterme SGA kinderen (p<0.001). 
De geboorteschedelomtrek was vergelijkbaar. Premature SGA kinderen hadden een 
significant hogere systolische (p=0.003) en diastolische bloeddruk SDS (p=0.026), 
een lager vetpercentage SDS (p=0.011), en een hogere insulinesecretie (p=0.033) en 
dispositie index (p=0.021), onafhankelijk van de ernst van SGA. Insulinegevoeligheid, 
serum lipiden spiegels, spiermassa en vetverdeling waren vergelijkbaar voor premature 
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en aterme SGA kinderen. Samengevat, prematuriteit heeft invloed op verschillende 
cardiovasculaire en metabole risicofactoren in een groep te kleine SGA kinderen. 
Premature SGA kinderen hadden een hogere systolische en diastolische bloeddruk, 
maar ook een lager vetpercentage en een hogere insulinesecretie en dispositie index 
dan aterme SGA kinderen.
Hoofdstuk 8
In 2005 werd 12.7% van alle babies prematuur geboren, en de incidentie is stijgende. 
Dankzij een verbeterde overleving, bereikt tegenwoordig een toenemend aantal 
prematuur geboren kinderen de volwassenheid. Een recent artikel suggereerde een 
lagere insuliegevoeligheid in prematuur geboren kinderen, hetgeen zou kunnen leiden 
tot de ontwikkeling van diabetes type 2 op latere leeftijd. Het was echter nog onduidelijk 
of deze lagere insulinegevoeligheid tot in de volwassenheid blijft bestaan. Wij bepaalden 
insulinegevoeligheid en ß-cel functie met behulp van zogenaamde “frequently sampled 
intravenous glucose tolerance” testen in 305 jong volwassenen (leeftijd 18-24 jaar; 169 
prematuur en 136 aterm). We onderzochten het effect van zwangerschapsduur, grootte 
bij de geboorte en volwassen lichaamssamenstelling op de insulinegevoeligheid. In een 
meer gedetaileerde analyse, bestudeerden we dezelfde parameters in klinisch relevante 
subgroepen: small-for-gestational-age (SGA) zonder inhaalgroei, SGA met inhaalgroei 
en appropriate-for-gestational-age (AGA) personen, allen ofwel prematuur ofwel 
aterm geboren. In tegenstelling tot eerdere publicaties vonden wij geen bewijs voor 
nadelige effecten van prematuriteit op de insulinegevoeligheid in jong volwassenen. 
Rompvet was de belangrijkste determinant van insulinegevoeligheid, onafhankelijk 
van de grootte bij de geboorte of de zwangerschapsduur. Uit de subgroep analyse bleek 
dat alleen aterme SGA personen met spontane inhaalgroei tot een normale lengte 
een lagere insulinegevoeligheid hadden dan aterme AGA controles. Wanneer men 
echter de insulinesecretie in acht neemt, bleek de glucose homeostase in alle klinisch 
relevante subgroepen vergelijkbaar met die van aterme AGA controles. Samengevat, in 
tegenspraak met onze hypothese, was prematuriteit niet geassocieerd met een lagere 
insulinegevoeligheid in jong volwassenen.
Hoofdstuk 9
In de algemene discussie vergelijken we onze bevindingen met de huidige literatuur en 
sluiten af met algemene overwegingen en suggesties voor toekomstig onderzoek. 

CHAPTER 11
213
Dankwoord
Een dankwoord is wellicht het meest gelezen deel van een proefschrift en dat is niet 
onterecht. Onderzoek doe je namelijk niet alleen, maar samen en met hulp van heel veel 
mensen. Op deze plek wil ik dan ook graag iedereen bedanken die het tot stand komen 
van dit proefschrift mede mogelijk heeft gemaakt. 
Een aantal mensen wil ik echter in het bijzonder bedanken: 
Allereerst wil ik graag alle ouders, kinderen en jong volwassenen bedanken die hebben 
deelgenomen aan de iugr-, program- en prems-studies. Jullie inzet en medewerking 
zijn van onschatbare waarde. Mede dankzij jullie bijdrage zijn we weer een stap verder 
gekomen in onze kennis over en zorg voor mensen die te klein waren bij hun geboorte. 
Ik zal jullie niet vergeten en wens jullie allemaal veel succes met school, studie, werk 
en verdere leven.   
Mijn promotor, prof. dr. A.C.S. Hokken-Koelega. Beste Anita, ik wil je heel erg 
bedanken voor de mogelijkheid die je mij hebt geboden dit onderzoek te doen. Ik 
waardeer je hulp, begeleiding, enthousiasme, de constructieve discussies en je steun. Je 
betrokkenheid bij patiëntenzorg en je passie voor het doen van onderzoek maken je een 
bijzonder iemand, met wie het prettig samenwerken was. Ik heb veel van je geleerd en 
wil je hiervoor hartelijk bedanken. 
Esther Lems en Marianne Huibregtse, ofwel Essebessie en Marianneke, research-
assistenten bij de iugr-2 studie. Wat was het fijn om met jullie te mogen samenwerken! 
Marianne, ik zal onze ritjes naar Arnhem en Utrecht in de eend met open dak niet 
snel vergeten. Esther, met jouw lach is de dag meteen weer goed. Hartelijk dank voor 
jullie hulp en ondersteuning bij alle polibezoeken, nacontroles, dataverwerking en 
organisatie van alle onderzoeken en al het plezier dat we samen hebben gehad. Dankzij 
jullie is de iugr-2 een geoliede trein.
Joke Dunk, beste Joke. Heel erg bedankt voor het uitvoeren van ontzettend veel fsigt-
testen, het meedenken en de strakke organisatie en coordinatie van de prems-studie. 
Prof. dr. A.J. van de Heijden en Prof. dr. J.B. van Goudoever wil ik bedanken voor hun 
snelle beoordeling van mijn manuscript. 
Prof. dr. W. Kiess, thank you for taking place in the Reading Committee.
Prof. dr. A.J. van der Lelij en dr. C.J. de Groot, bedankt voor het plaatsnemen in de 
commissie.
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Prof. dr. K. Ong and Prof. dr. E. Kajantie, thank you for your willingness to participate 
in the Committee. 
Alle kinderartsen die hebben meegewerkt aan dit onderzoek ben ik zeer dankbaar:  
dr. W.M. Bakker-van Waarde, dr. M. Jansen, dr. E.G.A.H. van Mil, drs. J.C. Mulder, drs. 
R.J.H. Odink, dr. H.M. Reeser, dr. W.H. Stokvis-Brantsma, drs. P. Voorhoeve, dr. C. 
Westerlaken en dr. J.J.J. Waelkens.
Prof. dr. S.L.S. Drop, dr. S.M.P.F. de Muijnck Keizer-Schrama, dr. A.M. Boot, 
dr. E.L.T. van den Akker en drs. J. van der Heijden, beste Sten, Sabine, Annemieke, 
Erica en Josine, bedankt voor het meedenken en jullie frisse blik tijdens de endo-
besprekingen. 
Prof. dr. Th. Stijnen, dr. P.G.H. Mulder, dr. M.A. de Ridder en drs. S.P. Willemsen wil ik 
bedanken voor hun hulp bij de statistiek. 
Dr. A.W. van Toorenenbergen wil ik hartelijk bedanken voor het bepalen van 
adiponectine, resistine, il-6, crp en mmp-9 en dr. Y.B. de Rijke voor het bepalen 
van adiponectine en resistine. Dhr. G. Klein Heerenbrink en dhr. H. Van Toor ben ik 
dankbaar voor het uitvoeren van de bepalingen. 
Prof. dr. E.P. Krenning wil ik bedanken voor de mogelijkheid die wij hebben gekregen 
om DXA-metingen te verrichten op de afdeling Nucleaire Geneeskunde. Jopie Sluimer 
ben ik zeer dankbaar voor het maken, analyseren en accorderen van de DXA scans. 
Dr. W.H. Hackeng wil ik hartelijk bedanken voor het bepalen van de insulines en 
glucoses van alle fsigt-testen en zijn interesse in het onderzoek van de afdeling. 
Inge Maitimu en haar collega’s uit het endo-lab van het Wilhelmina Kinderziekenhuis 
in Utrecht wil ik bedanken voor het uitvoeren van alle igf-bepalingen. 
Moniek de Maat en Christianne de Groot wil ik bedanken voor de plezierige 
samenwerking in het pai-1 project. Nog niet in dit proefschrift, maar hopelijk spoedig 
op papier.
Novo Nordisk Farma bv Nederland en Novo Nordisk Farma a/s Denemarken wil ik 
hartelijk bedanken voor de plezierige samenwerking en de financiële ondersteuning 
van de studies en dit proefschrift. 
Frederique, Kevin, Yvette en Marlies, studenten die hun wetenschapsstage op een deel 
van het onderzoek liepen, bedankt voor jullie gezelligheid en inbreng en veel succes 
met jullie verdere carriere. 
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Nicolette, Shailindra, Christa en Marga, studenten en medewerkers, hartelijk dank 
voor jullie enthousiasme en inzet bij de recrutering, dataverzameling en –verwerking 
van de prems-studie.  
Mijn collega endo-onderzoekers: Sandra, Ralph, Emile, Dederieke, Roderick, Ellen, 
Marieke, Marije, Robert, Danielle van der Kaay, Danielle Veenma, Wietske, Laura, Petra 
en Leonie. Bedankt voor alle gezelligheid, de luisterende oren, discussies, koffie, thee, 
wijnproefavonden en cocktail-shake avonden. Danielle vd K., het is altijd weer leuk om 
een mailtje met je belevenissen uit Canada te krijgen. Ontzettend jammer dat je er niet 
bij kan zijn, maar tot snel! Ralph en Emile, het opzetten van de vobs (Vrijdagmiddag 
Onderzoekers Borrel Sophia) was een heel goed idee! Petra, bedankt voor het overnemen 
van de iugr-2 studie. Ik hoop dat je er net zoveel plezier aan zult beleven als ik. Sandra, 
jij was mijn ‘roomie’. Bedankt voor alle gezelligheid, terrasjes en avondjes uit en heel 
veel succes met het afmaken van je promotie. Laura, de wervelwind uit Spanje, bedankt 
voor het mij introduceren in de salsa-band en het plezier dat ik daar elke week mag 
beleven.
De andere endo-researchassistenten en -verpleegkundigen: Janneke, Ingrid, Christel, 
Ineke, Colette, Marielle en Jolanda. Bedankt voor jullie hulp en ondersteuning, de 
antwoorden op vragen en het inspringen waar nodig.
De endo-pulmo lunchclub die zich getrouw elke dag stipt om 12 uur verzamelde bij de 
endo-headquarters: Ruben B., Jeroen, Marije, Sandra, Ralph en Emile, bedankt voor al 
die gezellige lunches. 
Mijn ploeggenoten en vrienden Roelf, Steven, Peter, Remco, Arien, Ernst en Martijn: 
ik kan het nog één keer zeggen hier: Lichte Acht 1997 Varahaghata! Ik ben blij jullie, 
zoveel jaren later, nog steeds te zien en hoop dat er nog veel weekjes in Franse villa’s 
mogen volgen. 
Mijn paranimfen Pepijn van Litsenburg en Marnix Willemsen. Pepijn, dankzij 
jouw relativeringsvermogen en humor ziet de wereld er altijd weer beter uit dan hij 
aanvankelijk leek. Marnix, mijn grote broer, in 2001 stond ik als paranimf aan jouw 
zijde en had ik nog geen idee dat het ooit ook andersom zou zijn. Nu sta jij naast mij. 
De cirkel is rond!
Mijn ouders, pap en mam, bedankt voor al jullie steun, betrokkenheid en liefde. Met 
twee gepromoveerde zoons mogen jullie best een beetje trots zijn!
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Curriculum vitae of Ruben Willemsen
Ruben Willemsen was born in Leiden on July 6th, 1977. In 1995 he graduated from high 
school (Stedelijk Gymnasium Leiden) and started his medical training at the University 
of Leiden. During his studies he rowed at a national level and was a coach for the 
student rowing club a.l.s.r.v. Asopos de Vliet. He taught anatomy and neuro-anatomy 
to medical students from 1998 to 2000. From 1998 to 1999 he worked as a research 
assistant for several projects at the Centre for Human Drug Research (cdhr) in Leiden. 
In 2000 he participated in a research project investigating the release of T-helper 1 as well 
as T-helper 2 cytokines by peripheral blood mononuclear cells of melanoma patients 
and controls at the Department of Clinical Oncology of Internal Medicine at Leiden 
University Medical Centre (supervisors dr. M. Griffioen, dr. P. Schrier and dr. S. Osanto). 
From 2000 to 2002 he did his internships. His final internship of 3 months was spent 
at the Department of Pediatrics of the Diakonessenhuis Paramaribo, Surinam. After 
obtaining his medical degree in August 2002, he started to work as a resident at the 
Department of Pediatrics at the Albert Schweitzer Hospital in Dordrecht. In December 
2003, he started as a research fellow at the Department of Pediatrics, Division of 
Endocrinology, Erasmus mc Sophia in Rotterdam (supervisor Prof.dr. A.C.S. Hokken-
Koelega), which has resulted in the present thesis. 
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